The impact of chromosome 17p alterations on cancer by Weissmueller, S.
  
 
 
 
The impact of chromosome 17p alterations on cancer 
 
 
 
 
 
A thesis submitted to the faculty of the Watson School of Biological Sciences 
In partial fulfillment of the requirement for the degree of Doctor of Philosophy 
 
 
By 
Susann Isolde Weissmueller 
 
 
 
 
Cold Spring Harbor, NY 
2014
ii 
 
Signature Page
iii 
 
Abstract 
One of the most frequently altered regions in the genome is the short arm of chromosome 17 
(17p). Mutational events target the tumor suppressor p53 whereas chromosome-arm 
deletions result in the loss of not only p53 but also other protein-coding genes located on 
17p. Interestingly, p53 mutations together with loss of heterozygosity of 17p are selected for 
during tumorigenesis and are apparent in most cancer cells. This phenomenon raises many 
questions and my forthcoming thesis work sets out to address some of the issues regarding 
the functional consequences of p53 mutations, the tumor suppressive role of 17p genes, and 
the causal effects of cooperative tumor suppressor gene loss. Therefore, we first analyzed 
the mRNA profile of mutant p53 expressing cancer cells, and found that mutant	  p53	  induces	  platelet-­‐derived	  growth	  factor	  receptor	  b	  (PDGFRb)	  through	  a	  cell-­‐autonomous	  mechanism	  to	  drive	  metastasis.	  Mutant	  p53	  inhibits	  the	  p73/NF-­‐Y	  complex	  that	  represses	  PDGFRb	  expression	  in	  p53-­‐deficient,	  non-­‐invasive	  cells.	  Blocking	  PDGFRb	  signaling	  prevented	  pancreatic	  cancer	  cell	  invasion	   and	  metastasis	   formation,	   implicating	   PDGFRb	   as	   a	   prognostic	  marker	   and	   possible	  target	  for	  attenuating	  metastasis	  in	  p53	  mutant	  tumors.	  Second,	  we	  studied	  the	  miRNA	  profile	  of	  mutant	  p53	  expressing	  cancer	  cells	  and	  used	  a	  systematic	  screening	  approach	  that	  identified	  miR-­‐155	  and	  miR-­‐181b	  as	  mediators	  of	  mutant	  p53	   to	  drive	   invasion.	  Both	  miRNAs	   function	  redundantly	   to	  modulate	   the	  MAPK	   pathway	   and	   to	   decrease	   active	   levels	   of	  MKK4,	   thereby	  inhibiting	   the	   anti-­‐metastatic	   function	   of	   MKK4.	   Interestingly,	   the	   induction	   of	   this	   discrete	  miRNA	  signature	  by	  mutant	  p53	  is	  Dicer-­‐independent.	  Both	  studies	  together	  revealed	  at	   least	  two	  mechanisms	  that	  underlie	  the	  gain	  of	  function	  mutation	  of	  p53,	  suggesting	  that	  mutant	  p53	  regulates	   several	  molecular	  mechanisms	   to	   execute	   its	   neomorphic	   activities.	   Lastly,	  we	   also	  investigated	   whether	   any	   of	   the	   other	   274	   protein-­‐coding	   genes	   on	   17p	   that	   often	   become	  heterozygously	  deleted	  in	  cancer	  cells	  has	  a	  tumor	  suppressive	  function.	  By	  conducting	  an	  RNAi	  screen	  we	   identified	  MKK4	  as	  a	  potential	   tumor	  suppressor	   that	  modulates	  antiapoptotic	  and
iv 
 
survival	  genes	  to	  promote	  cancer	  development.	  Moreover,	  we	  observed	  that	  MKK4	  functions	  in	  a	  haploinsufficient	  manner	  and	  drives	  tumorigenesis	  more	  potently	  with	  the	  simultaneous	  loss	  of	  p53.	  Therefore,	  the	  phenomenon	  of	  p53	  mutations	  concurrent	  with	  17p	  loss	  is	  selected	  for	  to	  potentiate	   tumorigenesis	   in	   a	   cooperative	   fashion. As 17p alterations are only one of many 
genetic changes that a cancer cell acquires during tumor development, a better 
understanding of the causal effects of combined genetic alterations is one of the most 
pressing needs in basic cancer research. Increased knowledge about the cancer genome will 
help to guide the development of more effective treatment options to reduce cancer 
mortality.  
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1. Chapter 1  
Introduction 
 
 
Comprehensive knowledge of genomic alterations in cancer is imperative for developing 
novel diagnostics, prognostics and targeted therapeutics. Increasingly sophisticated 
sequencing technologies have provided considerable insight into the landscape of genomic 
changes that occur in cancer, but functional studies are required to determine the 
mechanistic roles of mutated genes in tumorigenesis, and to discern whether their encoded 
proteins represent therapeutic targets. One of the most frequent genomic abnormalities in 
human cancers affects the short arm of chromosome 17 (17p). Such alterations include point 
mutations that target 17p13.1, the region that encodes the tumor suppressor p53, as well as 
heterozygous whole arm deletions that span most of the included 274 protein-coding genes. 
In many cancers, p53 mutations are missense, leading to expression of stable p53 proteins 
with gain of function activities that can cooperate with oncogenic mechanisms. p53 point 
mutations often accompany deletions of the remaining 17p allele and likely represent a 
major factor accounting for rapid disease progression, poor response to therapy, early 
relapse, and short patient survival. Mutations in p53 are primarily selected for during cancer 
development; however, the observation that loss of heterozygosity (LOH) of 17p occurs 
frequently raises the question whether altered gene function of other genes contributes to 
tumorigenesis. In this thesis, I try to shed light on the relevance of each of these genetic 
abnormalities to tumorigenesis and address several open questions regarding (i) the gain of 
new oncogenic functions of mutant p53, (ii) the identification of “driver” genes on 17p, and 
(iii) the consequences of attenuated gene function of multiple genes on 17p.  
Chapter 1 
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1.1. Genetic alterations in the cancer genome 
Cancer development is driven by the step-wise acquisition of genetic alterations that result 
in either the enhanced or decreased activity of the corresponding proteins. Affected genes 
are called “oncogenes” or “tumor suppressor genes”, referring to their respective abilities to 
either promote or inhibit cancer development. It was estimated that < 1% of genes in the 
human genome, 138 of the 20,000 coding genes, functionally affect tumorigenesis (“driver 
genes”) (Vogelstein et al., 2013). Alterations in these genes are being identified recurrently in 
different tumor types, suggesting that almost all causal cancer genes mutated at high 
frequency have been identified. In addition to changes in driver genes, there are many 
additional alterations in “passenger genes” that do not confer a selective growth advantage 
but rather reflect residual evidences of cancer genome evolution. Since every cell division 
generates a few new mutations, the number of mutations that distinguish any two cells 
marks the time from their last common ancestor 
 
Different types of somatic alterations can lead to the altered expression or activity of 
tumor suppressor genes and oncogenes. During the process of tumor evolution, the cancer 
genome is edited by single base substitutions, copy number alterations, and translocations 
(Figure 1.1.) (Futreal et al., 2004). Focal mutations mainly affect a single base or, in few cases, 
deletions or insertions of one or a few bases. On the other hand, chromosomal alterations, 
including amplifications or deletions, can affect small genomic segments, encompassing just 
a few genes, as well as large genomic areas that can affect megabases of DNA and large 
numbers of genes. Lastly, cancer cells also contain translocations that fuse two genes to 
create an oncogene and, in a small number of cases, that can inactivate a tumor suppressor 
Chapter 1 
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gene. However, regardless of the type of genomic alterations, the functional consequences of 
these alterations result in a suite of deleterious cellular outcomes, which include increased 
survival potential, altered cell fate, and/or disrupted genome maintenance processes 
(Vogelstein et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Genetic alterations as a hallmark of tumorigenesis 
The DNA sequence of a gene can be altered in a number of ways: (i) small scale mutations, including a single 
base substitution or the insertion/deletion of small DNA fragments, (ii) larger scale somatic copy number 
alterations, including deletions/amplification ranging in size from focal regions to whole chromosome arms, and 
(iii) translocations, bringing together separate genes from the same or distinct chromosomes to form functionally 
novel fusion genes.  
 
The distribution amongst the classes of genetic alterations in a tumor is uneven, with 
point mutations affecting 10 times more genes than any other aberration. However, ~80% of 
mutations are synonymous passengers with no causal effects on tumorigenesis (Stratton et 
al., 2009). It has been estimated that solid tumors display between 33 to 66 non-synonymous 
mutations in driver genes, with the exception of pediatric and leukemic malignancies 
(which have fewer mutations) and cancer types that are continuously exposed to mutagens, 
SINGLE BASE 
SUBSTITUTION 
TRANSLOCATION DELETION AMPLIFICATION 
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such as melanomas or lung cancer (which have >200 mutations) (Vogelstein et al., 2013). The 
mutational signatures across different cancer types differ and develop further over time, 
after treatment, and through the inactivation of DNA repair processes that create greater 
genomic instability (Greenman et al., 2007; Alexandrov et al., 2013). Oncogenes are 
recurrently mutated at the same amino acid positions (such as RAS, mainly mutated at 
codon 12 (Sukumar et al., 1983)), whereas tumor suppressor genes can be inactivated by 
mutations that occur throughout their coding regions, resulting in protein-truncations (p16 
(Kamb et al., 1994)). Despite the fact that sophisticated sequencing technologies have given 
us a glimpse at the diversity and complexity of mutational signatures buried within cancer 
genomes, the real challenges remains to identify causal consequences of somatic mutations 
by functional studies. Moreover, how different mutagens or the infidelity of the DNA 
maintenance machinery influence the mutational signature and the contribution of 
mutational signatures towards biological characteristics of each cancer remain elusive.  
 
In contrast to point mutations that affect normal cells at similar rates as cancer cells, 
somatic copy number alterations (SCNAs) occur much more frequently in cancer than in 
normal tissue. SCNAs affect large regions of the genome, ranging from one kilobase to 
several megabases in size (Pelizzola et al., 1994; Vogelstein et al., 2013), and it might be that 
cancer cells tolerate these changes due to the inactivation of DNA damage response 
pathways. Deletion events eliminate tumor suppressor genes, whereas amplifications yield 
multiple copies of an oncogene in a cell. Focal deletion- and amplification peaks, which can 
be shared across cancer types, contain an average of 7 genes (Beroukhim et al., 2010). 
Extensive sequencing studies identified ~150 focal SCNAs across 26 different cancer types. 
However, only 11% of them contain yet identified tumor suppressor genes and 33% of them 
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known oncogenes, respectively. Larger arm-level SCNAs, which are shared across cancers 
of similar developmental lineages only, affect the cancer genome much more frequently 
than focal SCNAs (Beroukhim et al., 2010). Especially in the case of large chromosomal 
deletions, it is difficult to separate the specific target gene(s), whose loss confers a growth 
advantage to the cell, from the many passenger genes without tumorigenic effect 
(Vogelstein et al., 2013). In some cases, however, it is not the loss of one single tumor 
suppressor gene but the combined loss of several linked genes that cooperate to cause 
cellular defects (Solimini et al., 2012; Xue et al., 2012). Therefore, as with point mutations, 
evidence of genomic alterations is not enough to identify the genes with causal effects on 
tumorigenesis, and functional studies need to complement sequencing results. 
 
Another frequently occurring class of genetic alterations encompasses chromosomal 
translocations, which juxtapose the regulatory region of one gene to another gene. These 
events have mostly dominant effects by combining two genes to create a “fusion” oncogene 
(e.g. BCR-ABL), but translocation can sometimes inactivate tumor suppressor genes by 
truncation or separation from their promoter. For example, the TEL1-AML gene fusion 
represses the expression of the tumor suppressor TEL1 (Kim et al., 1996). As most 
translocations target gene deserts devoid of known genes or fragile sites, the causal 
consequences mostly appear to be silent. These alterations occur predominantly in 
leukemias, lymphomas or mesenchymal tumors.  
 
 Identifying genetic modifications in the cancer genome has been of interest ever 
since the discovery that DNA sequences from transformed tumorigenic cells transform 
“normal” NIH-3T3 cells with oncogenic properties (Shih et al., 1979). One of the first genetic 
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alterations identified was an activating mutation in the HRAS oncogene (Der et al., 1982; 
Parada et al., 1982; Santos et al., 1982; Taparowsky et al., 1982). Since then, more than 
100,000 additional aberrations in the cancer genome have been reported (Futreal et al., 2009). 
Results from multiple sequencing studies suggests that cancers are initiated by only 2-8 
genetic alterations and continue to acquire ~150 additional genetic changes over a long 
period of time (Hanahan and Weinberg, 2011; Vogelstein et al., 2013). Consequently, 
strategies for eradicating cancer might be most fruitful during the early stages of cancer 
development, by means of early detection or preventative treatment, or by employing 
combination therapy that targets multiple pathways in advanced cancers.  
 
The signaling pathways and cellular processes that are altered in cancer cells are 
versatile. Three core cellular processes become deregulated and include (i) cell fate, (ii) cell 
survival, and (iii) genome maintenance. Many altered genes interfere with the balance of 
differentiation and division, and push the cell towards the latter. Since differentiated cells 
eventually die or become quiescent, cancer cells gain a growth advantage by evading those 
fates. Conserved pathways that operate through this process include NOTCH, HH, and 
APC. Genes that encode chromatin-modifying enzymes can also determine over the fate of a 
cell and are frequently genetically altered in cancer cells. Additionally, cancer cells acquire a 
growth advantage due to an increased cell survival potential. Mutations in genes that 
stimulate proliferation under limiting nutrient concentrations occur frequently. Most 
mutations affect genes encoding growth factor receptors (such as EGFR, HER2, FGFR2, 
PDGFRA, and TGFΒR2) or their downstream signaling mediators inside the cell (MET, KIT, 
RAS, RAF, PIK3CA, and PTEN) (Vogelstein et al., 2013). Cancer cells can also progress 
through the cell cycle in an uncontrolled way, thereby evading apoptosis. Genes encoding 
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for CDKN2A, MYC, and BCL2 become frequently altered and fall into this class. Increased 
angiogenesis also enhance cell survival and can be the result of mutations in VHL. Cancer 
cells with gross chromosomal changes or increased point mutation rates survive the damage 
and divide, instead of undergoing cell death. p53, ATM, MLH1, and MSH1 play a role in 
genome maintenance and are frequently mutated in cancers. Protein products from altered 
genes regulating cell fate, cell survival, and genome maintenance interact with each other 
and the pathways that govern such cellular processes overlap in cancer cells. It is not 
surprising that genetic modifications in different genes results in the same cellular outcome 
to drive growth advantage of tumor cells. But questions remain whether mutations in 
various components of a single pathway are mutually exclusive and as to how deregulated 
and uncontrolled pathways can be targeted for cancer therapy.  
 
A greater knowledge of the functional consequences of genetic alterations and their 
downstream pathways will allow the development and improvement of therapy. 
Therapeutic success by directly targeting the driver gene of a cancer has been achieved in 
PML-RXRα promyelocytic leukemias by treatment with all-trans retinoic acic (ATRA), in 
EGFRmut-driven lung cancer by treatment with gefitinib, or in KITmut-driven gastrointestinal 
stromal tumors by treatment with imatinib. Targeting the mediators of the driver gene 
represents another potentially effective therapeutic approach. Success has been observed 
when treating KRAS-driven tumors with MEK inhibitors. The dramatic, albeit transient, 
responses to agents that interfere with a single mutant gene product are difficult to reconcile 
given the genomic complexity of a cancer cell. Two points could explain this phenomenon. 
First, most of the genetic changes in a cancer genome are passenger alterations and are 
immaterial to tumorigenesis. Second, driver genes alter only a limited number of signaling 
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pathways through which the cancer develops. Therefore, a potential improvement to 
therapy involves the combined usage of multiple agents that target several genes of the 
same or parallel pathways to exploit synthetic lethal dependencies. Combination therapies 
targeting two affected molecular pathways or different components of the same pathway 
could potentially result in a more efficient inhibition. The detailed characterization of each 
molecular component of the affected pathways is imperative for designing such approaches. 
Novel strategies that exploit synthetic lethality in the context of loss-of-function alterations 
in tumor suppressor genes remain mainly unexplored (Stuart and Sellers, 2009). However, 
alterations in tumor suppressor genes, which are more frequently affected than oncogenes, 
can confer therapeutic susceptibility and, therefore, hold great promise for advancing the 
ability to cure cancer.  
 
 
1.2. An example: Genetics of pancreatic cancer  
The molecular analysis of pancreatic ductal adenocarcinomas (PDAC), the most common 
histological subtype of all pancreatic cancer cases, has provided insights into common 
genetic alterations, often implicating known cancer genes and classical cancer signaling 
cascades. PDAC arises from pancreatic intraepithelial neoplasms (PanINs), a preinvasive 
precursor state with cytological and genetic changes that become evident in invasive PDAC. 
These lesions stem from the small ducts of the exocrine pancreas, and are classified as 
PanIN-1 (low-grade dysplasia), PanIN-2 (moderate dysplasia) or PanIN-3 (high-grade 
dysplasia) lesions. PanINs are characterized, and most likely initiated, by oncogenic KRAS 
mutations, and are followed by INK4A/ARF loss, and finally, p53 mutations and loss of 
SMAD4. Collectively, these observations support a genetic progression model of pancreatic 
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carcinogenesis, resulting in the formation of an infiltrating cancer (Figure 1.2). Extensive 
sequencing studies have revealed that PDAC is characterized by a few high-frequency 
mutations (“mountains”) and many low-frequency mutations (“hills”), with the latter 
predominating in terms of the total number of alterations involved (Jones et al., 2008; 
Biankin et al., 2012). Less frequently mutated genes include LKB1, TGFβ, MKK4, AKT2, and 
MYB (Tuveson and Hingorani, 2005). The multitude of mutated genes affects the above-
mentioned cellular processes in the great majority of PDAC patients; however, the pathway 
components that are altered in any individual tumor vary widely (Jones et al., 2008). Our 
knowledge about the relationships and causal consequences of these genetic changes to 
tumor progression and metastasis development remains rather limited.  
 
Multiple genetic events, giving rise to e.g. epithelial-mesenchyman transition, 
upregulation of specific miRNA and/or oncogenic signaling pathways, are required for 
efficient metastasis to occur. The development of metastasis is a common feature of the 
natural history of PDAC, with up to 90% of patients having metastatic disease at death 
(Yachida and Iacobuzio-Donahue, 2013). The metastatic evolution requires at least 20 years 
from the first tumor-initiating mutation to the acquisition of metastatic abilities. The genetic 
changes discussed thus far represent initial events that occur during carcinogenesis upon 
which additional pro-metastatic events may be superimposed. When comparing mutation 
spectra from primary tumors and different metastatic lesions, two categories of mutations 
were identified: founder mutations, present in all samples analyzed from a given patient, 
and progressor mutations, present in a subset of samples from a patient (Yachida et al., 
2010). Therefore, clonal populations that give rise to distant metastases are represented 
within the primary tumor; however, these clones further evolve genetically from the 
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original parental, non-metastatic clone. Loss of Smad4 and mutations in p53 might represent 
two of many mediators of metastasis development, but how they function remains 
unknown (Yachida and Iacobuzio-Donahue, 2013). Sequencing studies also illustrate the 
genetic heterogeneity present in the primary tumor and metastatic lesions, but fail to 
identify the mechanism by which genetic heterogeneity arises. As in most solid tumors, 
heterogeneity is observed among affected pathway components and different mutations 
affecting one gene, but whether those arise from preexistent small populations of cancer 
stem cells or due to waves of clonal evolution in association with the accumulation of 
genetic alterations, remains unclear. To date, the molecular features of the metastatic 
subclones in the primary tumor that promote metastasis formation remain elusive and no 
consistent genetic signature of metastatic subclones could be identified. 
 
Figure 1.2. Pancreatic precursor lesions and genetic events involved in PDAC progression 
The various genetic events are listed and divided into those that predominantly occur early or late in PDAC progression 
(adapted from Hruban et al., 2000). 
 
? 
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Despite our knowledge of the genetic alterations in PDAC, the functional 
consequences on tumor initiation and progression as well as metastases formation remain 
unresolved. Engineered mouse models (GEMMs) of PDAC faithfully recapitulate the 
human disease and can therefore provide a more detailed understanding of the biological 
impact of the driver genes. Pdx1-Cre and Ptf1-p48-cre deleter strains have been used for Cre-
mediated excision of LoxP-flanked elements (genes or STOP cassette) specifically in the 
pancreas. The Pdx1 and Ptf1-p48 promoters are active in the common progenitors of all 
pancreatic cell types with relatively restricted expression outside of the pancreas (Hezel at 
al., 2006). Therefore, this system can be used to mimic the acquisition of activating point 
mutations or the loss of tumor suppressor genes, frequently occurring in human cancers. 
Cre-induced activation of LSL-KrasG12D rapidly initiates the development of PanIN lesions 
and the progression to frank PDAC after long latency (Hingorani et al., 2003). Thus, 
oncogenic Kras mutations need to be potentiated by other genetic alterations to induce 
neoplastic changes, as other rate-limiting events are likely to constrain progression of 
KrasG12D-driven neoplasms towards invasive PDAC. When Kras activation is combined with 
mutations in the tumor suppressors p53 or Ink4a/Arf, a rapid PDAC progression and lethal 
tumor burden is observed. Homozygous deletion of either p53 or Ink4a/Arf in a Kras-mutant 
background gives a more rapidly developing PDAC phenotype and mice succumb within 7-
11 weeks. These PDAC tumors resemble histologically and molecularly the human disease, 
including a proliferative stroma (Aguirre et al., 2003; Hingorani et al., 2005; Bardeesy et al., 
2006). Since mice with a pancreas-specific deletion of only p53 or Ink4a/Arf do not develop 
pancreatic neoplasia, the primary role of these two genes might not be in the onset of PanIN 
but, rather, to form a critical barrier in blocking progression of PanIN initiated by KrasG12D. 
Interestingly, while tumors of these genotypes are locally invasive, gross metastases 
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formation seems to be restricted to mice with only heterozygous loss or mutations of tumor 
suppressor genes (Hingorani et al., 2005; Bardeesy et al., 2006). This may reflect the fact that 
the homozygous models develop multifocal tumors resulting in a rapidly lethal tumor, 
whereas the longer latency of heterozygous GEMMs allow enough time for clonal 
maturation, progression, and metastasis. Collectively, these mouse models recapitulate 
histologic variants from those seen in spontaneous human tumors and can be used to study 
the underlying mechanisms of cellular processes manipulated by genetic alterations. 
 
Despite the data of many sequencing studies that have provided an outline of the 
genetic alterations associated with PDAC development and progression; the current picture 
remains static, with only correlative links to underlying tumor biology. Because PDAC is the 
fourth most common cause of cancer death, there is an urgent need for the identification of 
therapeutic targets and biological pathways of significance (Yachida and Iacobuzio-
Donahue, 2013). The categorization of genetic events into driver and passenger events and 
the quest for specific genetic events that promote metastatic dissemination remains ongoing. 
Only a full comprehension of the intricate network of genetic alterations will allow for early 
detection, improved therapy, and increased patient survival. 
 
 
1.3. The many faces of p53 
1.3.1. Wild type p53 induces tumor suppression via multiple mechanisms 
When p53 was first discovered in 1979 (Lane and Crawford 1979; Linzer and Levine 1979), it 
was believed to carry proto-oncogenic functions. For example, studies reported that p53 
accumulates abundantly in cells (DeLeo et al., 1979), and others described p53’s capacity to 
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transform primary cells in conjunction with oncogenic Ras (Eliyahu et al., 1984), and its 
ability to increase tumorigenesis when overexpressed in p53-/- cells (Wolf et al., 1984). Only 
upon analyzing the sequences of the over-expressed p53 cDNA, which was isolated from 
tumor cells, it was found that the constructs carried mutations. Indeed, some of the tumors 
that were utilized to extract the p53 sequences exhibited loss of heterozygosity (LOH) with 
one p53 allele mutated and the other lost, which represents a hallmark of tumor suppressor 
genes (Baker et al., 1989). Multiple lines of evidence subsequently reaffirmed the conclusion 
that p53 acts as a tumor suppressor. It was found that over expression of wild type p53 
suppressed oncogenic transformation (Hinds et al., 1987; Finlay et al., 1988; Eliyahu et al., 
1989; Finlay et al., 1989), cancer-prone patients with the Li-Fraumenis syndrome (LFS) carry 
germline p53 mutations (Malkin et al, 1990), and p53-/- mice, although developmentally 
normal, have increased susceptibility to developing tumors (Donehower et al., 1992; Jacks et 
al., 1994). By now, thousands of studies have confirmed the role of wild type p53 in tumor 
suppression.  
 
 p53 is a tetrameric transcription factor, heavily regulated by posttranscriptional 
modifications, that binds to p53 response elements composed of two decamers separated by 
a spacer of 0–14 nucleotides (el-Deiry et al., 1992; Funk et al., 1992). The p53 protein is made 
up of the usual features of a transcription factor, with an amino terminal transactivation 
domain, a sequence-specific core DNA binding domain (DBD) and carboxy terminal 
tetramerization and regulatory domains (Bullock and Fersht, 2001). p53 regulates a myriad 
of different genes that are central to its critical role in mediating diverse aspects of cell and 
organismal biology, including metabolism (Gottlieb and Vousden, 2010), development (Sah 
et al., 1995), differentiation (Zheng et al., 2008), and aging (Maier et al., 2004). More 
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important to my work, however, is the ability of p53 to efficiently block cell proliferation in 
order to inhibit cancer development. Under physiological conditions, p53 levels are kept 
low by its negative regulator, the E3 ubiquitin ligase MDM2, which targets p53 for 
ubiquitin-dependent degradation through the proteasome (Kubbutat et al., 1997). However, 
stress signals, such as genotoxic damage, oncogene activation, and hypoxia, disrupt the 
MDM2-p53 interaction, triggering p53 stabilization and tumor suppressive responses. The 
p53 responses include: (i) cytoplasmic or mitochondrial-dependent apoptosis (Yonish et al., 
1991); (ii) cell cycle checkpoint arrest (Kastan et al., 1992); (iii) DNA repair (Smith et al., 
1994); (iv) altered differentiation (Schmid et al. 1991); (v) senescence; (Shay et al., 1991) (vi) 
autophagy (Feng et al., 2005); and (vii) induction of reactive oxygen species (Johnson et al., 
1996) (Figure 1.2.).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. p53-dependent tumor suppressive pathways 
Cancer development is stalled by the activation of p53 to control multiple pathways that influence proliferation 
and cell death. These mechanisms have the potential to lead to tumor suppression 
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p53’s response in mediating tumor suppression strongly depends on the type of tissue, the 
nature of the stress signal, the extent of stress-induced damage, and the availability of 
survival signals (Oren, 2003). However, the mechanism of p53-mediated cell fate decisions 
remains to be scrutinized. 
 
 
1.3.2. Missense mutations induce oncogenic properties 
Remarkably, p53 has been found to be the most frequently altered gene in cancer (Freed-
Pastor and Prives, 2012). p53 expression and function is mainly perturbed by single-base 
pair substitutions but can also be altered through deletions, viral inactivation, and 
upregulation of negative regulators. Multiple lines of evidence have implicated that p53 
point mutations turn the p53 pathway into a tumor-promoting network that contribute to 
malignant progression. These mutations usually cancel the tumor suppressive effects of p53 
by blocking its ability to bind DNA and transactivate p53 target genes. The presence of point 
mutations drastically alters p53 function and goes beyond simple loss of wild type function. 
On the one hand, the tetrameric nature of p53 allows many of the mutant forms to assemble 
with the wild-type protein, enabling the mutant forms to act in a “dominant- negative” 
manner in inactivating wild type p53 function. Thus, inactivating mutations that target only 
one of two wild type alleles in a cell can abrogate tumor suppression in a manner analogous 
to bi-allelic deletion of two wild type alleles. On the other hand, some missense mutations 
endow p53 with additional oncogenic properties, which actively promote the development 
of and aggressive and metastatic phenotype, collectively known as gain-of-function 
activities. Compelling evidence from animal and in vitro models, supported by human data, 
confirm that the acquisition of p53 point mutations is a crucial event during tumor 
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development and a driving force for overt malignant progression (Lozano, 2010). Even 
though the “gain-of-function hypothesis” has existed almost as long as p53 has been 
studied, the focus on understanding p53 mutants and their deleterious consequences on 
tumor progression has only been unveiled during the last decade (Girardini et al., 2014).  
 
Mutations in p53 occur in approximately half of all human cancers, but vary 
considerably between tumor types, ranging from 10% frequency in hematopoietic cancers to 
70% in pancreatic malignancies (Brosh and Rotter, 2009). Mono-allelic single-base pair 
missense mutations comprise 77% of all mutant forms of p53 and occur predominantly in 
the DNA binding domain. The resulting full-length proteins have no sequence specific-
DNA‑binding activity, and because MDM2 is a p53-responsive gene, mutant p53 exhibits 
increased stability as compared to the wild type protein (Haupt et al., 1997; Kubbutat et al., 
1997), leading to the accumulation of high levels of mutant p53 in tumor cells (Iggo et al., 
1990; Strano et al., 2007). While 1,800 cancer-associated amino acid changes in the p53 
sequence have been reported (Soussi, 2011), mutations in ‘‘hot spot’’ residues occur with 
unusually high frequency. According to their effect on the thermodynamic stability of the 
p53 protein, mutations can be divided into two classes: “DNA contact” mutants refer to 
changes in residues that directly abrogate DNA binding ability (e.g. R248Q or R273H), and 
“conformational” mutants comprise those that cause local (e.g. R249S) or global (e.g. R175H) 
conformational distortions (Cho et al., 1994). Both categories not only result in a loss of 
function, but also in dominant-negative activity over the remaining wild type allele through 
the formation of hetero-oligomers (Chan et al., 2004; Xu et al., 2011). More importantly, a 
growing body of evidence supports the notion that p53 mutants acquire novel oncogenic 
functions. For instance, mutations in p53 are accompanied with drug resistance through the 
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activation of the multi drug resistance 1 (MDR1) gene (Bush and Li, 2002) and are associated 
with poor clinical outcome of different cancer types (Goh et al., 2010). In fact, it seems that 
p53 mutants contribute to almost all of the so-called hallmarks of cancer: (i) invasion, (ii) 
metastasis, (iii) genomic instability, (iv) apoptosis resistance, (v) survival, (vi) drug 
resistance, and (vii) chronic inflammation (Figure 1.2.). However, a key question concerns 
how mutant p53 conveys a gain of function; knowing the answers may allow the 
identification of potential strategies to develop novel anti-cancer therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Gain of function activities of mutant p53 
A summary of the biological effects of mutant p53 function and its mediators are indicated. 
 
 
1.3.3. Gain of function mutation spectra 
Mutant p53 carries out its gain of function properties through either one of two non-
mutually exclusive mechanisms that involve the modulation of gene transcription or the 
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interaction of p53 with other cellular proteins to form aberrant protein complexes. Mutant 
p53 has been shown to form abnormal complexes with a wide variety of proteins to affect 
signaling through different pathways. For example, mutant p53 interacts with the prolyl 
isomerase PIN1 to potentiate formation of a complex with SMAD2 and p63 downstream of 
TGFβ signaling to increase invasiveness of breast cancers (Girardini et al., 2011). The 
nuclease MRE11 aggregates with mutant p53 to suppress the binding of the MRE11-RAD50-
NBS1 (MRN) complex to DNA double-stranded breaks, thereby disrupting critical DNA 
damage-response pathways (Song et al., 2007). Moreover, mutant p53 can modulate gene 
transcription by interacting with other transcription factors, thereby impairing their ability 
to bind their target gene promoters to initiate transcription. The list of affected transcription 
factors is long and includes SP1, NF-Y, ETS1, ETS2, and the Vitamin D receptor, as well as 
transcriptional cofactors.  
 
The most pivotal example of aberrant oligomerization with transcription factors 
represents the inhibitory effect of mutant p53 on its family members p63 and p73. Despite 
the homology of all three family members, neither p63 nor p73 form heterotetramers with 
wild-type p53, but do so, surprisingly, with different classes of mutant p53 (Di Como et al., 
1999). These interactions, mediated through p53’s DNA binding domain (Li and Prives, 
2007), appear to explain a number of cellular properties conferred by p53 gain of function 
mutation, including chemoresistance (Sampath et al., 2001), cell migration (Adorno et al., 
2009), and tumor metastasis (Muller et al., 2009).  
 
 As mentioned above, mutant p53 induces oncogenic functions also through DNA 
binding, a mechanism that is less well explored. Even though mutations in p53 impair its 
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sequence-specific binding to DNA, mutant p53 retains its ability to bind to certain DNA 
structures with differential affinity (Gohler et al., 2005). These target structures are rich in 
repetitive elements and most likely adopt non-B conformations (Kogar et al., 2000). Hence, 
binding of mutant p53 to structural motifs rather than promoter sequences would explain 
the lack of consensus DNA sequences amongst genes regulated by mutant p53. Taken 
together, the study of p53 mutants has identified multiple routes to modify the gene 
expression landscape to impair or promote pivotal signaling pathways of a cell in order to 
exert oncogenic functions.  
 
 
1.3.4. Mouse models of mutant p53 
The most convincing evidence for neomorphic functions induced by a mutation in p53 
comes from genetically engineered mouse models (GEMMs) expressing mutant p53. The 
first proof of a gain of function in vivo came from germline transgenic mice that expressed a 
mutant p53 genomic fragment under the control of its own promoter. These mice exhibited 
increased tumor susceptibility, including lung adenocarcinomas, osteosarcomas, and 
lymphomas (Lavigueur et al., 1989), which was later verified in mice that were manipulated 
at their endogenous p53 locus to express mutant p53 under physiological control (Lang, et 
al., 2004; Olive, et al., 2004). Even though tumor-free survival was similar in p53null versus 
p53mutant mice, the mutant counterparts exhibited a higher incidence of metastasis (Lang et al., 
2004) and were more prone to develop carcinomas instead of osteosarcomas (Olive et al., 
2004). Taken together, mutant p53 acquires novel oncogenic potential beyond that conferred 
by loss of p53 function.  
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 The role of mutant p53 has also been investigated in a tissue-specific manner. When 
mice expressing mutant p53 specifically in the liver or mammary tissues were challenged 
with carcinogens, tumorigenesis was accelerated and, in the latter context, increased 
genomic instability was observed (Ghebranious and Sell, 1998; Adams and Horton, 1998). 
Neomorphic functions of mutant p53 were also observed in collaboration with other 
oncogenes. For example, when p53null, or p53R172H, or p53R270H transgenic mice were crossed 
to animals harboring a lung-specific KrasG12D allele, mice expressing the R270H allele 
showed higher lung lesion progression than the p53null or the R172H mice, indicating that 
only some missense mutations exhibit observable gain-of-function in this cell type setting 
(Jackson et al., 2005). Many other mutant p53 knock-in mice have exhibited not only 
increased tumor aggressiveness but also higher frequencies of metastasis. Examples include 
KrasG12D, p53R172H-driven non-melanoma skin tumors (Caulin et al., 2007); KrasG12D, p53R172H-
driven pancreatic cancer (Morton et al., 2010); Apc, p53R172H-driven intestinal cancer (Muller 
et al., 2009); and SV40 T-antigen, p53R270H-driven breast cancer (Heinlein et al., 2008) models. 
Hence, tumors carrying a mutant form of p53 are more aggressive and invasive than those 
found in p53null mice. The in vivo evidence for mutant p53 gain of function is consistent with 
data from clinical studies of human cancer patients where a mutation in p53 conveys with 
worse trends in prognosis and survival in patients with glioblastoma (Wang et al., 2013), 
colorectal (Russo et al., 2005), breast (Bonnefoi et al., 2011), ovarian (Levesque et al., 1995), 
and pancreatic cancer (Weissmueller et al, 2014).  
 
The p53 family members p63 and p73 seem to be important downstream mediators 
of p53 tumor suppression. Interestingly, when p63 or p73 were deleted in p53null animals, 
compound mutant mice developed lymphomas, sarcomas and carcinomas that could more 
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readily metastasize (Flores et al., 2005; Tan et al., 2013). The tumor spectrum and enhanced 
metastatic burden were remarkably similar to the phenotypes observed in mice expressing 
p53mutant but exhibited reduced metastatic frequency, suggesting that mutant p53 signals 
through additional nodes beyond its family members. 
 
In addition to insights about the neomorphic activities of mutant p53, GEMMs can 
also reveal intricate insights about the molecular characteristics of the mutant p53 protein. 
The question why p53 mutants accumulate to high levels in cancerous tissue but not in 
normal cells was tackled by manipulating its upstream regulators. When p53mutant mice were 
studied in a Cdkn2a-/- or Mdm2-/- background, mutant p53 accumulated also in normal tissue 
and mice showed decreased overall survival (Terzian et al., 2008). Therefore, missense 
mutations in p53 alone are not sufficient to cause accumulation of high levels of mutant p53, 
but there are other events needed to impair MDM- or CDKN2A-mediated degradation. 
 
The combined knowledge about mutant p53 raises the question whether targeting 
this core tumorigenic driver constitutes a promising therapeutic approach. Multiple 
approaches could potentially attenuate the oncogenic potential of mutant p53 by either (i) 
eliminating mutant p53, (ii) restoring mutant p53 to wild-type p53, (iii) targeting the p53 
family members, or (iv) targeting downstream p53-mediators. Mouse models are ideal 
systems to study such therapeutic approaches and several of these approaches are currently 
being developed and tested. Most promising have been small molecules, such as PRIMA-1, 
which functions as a chaperon to stabilize the wild type p53 conformation, RETRA, which 
disrupts the interaction of mutant p53 with p63 and p73, and the HDAC inhibitor SAHA, 
which leads to mutant p53 destabilization. However, the validation of any beneficial 
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activities of these inhibitors in mice is only the first step in a long journey where the goal is 
to treat large numbers of cancer patients carrying mutant p53. 
 
 Mutant p53 GEMMs clearly support the gain of function hypothesis, but a number of 
critical questions continue to exist. First, it remains to be discovered whether different p53 
mutants induce mutation-specific phenotypes. Second, questions remain regarding the 
selective pressure towards p53 mutations rather than p53 loss. In GEMMs, both modes of 
genetic alterations favor different tumor spectra and frequencies of metastasis but result in 
similar tumor latency, and, therefore, should be prevalent at equal rate in the cancer 
genome. Moreover, how mutant p53 drives cell dissemination and metastasis development 
remains unclear; however only a comprehensive understanding would allow the 
identification of novel targets and therapeutic strategies.  
 
 
1.4. 17p deletions – simply LOH? 
Cancer development is characterized by a stepwise progression. Pre-malignant lesions, such 
as dysplasia and hyperplasia, can be detected in diverse organs prior to the appearance of 
fully malignant invasive tumors. Expansion of pre-malignant lesions and further 
accumulation of genetic alterations results in malignant conversion and the development of 
a primary tumor. Fully malignant cells subsequently acquire the invasive and metastatic 
ability.  
 
The chronology of genetic alterations during the tumorigenic process and their 
contribution to the distinct steps of malignant progression is an area of intense research. 
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Mutations in p53 can occur in different stages of tumorigenesis and are extremely variable 
from one cancer to another. Moreover, they can contribute to the initiation of malignant 
transformation (Cagatay and Ozturk, 2002) or can arise as late events, leading to increased 
aggressiveness of advanced tumors (Hruban et al., 2000). However, the heterozygous state 
of mutated p53 is transient and often followed by LOH for the short arm of chromosome 17 
(17p), where the remaining wild type p53 allele is located (Rivlin et al., 2011). Heterozygous 
17p deletions occur frequently in human tumors and are often late events associated with 
the transition from benign to malignant states. For example, 17p loss is found in 7% and 15% 
of early chronic lymphocytic leukemia and colorectal cancer cases at diagnosis, respectively, 
but the frequency increases to 40% and 60% at the time of disease relapse or progression 
(Schnaiter and Stilgenbauer, 2013; Risio et al., 2003). Heterozygous 17p deletions might 
specifically arise from selective force to inactivate the remaining p53 wild type allele to 
potentiate the gain of function activities of the mutated allele. However, losing the 
remaining p53 allele could be achieved by focal deletions, a second mutation, or uniparental 
disomy (UPD) instead of losing an entire chromosome arm. Hence, the possibility remains 
that 17p loss attenuates the activity of multiple genes on the same chromosome arm that are 
separated by large distances. Therefore, the hypothesis arises that 17p events are selected 
during tumor progression not only to inactivate the p53 allele but also because of the 
presence of linked tumor suppressor genes whose complete or partial loss individually may 
have only a modest effect on tumor growth.  
 
The canonical view of the “two-hit hypothesis”, where the inactivation of both 
copies of a tumor suppressor gene is considered a pre-requisite for tumor development, was 
first formulated in 1971. Tumor prone families with retinoblastoma were shown to transmit 
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one mutation in RB through the germ line and affected children developed disease early in 
life after acquiring a second mutation in the remaining wild type allele (Knudson, 1971). 
However, the cancer genome is rattled by the recurrent presence of large, heterozygous 
deletions and only 22% of such recurrent deletions can be explained by known or putative 
tumor suppressor genes (Solimini et al., 2012). Possible explanations for such frequent 
deleterious events go beyond Knudson’s hypothesis and could include that (i) tumor 
suppressor genes on the remaining allele are silenced by mutations or epigenetic marks, (ii) 
unstable genomic regions induce large deletions randomly, or (iii) mono-allelic loss of one 
or multiple genes provides a selective growth advantage in a haploinsufficient manner. In 
depth analysis of chromosomal distribution of recurring deletions revealed that they 
preferentially overrepresent “STOP” genes and underrepresent “GO” genes, which 
negatively and positively regulate proliferation, respectively (Solimini et al., 2012). 
Therefore, the “cancer gene island hypothesis” proposes that heterozygous deletions do not 
occur randomly but are rather selected to target gene islands with high densities of STOP 
genes and low densities of GO genes. Moreover, recurrent cancer-associated deletions could 
reflect the selective advantage of simultaneously targeting multiple two-hit and/or 
haploinsufficient tumor suppressor genes. Those deletions might target more than just well-
characterized tumor suppressor genes and could potentially encompass additional genes 
that can impact on tumorigenesis, supporting the idea that the biology mediated by these 
large deletions goes beyond the effects of individual genes. Functional studies support such 
hypothesis and elucidate that multiple genes within such regions contribute to the 
tumorigenic phenotype. For example, cosuppression of linked genes on chromosome arm 
8p, a large deletion event occurring frequently in epelthelial cancers, promoted liver cancer 
formation more potently than loss of any individual gene (Xue et al., 2012). Collectively, the 
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prevalence of large, recurring heterozygous deletions results in the elimination of multiple 
haploinsufficient growth control genes to optimize fitness and drive tumorigenesis. 
 
Table 1.1. Large somatic deletions occur frequently in human tumors (adapted from Nita et al., 2002) 
 
Allelic loss of 17p and the presence of p53 mutations are prognostic markers for 
resistance to treatment regimens. Given the gain of function caused by mutations in p53, it is 
attractive to hypothesize that LOH of the remaining allele is positively selected during 
tumorigenesis in order to lose the remaining p53 wild type allele and potentiate mutant p53 
neomorphic attributes. In some tumors, however, allelic losses of the entire 17p arm or 
encompassing the 17p13.3 band only have been detected in the absence of p53 mutations 
(Risio et al., 2003), suggesting that the loss of gene function in this chromosome region is 
relevant for tumorigenesis. In fact, some tumor types favor a whole chromosome arm loss 
over focal peak deletions that encompass p53 only, suggesting that the loss of other genes 
together with p53 might have a cooperating effect to drive tumorigenesis (TCGA database). 
 
 The potential tumor suppressive function of other genes located on 17p has 
remained largely unexplored, despite evidence for the existence of a few, yet controversial, 
tumor suppressor genes in that region. Only few examples exist, including MKK4 and HIC1. 
Chromosome Frequency of LOH Identified TSG 
1p 32% p73 
4q 40 – 83% - 
6p 35 – 80% Igf2/M6p 
8p 50 – 60% Dlc1, Lpts 
10q 25% Pten 
13q 25 – 50% Rb, Brca2 
16p 40% Axin 
16q 36 – 70% E-cadherin 
17p 36 – 54% p53 
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The former is located on chromosome 17p11.2 and lies centromeric to p53. MKK4 is a 
mitogen-activated protein kinase (MAPKs) that translates external signals into activation of 
a series of downstream targets, including JNK and p38 (Whitmarsh and Davis, 2007). The 
MKK4 gene was first identified in 1995 during a search for MAP2Ks that could 
phosphorylate JNK, and its tumor suppressive role in cancer was first mentioned two years 
later (Teng at al., 1997). Multiple tumors exhibit loss-of-function mutations in, or LOH at, 
the MKK4 locus (Su et al., 2002), and some studies suggest a link between the lack of MKK4 
and metastasis formation (Yamada et al., 2002). However, the few existing studies about the 
role of MKK4 in tumorigenesis are contradictive, and some favor an oncogenic role of 
MKK4 in cancer development and progression (Wang et al., 2004; Finegan and Tournier, 
2010). 
 
HIC1 is another candidate tumor suppressor gene located on chromosome 17p, 
telomeric to p53 (17p13.3). HIC1, a zinc-finger transcription factor, is a direct p53 target and 
represses the transcription of several genes, such as the SIRT1 deacytelase. Mono-allelic 
deletion of HIC1 is frequently accompanied by hypermethylation of the second allele, 
indicating biallelic inactivation of the locus (Wales et al., 1995). The molecular mechanism 
underlying HIC1-mediated transcriptional and growth suppression remains elusive. One 
study suggested that HIC1 targets E2F-responsive genes responsible for transcriptional 
regulation and growth suppression whereas others have implicated HIC1 in the repression 
of Ephrin-A1 transcription (Zhang and Yu, 2011) 
 
How the loss of physically linked tumor suppressor genes synergizes to drive 
tumorigenesis remains elusive. The possibility remains, but is less likely, that none of these 
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frequently deleted genes is directly causally involved in tumorigenesis and that allelic losses 
are secondary effects of chromosomal instability. This might be especially true for 17p, as 
telomeres on 17p are shorter than the median telomere length (Martens et al., 1998), and the 
relatively short telomeres could possibly contribute to the frequent loss of 17p. Here, the 
loss of telomeres can result in sister chromatid fusion and prolonged 
breakage/fusion/bridge (B/F/B) cycles, leading to extensive DNA amplification and large 
terminal deletions (Bailey and Murnane, 2006). If indeed 17p deletions are initiated due to 
genomic instability, both alleles should be impacted at equal frequency. However, loss of 
17p usually affects the chromosome arm carrying the wild type p53 allele to allow the 
continued expression of mutant p53.  
 
The idea of cooperating tumor suppressor genes that are simultaneously targeted by 
a chromosomal deletion challenges the view of a single “driver” gene in the region. The 
presence of large deletions on chromosomes, such as 3p, 5q, 8p, 9p, and 17p, suggest that 
deletion of linked cancer genes may play a broad role in cancer phenotypes. However, this 
idea greatly complicates the identification of genes with causal effects on tumorigenesis and 
strategies for cancer treatment if these genes affect different pathways. 
 
In my graduate studies, I set out to understand causal effects of 17p alterations on 
tumorigenesis. As genetic changes are manifold and include mutations in the sequence of 
the tumor suppressor p53 as well as subsequent LOH of the remaining allele, we studied 
both alterations individually to understand how they affect tumor growth and 
development. We first analyzed the gain of function of p53 mutants and how mutant p53 
induces invasive and metastatic features of pancreatic cancer cells. By combining orthogonal 
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approaches, we found that mutant p53 regulates distinct mRNA and miRNA expression 
levels to carry out its enhanced oncogenic potential. On the other hand, we analyzed the 
causal effects of losing the remaining genes on 17p by LOH. We identified at least one 
additional tumor suppressor on 17p that can promote tumor growth and invasive potential 
in a haploinsufficient manner. Moreover, reduction of gene function of multiple genes on 
17p has a cooperative effect on tumorigenesis. Together, these data suggest that 17p 
alterations result in different tumorigenic outcomes through contrasting molecular 
mechanisms. Therefore, p53 mutations and LOH of the remaining 17p allele are under 
positive selective pressure, as both events allow for a more aggressive behavior of cancer 
cells than the individual alteration of p53 alone.  
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2. Chapter 2  
Mutant p53 drives pancreatic cancer metastasis through cell-autonomous 
PDGF receptor beta signaling 
 
 
2.1. Introduction 
Mutations in the p53 tumor suppressor gene represent the most common genetic lesions in 
cancer (Freed-Pastor and Prives, 2012). Functional studies indicate that wild-type p53 
possesses a series of anti-proliferative activities that limit the proliferation and survival of 
pre-malignant cells. p53 exerts these activities, at least in part, through its ability to bind 
DNA in a sequence-specific manner to regulate gene expression, and the vast majority of 
mutations that occur in human tumors disable this property of p53 and, consequently, its 
anti-proliferative effects.  
 
p53 mutations typically occur within the DNA-binding region and involve either 
DNA contact residues or residues important for conformational structure, both resulting in 
loss of DNA binding (Joerger and Fersht, 2007). Because p53 functions as a tetrameric 
transcription factor, mono-allelic p53 mutations can exert dominant-negative effects on a 
coexpressed wild-type p53 protein. p53 activates E3 ubiquitin ligases that feed back to 
trigger p53 destruction and its rapid turn over; however, p53 missense mutants defective in 
regulating gene expression lead to the stable accumulation of the variant proteins (Oren et 
al., 2010). Interestingly, genetically engineered mice harboring common p53 point mutations 
develop more aggressive and metastatic tumors compared to those arising in their p53 
heterozygous or null counterparts (Lang et al., 2004; Olive et al., 2004, Hanel et al., 2013), 
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suggesting that the mutant forms of p53 exert gain-of-function activities independent of 
their effects on wild-type p53. Accordingly, human tumors with mutant p53 are associated 
with poor patient prognosis (Soussi and Beroud, 2001) and drug resistance (Masciarelli et 
al., 2013).  
 
Recently, targeting mutant p53 function has been proposed as an anti-metastatic 
measure. As p53 mutant proteins have to date proved undruggable (Levine and Oren, 2009; 
Lehmann and Pietenpol, 2012), efforts have focused on identifying the underlying 
mechanisms that mediate its effects. Such efforts have identified proteins involved in 
integrin recycling (Muller et al., 2009), the mevalonate pathway (Freed-Pastor et al., 2012) or 
miRNA biogenesis (Su et al., 2010) as potential mediators of mutant p53 action in invasion 
and metastasis. So far, most studies have been performed in breast cancer and the proposed 
mechanisms do not necessarily validate across cancer types. These observations underscore 
the importance of the cellular context in assessing mutant p53 action, and highlight the 
potential complexity of the effector network.  
 
Pancreatic ductal adenocarcinoma (PDAC) is one cancer type in which mutant p53 
impacts disease progression. PDAC arises from indolent pancreatic intraepithelial 
neoplasias (PanINs) that frequently go undetected and persist for many years. However, the 
conversion of PanINs to highly aggressive, frankly invasive and metastatic PDACs, in which 
p53 is mutated in 75% of cases, carries a dire prognosis due to late stage detection, the 
presence of metastases, and ineffective treatment options (Li et al., 2004). Even those 
patients with a surgically approachable pancreatic lesion develop recurrent and metastatic 
disease after local tumor resection (Hidalgo, 2010). Consistent with a role for mutant p53 in 
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this process, mice harboring pancreatic cancers driven by oncogenic Kras and a mutant p53 
allele show more metastases compared to identical mice harboring a p53 null allele (Morton 
et al., 2010). However, it is not known whether mutant p53 is needed to sustain the 
metastatic phenotype and how it is regulated. Such information would produce insights 
into p53 action and validate mutant p53 as a therapeutic target.  
 
In this study, we combined several orthogonal approaches and models to 
systematically explore the molecular basis whereby mutant p53 promotes invasion and 
metastasis in PDAC and the clinical implications of its effects. These studies identified the 
platelet-derived growth factor receptor beta (PDGFRb) as necessary and sufficient to 
mediate the effects of mutant p53 on invasion and metastasis in both a murine model and 
human PDAC cells. Further, we identified elevated PDGFRb expression as an indicator of 
poor metastasis-free survival in human PDAC patients. Taken together, our data identify a 
key mediator of mutant p53 activity and suggest that PDGFRb inhibitors may act as anti-
metastatic agents in some patients with tumors expressing mutant p53. 
 
 
2.2. Results 
2.2.1. Transcriptional profiling and functional screening identifies PDGFRb as a 
downstream mediator of mutant p53  
Genetically engineered mouse models of pancreatic cancer harboring a latent oncogenic Kras 
allele (lox-stop-lox KrasG12D), a latent mutant p53R172H, and a tissue specific Cre recombinase 
(Pdx1-Cre), also known as KPC mice, develop highly metastatic pancreatic cancer that 
faithfully mimics the human disease (Hingorani et al., 2005). To understand the impact of 
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p53 mutations on cell invasion and metastasis in this well-defined genetic system, we 
employed a murine KPC pancreatic cancer cell line that lost the remaining p53 wild type 
allele during disease progression (Morton et al., 2010). The behavior of KPC cell lines stably 
expressing shRNAs targeting (mutant) p53, or control shRNAs targeting Renilla 
(KPC+sh.Ctrl), were compared to one another and to a p53-null KPflC cell line (from a Pdx-
Cre, LSL-KrasG12D/+, LSL-p53loxP/+) expressing the control shRNA (KPflC+sh.Ctrl).  
 
We confirmed that KPC+sh.Ctrl cells expressing mutant p53 efficiently migrated in 
scratch-wound assays. This motility depended on mutant p53, as mutant p53 knockdown in 
KPC+sh.p53 cells reduced motility similarly to p53-/- KPflC +sh.Ctrl cells (Figure 2.1.A). Next, 
we examined the invasive capacity of KPC cells into collagen gels in an inverted invasion 
assay. The presence of mutant p53 in KPC+sh.Ctrl cells enhanced invasiveness, which was 
significantly abrogated upon p53 knockdown (Figure 2.1.B). The ability of mutant p53 to 
drive cell invasion was also evident following enforced expression of p53R175H and p53R273H, 
two mutants frequently found in human PDAC, in KPflC cells. This result indicates that the 
differences in invasiveness of KPC and KPflC cells depends on mutant p53 and were not 
acquired during generation and selection of cell populations expressing shRNAs or through 
RNAi off-target effects.  
 
To test whether mutant p53 expression was required to sustain the metastatic 
potential of KPC cells, we orthotopically injected KPC+sh.Ctrl and KPC+sh.p53 cells into 
the pancreata of athymic mice and scored the number of metastases formed in both lung 
and liver, the most common sites of pancreatic cancer spread in patients. Although the 
primary tumor burden was independent of p53 status, tumors originating from 
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Figure 2.1. Depletion of Mutant p53 Abrogates Invasiveness of Pancreatic Cancer Cells 
(A) Quantifications of wound distances in scratch-wound assays from 0, 3, 7, and 10 h after wounding of KPC 
cells stably expressing a nontargeting control shRNA (sh.Ctrl) or a shRNA targeting mutant p53 (sh.p53) or 
KPflC cells stably expressing a sh.Ctrl (left panel). Data presented as mean ±SD. ***p < 0.001. Representative 
phase contrast images from live cell recordings of each condition are shown at 0 and 10 h (right panel). (B) 
KPC+sh.p53 and +sh.Ctrl as well as KPflC cells expressing the GFP control and mutant p53 (175H and 273H) 
vector were allowed to invade into Collagen for 72 h before quantification as described in the Experimental 
Procedures (left panel). The average of invaded cells from 9 replicates ±SD is shown. A representative result of 
three repeated experiments is shown. **p < 0.01, ****p < 0.0001. Representative 3D reconstructions of each 
condition are shown (right panel). Cells were stained for F-actin (red) and DAPI (blue); dashed line indicates the 
approximate position of the Transwell membrane; the arrow indicates the direction of movement. (C) 
KPC+sh.p53 or +sh.Ctrl were orthotopically injected into the pancreata of athymic mice. When symptomatic, 
mice were euthanized and metastatic spread in lung and liver was quantified by counting GFP-positive 
macroscopic nodules (left panel). Data presented as mean ±SD. *p < 0.05, **p < 0.01. Panels show representative 
merged brightfield/GFP images from lung and liver (right panel). 
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KPC+sh.Ctrl cells expressing mutant p53 were significantly more metastatic than those in 
which mutant p53 was silenced, and metastases in the lung and liver were detected to a 
greater extent in mice that had been injected with cells expressing mutant p53 (Figure 2.1.C). 
Together, these results demonstrate that mutant p53 can contribute to PDAC invasion and 
metastasis and that inhibiting its activity can have an anti-metastatic effect. 
 
To gain insight into how mutant p53 mediates the invasive phenotype of PDAC, we 
performed genome-wide transcriptome profiling of KPC cells by RNA sequencing 
(RNAseq). Four days following knockdown of mutant p53 in three independent clonal KPC 
populations, we observed a complex pattern of gene expression changes compared to three 
independent KPC+sh.Ctrl cell lines. We identified 441 genes either significantly up- or 
down regulated upon shRNA-mediated depletion of endogenous mutant p53 (Figures 2.2.A 
and S2.1.A). Ingenuity pathway analysis revealed that ~20% of the affected genes fall into 
the functional class of “cellular movement”, supporting our experimental observations that 
mutant p53 can govern the invasive phenotype of pancreatic cancer cells (Figures 2.2.B and 
S2.1.C). 
 
To facilitate the identification of mediators of mutant p53 activity, we focused on 
genes whose expression was positively regulated by mutant p53, as such molecules might 
both mediate effects of mutant p53 and be targets for pharmacological inhibition. Therefore, 
we generated pools of 3-6 shRNAs targeting individual upregulated genes, and screened 
them one-by-one to identify those that phenocopied the decreased invasion seen upon 
downregulation of mutant p53 (Table 2.1.). We identified three genes whose knockdown 
abrogated invasion driven by mutant p53 (Figure 2.2.C). SLC40A1 is a cell membrane 
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Figure 2.2. Identification of PDGFRb as a Downstream Mediator of Mutant p53 in Regulating Cell Invasion 
(A) Schematic workflow of RNA sequencing. (B) Ingenuity pathway analysis (Ingenuity Systems, 
www.ingenuity.com). Bars (p < 0.05) represent molecular and cellular functions that are significantly changed 
following mutant p53 depletion. (C) One-by-one invasion assay screen. Quantification of invaded KPC cells 
infected with individual shRNA-pools (~3.6 shRNAs/gene) targeting the top 40 upregulated genes identified by 
RNAseq. Data presented as mean ±SD. (D) qRT-PCR for PDGFRb in KPC+sh.p53 (2 or 3) or +sh.Ctrl cells. Data 
presented as mean normalized PDGFRb expression ±SD of triplicate samples. A representative result of three 
repeated experiments is shown. (E) Western blotting analysis of PDGFRb, p53, and Actin in sh.p53- or sh.Ctrl-
expressing KPC cells. The two bands of PDGFRb represent differentially glycosylated forms of the protein. 
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UP DOWN 
Slc1a3 Prl2c3 
Calml4 Nckap1l 
Fgf13 Vmn1r44 
4933439K11Rik* Gm14547 
Lmo1 Armcx2 
Gm13318* 1600029D21Rik 
Gpc4 4930452B06Rik 
Pde9a Trim54 
Ptn Prl2c2 
Angpt1 Selp 
Pde8a Serpinb9g 
Psmb8 Prrg1 
Fam5c Slc25a48 
Ppp1r3c Prokr2 
5330417C22Rik* Rims2 
Robo2 Fat2 
Armcx6 Siglec15 
Smarca1 Ctf1 
Tmigd1 Spsb4 
Sned1 Cd300lb 
Oprd1 Gm15854 
Psmb9 Klk8 
Sgk3 Igfbp3 
Fam198a* Il18rap 
Fsd1 Fam110c 
Nfkbid Acsbg1 
C4bp 9030425E11Rik 
Nlgn1 Nefl 
Cyp4b1 Tnnt2 
Gatm Atg9b 
1110032A04Rik Stk39 
BC028528* Aqp8 
Cul9 Tmem117 
2610305D13Rik* Klra4 
C1s Wnt10a 
Unc5c Hck 
Slc40a1 Kcnf1 
Pdgfrb Ripply1 
Cacna1b Fam78b 
Bicc1 Slc25a43 
Table 2.1. Top 40 genes up- and downregulated in KPC cell expressing mutant p53  
compared to p53-knockdown cells 
* published transcriptional tragets of NF-Y 
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protein that has been shown to mediate cellular iron efflux (Montalbetti et al., 2013); SNED1 
is a stromal marker that induces cisplatin-resistance in head and neck squamous carcinoma 
(Longati et al., 2013); and PDGFRb is a receptor tyrosine kinase that mediates PDGF-
regulated proliferation, survival and chemotaxis (Dai, 2010).  
 
Oncogenic properties of mutated or amplified PDGFRa have been extensively 
studied in several tumor types, whereas PDGFRb has been exclusively linked to tumor 
angiogenesis via paracrine effects (Pietras et al., 2003; Cao et al., 2004). Based on our 
screening results, we hypothesized that PDGFRb may also have a cell-autonomous impact 
on cell invasion in pancreatic cancer. First, we verified by RT-qPCR and western blotting 
that PDGFRb mRNA and protein were reduced upon knockdown of mutant p53 (Figures 
2.2D and 2.2.E). Expression of mutant p53 correlated with high PDGFRb expression levels 
and also with the expression of key downstream mediators of the PDGFRb signaling 
cascade (Figure S2.1.B).  
 
We next examined the effects of depleting each PDGFR isoform on the invasive 
potential of KPC cells in vitro (Figure 2.3.A). Although knockdown of PDGFRa had no 
effect, depletion of PDGFRb decreased the ability of KPC cells to invade (Figure 2.3.B). 
Conversely, overexpression of PDGFRb in p53-/- KPflC enhanced cell migration and invasion, 
similarly to cells over-expressing mutant forms of p53 (Figure S2.2.A). Reduced levels of 
PDGFRb in KPC cells neither altered the rate of cell proliferation (Figure S2.2.B) nor led to a 
competitive proliferative disadvantage over KPC cells expressing high PDGFRb levels 
(Figure S2.2.C). When GFP-positive KPC+sh.PDGFRb cells were mixed with dsRED-positive 
KPC+sh.Ctrl cells and injected subcutaneously into athymic mice, the GFP:dsRED ratio of 
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pre-injected cells was maintained in the established tumors, indicating that increased 
PDGFRb levels did not confer a selective advantage to tumor cell proliferation at the site of 
injection (Figure S2.2.D). Thus, cell-autonomous activity of PDGFRb is not required for the 
proliferation and tumorigenic potential of p53 mutant murine cancer cells but specifically 
impacts their invasive potential. 
 
To determine if the mutant p53-PDGFRb signaling axis acts in human cancer cells, 
we analyzed PDGFRb expression levels in a panel of human pancreatic cancer cell lines. As 
in our model, PDGFRb mRNA levels were significantly higher in cells expressing mutant 
p53 compared to those in cell lines that maintained or lost the wild type p53 allele (Figure 
2.3.C). Furthermore, knockdown of mutant p53 in Miapaca2, BXPC3, CFPAC and A2.1 cell 
lines (carrying the 248W, 220C, 242R, and 155P alleles, respectively) decreased PDGFRb 
mRNA levels to varying degrees (Figure 2.3.D). Knockdown of mutant p53 also decreased 
PDGFRb expression in several human colon (SW620, p53273H/P309S), lung (H1975, p53273H), 
and breast (MDA-MB-231, p53280K) cancer cell lines (Figure S2.3.A). Thus, the ability of 
mutant p53 to induce PDGFRb levels is not strictly confined to a particular p53 allele or 
tumor type. 
 
We further analyzed the functional connection between mutant p53 and PDGFRb in 
promoting the invasiveness of human PDAC lines. Consistent with our studies in mouse 
PDAC lines, knockdown of either mutant p53 or PDGFRb reduced invasiveness of the A2.1 
pancreatic cancer cell line (Figure 2.3.E). Conversely, overexpression of PDGFRb in the 
human p53-/- ASPC pancreatic cancer cell line enhanced invasion compared to cells infected 
with a GFP control vector (Figure S2.3.B). Collectively, these results confirm that 
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Figure 2.3. Depletion of Mutant p53 in Murine and Human Pancreatic Cancer Cells Decreases PDGFRb 
Expression Levels to Enhance Cell Invasion 
(A) PDGFRa, PDGFRb and Actin levels of KPC cells infected with shRNAs targeting PDGFRa, PDGFRb or a 
nontargeting control (Ctrl) as determined by western blotting. (B) Quantification of the invasion into collagen of 
cell lines from (A), compared to KPC+sh.p53. Data presented as mean ±SD. **p < 0.005. (C) qRT-PCR for 
PDGFRb in 21 human pancreatic cancer cell lines of different p53 status. Data presented as mean normalized 
PDGFRb expression ±SD. (D) qRT-PCR for PDGFRb in the human pancreatic cancer cell lines Miapaca2, BXPC3, 
CFPAC, and A2.1 expressing sh.p53 or sh.Ctrl. Data presented as mean normalized PDGFRb expression ±SD. *p 
< 0.05, ***p < 0.001. p53 mutation of each cell line as indicated. p53 and actin levels were determined by western 
blotting (lower panel). (E) Quantification of invasion of human A2.1 cells infected with sh.PDGFRb, sh.p53 or 
sh.Ctrl (right panel). Data presented as mean ±SD. **p < 0.005, ***p < 0.001, ****p < 0.0001. Representative 3D 
reconstructions of invaded cells are shown (Left panel). 
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upregulation of PDGFRb receptor is important for the action of mutant p53 in PDAC and 
possibly other tumor types.Mutant p53 disrupts the p73/NF-Y complex to mediate PDGFRb 
expression and tumor cell invasion  
 
2.2.2. Mutant p53 disrupts the p73/NF-Y complex to mediate PDGFRb expression and 
tumor cell invasion 
Several pro-oncogenic properties of mutant p53 depend on its ability to physically interact 
with and inhibit the p53 family members, p63 and p73 (Li and Prives, 2007). Since a 
previous report indicated that p73 can repress the transcription of PDGFRB (Hackzell et al., 
2002), and because our KPC cells expressed p73 but not p63 as determined by RNA-seq 
(data not shown), we aimed to understand whether the physical interaction of mutant p53 
with p73 might impair the ability of p73 to negatively regulate the expression of PDGFRb.  
  
First, we verified the interaction between p73 and mutant p53 proteins by reciprocal 
co-immunoprecipitation (Figure 2.4.A) and, consistent with previous reports, p73 binding to 
a “conformation” p53 mutant (R175H) appeared stronger than to a “DNA-binding” p53 
mutant (R273H) (Gaiddon et al., 2001; Muller et al., 2009). Next, using a luciferase reporter 
driven from the PDGFRB promoter, we confirmed that overexpression of p73 in KPflC cells 
decreased transcriptional activity of PDGFRB and, conversely, that knockdown of 
endogenous p73 increased luciferase expression (Figures 2.4.C and S2.4.A). We also 
observed a similar increase in luciferase signal upon overexpression of two distinct forms of 
mutant p53 in KPflC cells (Figure 2.4.C) as well as a significant decrease upon depletion of 
mutant p53 or overexpression of p73 in KPC cells (Figure S2.4.C). Importantly, depletion of 
endogenous p73 in KPC cells expressing mutant p53 did not enhance the transcription of 
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PDGFRB (Figure S2.4.C), indicating that the repressing activity of p73 is regulated by its 
interaction with mutant p53. Hence, mutant p53 cancels the ability of p73 to repress 
PDGFRb transcription, leading to an increase in its expression. 
 
To better understand how p73 represses PDGFRB transcription, we performed 
chromatin immunoprecipitation (ChIP) analysis in KPflC cells but failed to detect direct 
binding of p73 to the PDGFRB promoter (data not shown), a result consistent with previous 
reports (Matys et al., 2006). Nevertheless, promoter analysis of PDGFRB (Transfec®, 
Biobase) identified a conserved CCAAT binding motif for NF-Y, a well-characterized 
heterotrimeric transcriptional activator (NF-YA, NF-YB, and NF-YC) of PDGFRB, where the 
NF-YB subunit interacts with p73 but is devoid of transcriptional activity (Ballagi et al., 
1995; Ishisaki et al., 1997; Serra et al., 1998). We verified NF-Y binding to the PDGFRB 
promoter by use of ChIP analysis (Figure 2.4.B). Remarkably, this binding was prevented by 
p73 overexpression, suggesting that the p73/NF-Y interaction hampers its ability to bind 
and activate the PDGFRB promoter (Figure 2.4.B). Indeed, when we immunoprecipitated 
p73 in KPflC cells, we detected direct binding of NF-YB to p73 (Figure 2.4.A). This 
interaction was abrogated upon expression of mutant p53, indicating that it disrupts or 
interferes with the formation of the inhibitory p73/NF-Y complex (Figure 2.4.A).  
 
Next, we tested whether the repressive action of p73 on PDGFRB transcription was 
mediated by NF-Y and modulated by mutant p53, and the implications of this regulatory 
circuit for invasion. Interestingly, the ability of p73 overexpression to inhibit the PDGFRB-
luc reporter was abolished by depletion of NF-YB (Figures 2.4.D and S2.4.B), and NF-YB 
knockdown suppressed the ability of mutant p53 to enhance PDGFRb expression in KPflC 
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Figure 2.4. Mutant p53 Sequesters p73 to Impede the Repressive Function of the p73/NF-Y Complex on the 
PDGFRB Promoter 
(A) KPflC cells stably expressing a GFP-, p53R175H-, or p53R273H vector were transfected with HA.TAp73 . Either 
p53 or HA were immunoprecipitated and the expression of HAp73α, p53, or NF-YB was determined in both the 
input (10% of lysates) and immunoprecipitation. (B) Chromatin immunoprecipitation (ChIP) using NF-YB 
antibodies in KPflC cells stably expressing sh.Ctrl, sh.NF-YB or HAp73α. Values are means ±SD. **p < 0.01. (C) 
KPflC cells stably expressing a GFP-, HAp73α-, p53R175H-, or p53R273H vector or sh.p73 (1 or 2) were co-transfected 
with the PDGFRB-promoter-luciferase construct and renilla-luciferase vector. Firefly-luciferase activity of GFP-
vector cells was set to 1. Values are relative Firefly-luciferase (Fluc) units normalized by renilla expression (Rluc) 
±SD of quadruplicate samples. **p < 0.01, ***p < 0.001. A representative result of three repeated experiments is 
shown. (D) KPflC+GFP cells as well as KPflC+HAp73α superinfected with sh.Ctrl, or sh.NF-YB (1 or 2) were co-
transfected with the PDGFRB-promoter-luciferase construct and Renilla-luciferase vector. Luciferase activity was 
measured as described above. ***p < 0.001. (E) Quantification of invasion of the same cells as in (C). Data 
presented as mean ±SD. *p < 0.05, ***p < 0.001, ****p < 0.0001. (F) Quantification of invasion of same cells as in 
(D). Data presented as mean ±SD. **p < 0.01, ****p < 0.0001.  
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cells (Figure S3D). As expected, p73 overexpression reduced the invasive potential of KPflC 
cells, whereas knockdown of p73 or overexpression of mutant p53 significantly increased 
invasiveness (Figure 2.4.E). Conversely, as occurred in mutant p53 cells following p73 
overexpression, depletion of p53 also reduced the invasive behavior in KPC cells (Figure 
S2.4.E). Finally, NF-YB knockdown restored the invasive potential of KPflC cells that 
overexpressed p73 (Figure 2.4.F) and suppressed the ability of mutant p53 to enhance cell 
invasion (Figure S2.4.F). Together these results support a model in which mutant p53 
promotes invasion in pancreatic cancer cells, in part, via an indirect mechanism that 
depends on its ability to enhance PDGFRb expression through the disruption of the 
inhibitory p73/NF-Y complex (Figure 2.5.).  
 
 
 
 
 
 
Figure 2.5. Scheme summarizing the mechanism of action of mutant p53 in promoting invasiveness 
  
 
2.2.3. Modulation of PDGFRb expression levels mediates the phenotypic effects of 
mutant p53 depletion in vivo 
Following the observation that p53 mutants induce the expression of PDGFRb to promote 
cell invasion in PDAC cultures, we investigated whether PDGFRb levels regulate metastatic 
behavior of PDAC cells in mice. To this end, we performed a lung colonization assay by 
injecting KPC+sh.p53, KPC+sh.PDGFRb, KPC+sh.PDGFRa or KPC+sh.Ctrl-cells 
intravenously via the tail vein into athymic mice and scored the number of colonies formed 
Chapter 2 
46 
 
in the lungs. We found that, whereas KPC+sh.Ctrl and KPC+sh.PDGFRa cells expressing 
mutant p53 formed tumor nodules in the lungs at high frequency, PDGFRb depletion 
significantly reduced the number of lung colonies, phenocopying the anti-metastatic effect 
observed upon knocking down mutant p53 (Figures 2.6.A and S2.5.A). However, depletion 
of PDGFRb did not affect the size of the metastatic foci, suggesting that PDGFRb does not 
alter their capacity to grow and proliferate in a new environment (Figure S2.5.B). In whole 
lung sections, GFP-positive signals coincided with metastatic nodules, indicating that 
metastases formed from cells expressing shRNAs, and likely not from the proliferation of 
tumor cells that lost shRNA expression (Figure S2.5.C). 
 
We next sought to examine whether pharmacologic inhibition of the PDGFRb 
pathway recapitulates the effects of PDGFRb or mutant p53 depletion (Figure 2.6.A and 
S2.5.A). We used the compound crenolanib, a small molecule inhibitor of type III tyrosine 
kinases, potent against PDGFRa, PDGFRb, and FLT3 but not other known receptor tyrosine 
kinases (VEGFR, FGFR), serine/threonine (RAF) or tyrosine kinases (ABL1) (Lewis et al., 
2009). We assessed the potency and efficacy of crenolanib on inhibiting the viability of 
murine KPC and human A2.1 pancreatic cancer cells and found that the dose-response 
patterns were comparable between the two cell lines, with IC50 values of 13.1 µM and 8.5 
µM, respectively (Figure 2.6.B). Strong inhibition of PDGFRb activity, as measured by 
phospho-PDGFRb, was achieved in both cell lines at 0.3 µM, a dose at which no toxicity was 
observed (Figures 2.6.C and S2.5.D). Time course experiments revealed that strong target 
inhibition was achieved within 10 min of drug treatment (Figure S4E). Accordingly, 
crenolanib treatment of KPC and A2.1 cells substantially reduced invasion relative to that 
seen with cells treated with DMSO (Figure 2.6.D).  
Chapter 2 
47 
 
 
To test whether crenolanib can suppress metastasis, KPC cells were pretreated with 
the drug overnight and injected intravenously into recipient mice that were subsequently 
assessed for colony formation in the lung. Although drug treatment had no effect on the 
viability of the injected cell population, mice injected with drug-treated KPC cells showed 
significantly fewer lung nodules compared to controls pre-treated with DMSO (Figures 
2.6.E and S2.6.A). Conversely, the same concentration of crenolanib did not reduce the 
metastatic potential of KPflC cells in a lung colonization assay, suggesting that PDGFRb acts 
autonomously in KPC cells to potentiate cell invasion and metastasis (Figure S2.6.B). Further 
supporting this notion, conditioned media from KPC cells and most human pancreatic cell 
lines tested triggered PDGFRb phosphorylation in serum-starved 3T3 cells, indicating 
pancreatic cancer cells can provide a source of PDGF ligand that could trigger autocrine 
activation of PDGFRb (Figure S4H and data not shown). Therefore, abrogation of this 
signaling by RNAi or small molecule inhibitors leads to a significant reduction of invasion 
and metastasis driven by mutant p53 in vitro and in vivo.  
 
The results described above imply that pharmacologic inhibition of PDGFRb could 
have anti-metastatic effects. We therefore sought to determine whether PDGFRb inhibition 
prevents metastasis in KPC mice that develop metastatic disease with a variable latency of 3 
to 10 months in 50 - 80% of animals (Hingorani et al., 2005). For long-term treatment of KPC 
mice, we decided to use FDA-approved imatinib, a potent inhibitor of PDGFRb, c-KIT and 
BCR-ABL activity. Notably, the c-KIT and BCR-ABL kinases have not been linked to PDAC 
development (Jones et al., 2008).  
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Figure 2.6. PDGFRb Mediates Mutant p53 Pro-Metastatic Function in vivo 
(A) Lung colonization assays after tail vein injection of KPC cells +sh.PDGFRa, +sh.PDGFRb (1 or 2), +sh.p53, or 
+sh.Ctrl. Total number of lung metastatic nodules in individual mice (n>6) was counted on serial histological 
sections (left panel). Data presented as mean ±SD. **p < 0.01, ****p < 0.0001. Representative merged 
brightfield/GFP images of whole lung from indicated mice (right panel). (B) MTS assay (E490) of murine KPC 
and human A2.1 cells treated with crenolanib with various doses for 72 h. Normalized values presented as mean 
±SD form quadruple replicates. (C) Immunoprecipitation of PDGFRb from KPC cells stimulated with 50 ng/ml 
PDGF-BB, after crenolanib or DMSO treatment for 4 h. Protein levels of PDGFRb, phospho-Tyrosine and Tubulin 
were determined by western blotting. (D) Quantification of invasion of murine KPC and human A2.1 treated 
with either DMSO or crenolanib at 300 nM (left panel). Data presented as mean ±SD. **p < 0.01, ***p < 0.001. 
Representative 3D reconstructions of invaded cells are shown (right panel). (E) Lung colonization assays after 
tail vein injection of crenolanib (300 nM)- or DMSO-treated KPC cells. Representative merged brightfield/GFP 
imaged of whole lung as well as H&E stains of pulmonary lobes are shown (left panel). Quantification of total 
number of lung metastatic nodules in individual mice (n > 6) (right panel).   
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Inhibition of PDGFRb by imatinib in KPC cells strongly reduced PDGFRb tyrosine 
phosphorylation at 3 uM (Figure 2.7.A), a dose of the drug that is significantly lower than 
that required to inhibit cell proliferation (IC50 of 29.7 µM) (Figure S5A). Nonetheless, 
imatinib treatment significantly reduced the invasive potential of KPC cells in vitro (Figure 
S5B). More importantly, pre-treatment of KPC cells with imatinib decreased their potential 
to colonize the lungs of recipient athymic mice to a similar extent as that seen upon 
crenolanib treatment (Figure 2.7.B).  
 
We next treated KPC mice with imatinib to assess its effects on metastasis. To this 
end, mice were treated with a dose of 50 mg/kg imatinib by oral gavage twice daily, a 
regimen previously shown to produce therapeutic concentrations of imatinib in mice (Wolff 
et al., 2003). Treatment was initiated in mice of 8 weeks of age, a time at which KPC mice 
have developed preneoplastic lesions (Hingorani et al., 2005), and mice were monitored 
until they became symptomatic. Imatinib had no impact on tumor volume in the pancreas or 
overall survival, suggesting that the high disease burden in the pancreas was the primary 
cause of death (Figures 2.7.C and S5C). 
 
However, Imatinib induced a striking reduction in the occurrence of metastasis. The 
incidence of metastasis was 92% in vehicle-treated animals compared to 15% in mice treated 
with imatinib, as assessed by macroscopic examination and confirmed by histopathological 
analyses (χ2 test, p<0.0001) (Figures 2.7.D and S5D). The anti-metastatic effect was observed 
across several organs such as liver, peritoneum and lung (Figures 2.7.E and 2.7.F). As 
expected, imatinib was able to effectively inhibit PDGFRb activity in primary tumors based 
on reduced levels of phospho-PDGFRb in the tumor cells (Figures 2.7.G and S5E). Together, 
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Figure 2.7. Imatinib Reduces the Incidence of Metastasis in KPC Mice Through PDGFRb Inhibition 
(A) Immunoprecipitation of PDGFRb from KPC cells stimulated with 50 ng/ml PDGF-BB, after imatinib or 
DMSO treatment for 4 h. Protein levels of PDGFRb, phospho-Tyrosine and Tubulin were determined by western 
blotting. (B) Lung colonization assays after tail vein injection of imatinib (3 μM)- or DMSO-treated KPC cells. 
Representative merged brightfield/GFP imaged of whole lung as well as H&E stains of pulmonary lobes are 
shown. Arrows indicate metastases (left panel). Quantification of total number of lung metastatic nodules in 
individual mice (n > 5) (right panel). Data presented as mean ±SD. **p < 0.01. Scale bars represent 100 μm. (C) 
Weight of pancreatic tumors of KPC mice treated with vehicle or imatinib at time of death. (D) Quantification of 
the number of mice with metastatic disease at the time of death. Values are percentages of the total number of 
mice in each cohort. Colored columns represent mice with metastases (METS) and white columns represent 
disease-free (DF) animals. (E) Quantification of the number of mice with lung, peritoneal (Peri.) or liver 
metastatic disease at the time of death. Values are percentages of the total number of mice in each cohort. (F) 
Representative H&E stains of harvested organs (primary tumor, lung, liver, peritoneal tissue) from vehicle and 
imatinib-treated animals. (G) Representative immunofluorescence images of pancreatic tumors of vehicle- or 
imatinib-treated KPC mice. DAPI, blue; CK8, red; and pPDGFRb, green. Scale bars represent 100 μm.  
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these data suggest that by inhibiting the kinase activity of PDGFRb, imatinib significantly 
diminishes the metastatic potential of pancreatic cancer cells.  
 
2.2.4. PDGFRb Expression Correlates with Disease Free-Survival in Human Pancreatic, 
Colorectal, and Ovarian Cancer Patients 
To investigate the clinical significance of PDGFRb expression, we examined whether 
upregulation of this gene is correlated with prognosis or with the clinicopathological 
characteristics of PDACs in patients. To avoid confounding signals from the tumor stroma, 
PDGFRb mRNA levels were assessed in tumor samples with high purity score. Strikingly, 
we observed that pancreatic cancer patients with tumors expressing high levels of PDGFRb 
showed a poor disease-free survival and, hence, shorter time to relapse including metastases 
in distant organs (p=0.019) (Figure 7A). Additionally, PDGFRb expression levels were 
significantly elevated in late-stage PDAC as compared to the earlier stages (Figure 7B). 
Patients with high PDGFRb levels also displayed an increase in tumor cells invading the 
vascular space, another clinicopathological characteristic of tumor dissemination (Figure 
7C).  
 
Next, we tested whether PDGFRb levels correlate with the status of p53 by analyzing 
a panel of PDAC tissue microarrays (TMAs). Of importance, we observed significantly 
higher levels of activated PDGFRb in those tumors that showed an accumulation of p53 
(p=0.009), which generally represents tumors with p53 mutation (Cooks et al., 2013) (Figures 
7D and S6A). These data confirmed results obtained with mice and underscore a role of 
mutant p53 in regulating the PDGFRb signaling in human pancreatic cancer.   
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Figure 2.8. High PDGFRb Expression in Human Pancreatic and Colorectal Cancer Correlates with Reduced 
Metastases Free Survival 
(A) Kaplan-Meier survival curves of 103 pancreatic cancer patients (clinical variable = DFS) as a function of 
PDGFRb-high versus PDGFRb-low expressing tumors. (B) Box plot of PDGFRb expression versus tumor grade 
of pancreatic tumors. (C) Clinicopathologic analysis of vascular space invasion of pancreatic cancer patients 
stratified by the expression levels of PDGFRb in the primary tumor. (D) Stratification of human PDAC samples 
(n = 961) based on high and low pPDGFRb and p53 expression levels. Chi-Square test was performed (p = 0.009). 
p53 and pPDGFRb levels were assessed by IHC and scored using a relative scale from 0 to 3. (E) Kaplan-Meier 
survival curves of colorectal cancer patients (clinical variable = DFS) as a function of PDGFRb-high versus 
PDGFRb-low expressing tumors. (F) Box plot of PDGFRb expression versus tumor grade of colon tumors. 
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Other tumor types for which p53 mutations are predictive of metastatic disease are 
colorectal and ovarian cancer (Russo et al., 2005; Levesque et al., 1995). Thus, we analyzed 
the clinical significance of PDGFRb in these cancer types and found that levels of PDGFRb 
significantly stratified colorectal and ovarian tumor patients into two distinct cohorts. 
Patients with tumors expressing low PDGFRb levels exhibit a lower probability to form 
metastases compared to patients with PDGFRb high-expressing tumors (p=0.003 and 
p<0.0001) (Figures 7E and S6C). As in PDAC, a significant increase in PDGFRb expression 
was observed in higher stage colorectal cancers (Figure 7F). In addition to PDGFRb, our 
mutant p53 gene signature significantly scored as a prognostic marker in colorectal and 
ovarian tumor patients (top 40 genes upregulated in KPC cells; Figure 2C and Table S1). 
When we analyzed the three genes that scored in our invasion assay screen, we found that 
the PDGFRB gene was the strongest predictor for the probability to develop metastasis in 
colorectal and ovarian cancer patients (Figures S6B and S6C). In summary, consistent with 
our functional studies, elevated PDGFRb expression correlated significantly with the status 
of p53, higher tumor stage, and a poorer disease-free survival rate in pancreatic, colorectal 
and ovarian cancer patients.  
 
 
2.3. Discussion 
Mutations that occur in the p53 tumor suppressor inactivate wild-type p53 functions but can 
also produce “gain-of-function” oncogenic properties that can contribute to cell 
proliferation, survival and metastasis. Here, we explored the phenotypic effects of mutant 
p53 in pancreatic cancer and showed that the sustained expression of the mutant p53 allele 
is necessary to maintain the invasive phenotype of PDAC cells by increasing the expression 
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of PDGFRb. These results have several ramifications for our understanding of mutant p53 
action as well as the behavior and potential treatment of pancreatic cancer. 
 
Signaling through PDGFRb contributes to multiple tumor‐associated processes 
including cell invasion and metastasis. Given the generally restricted expression of PDGFRb 
to mesenchymal cell types, most of its oncogenic properties are thought to reflect paracrine 
effects of tumor cell-secreted PDGF. Indeed, previous work on the role of PDGFRb in 
carcinoma progression and metastasis suggest that it mainly elicits responses in the tumor 
stroma by promoting tumor angiogenesis (Pietras et al., 2003; Cao et al., 2004). In contrast, 
our study provides new evidence for tumor cell-specific expression of PDGFRb in 
promoting metastasis. We show that genetic or pharmacological inhibition of PDGFRb in 
the pancreatic cancer cells themselves dramatically reduces their invasive and metastatic 
potential, and that treatment of mice harboring genetic and histologically relevant tumors 
prevents metastatic spread in vivo. Together, our data indicate that pancreatic tumor cells 
expressing mutant p53 not only synthesize PDGF but also up-regulate PDGFRb, leading to a 
tumor autocrine, cell-autonomous effect. 
 
 The ability of the PDGF signaling axis to induce migration occurs also in wound 
repair, where fibroblasts respond to PDGF released from platelets (Seppä et al., 1982). When 
platelets aggregate early in clot formation they release PDGF, inducing the recruitment of 
fibroblasts into the wound. Here, PDGF-A has a more prominent role during early stages of 
healing whereas the expression of PDGFRb appears later in the wounded epithelium, 
indicating that PDGF-B regulates later wound healing events (Green et el., 1997). In addition 
to the induced migratory phenotype, mitogenic activity of PDGF also causes a rapid 
Chapter 2 
55 
 
proliferation of fibroblasts and the synthesis of constituents of the extracellular matrix of 
connective tissue to repair the wound. Inappropriate responses lead to fibrosis.  
 
Though increases in PDGFRb expression were necessary and sufficient to mediate 
mutant p53 effects in our model, we identified at least two additional genes (SNED1 and 
SLC40A1) that also contribute to the invasive phenotype through as yet unknown 
mechanisms. Studies in other systems, primarily breast cancer, have suggested that CXCR4, 
cyclin-G2, and the mevalonate pathway are important mediators of the pro-metastatic 
activities of mutant p53 (Mehta et al., 2007; Adorno et al., 2009; Freed-Pastor et al., 2012). In 
addition, mutant p53 has also been reported to drive invasion by regulating several 
miRNAs such as miR155 and miR130b (Neilsen et al., 2013; Dong et al., 2013). In agreement, 
we found that miR155 is positively regulated by mutant p53 in KPC cells and can promote 
metastasis in our model (data not shown); however, in contrast to a previous report (Su et 
al., 2010), no effects on Dicer expression were observed, arguing that in pancreatic cancer 
the mutant p53-associated changes in microRNA expression and metastasis are Dicer 
independent. Additionally, miR34a expression levels were not dependent on p53 status in 
our system (data not shown), even though this miRNA acts as negative regulator of 
PDGFRb in lung cancer (Garofalo at al., 2013). Regardless, as for wild type p53, mutant p53 
exerts effects through the regulation of multiple genes rather than by modulating a single 
signaling pathway. 
 
Most of our understanding of how mutant p53 mediates its oncogenic activity has 
been derived from exploring the consequences of the physical interaction between the 
mutant protein and the p53 family members, p63 and p73. Whereas the mutant p53-p63 
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interaction modulates the expression of p63 target genes to enhance invasion and metastasis 
(Adorno et al., 2009; Muller et al., 2009), how p53-p73 interactions produce similar outcomes 
is poorly understood. Here, we show that mutant p53 enhances pancreatic cancer cell 
metastasis by modulating p73 and its interaction with the transcriptional activator NF-Y. 
This model is consistent with previous studies showing that: (1) loss of p73 in a p53-null 
background might be functionally equivalent to the expression of mutant p53 (Lang et al., 
2004); (2) aberrant transcriptional regulation by mutant p53 is mediated through the 
transcriptional activator NF-Y (Di Agostino et al., 2006); and (3) mutant p53 promotes 
recycling of receptor tyrosine kinases to initiate invasion (Muller et al., 2009). Whether 
structurally distinct p53 mutants enhance metastasis to the same extent and through the 
same mechanism remains unclear, and certainly most truncating mutants arising from the 
nonsense mutations occurring in a fraction of pancreas cancers are predicted to behave as if 
p53 null. Still, in our study both conformational (e.g. R175H) and structural mutants (e.g. 
R273H) were capable of inducing PDGFRB through a similar mechanism. 
 
Questions remain as to how the mutant p53/p73/NF-Y regulatory axis acts 
mechanistically. For instance, it remains unclear whether p73 acts to suppress the 
transactivation capacity of NF-Y or whether it sequesters the activator and prevents its 
binding to the PDGFRB promoter. Even though our results indicate that p73 overexpression 
hampers the ability of NF-Y to bind to the PDGFRB promoter, further studies will be 
required to distinguish between mechanisms. In addition, we noted slightly stronger 
induction of PDGFRB transcription as well as higher levels of invasion upon overexpression 
of mutant p53 compared to depletion of p73, indicating that mutant p53 may exert 
additional regulatory effects on PDGFRb expression. Although studies suggest that mutant 
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p53 can directly bind to NF-Y to regulate its transcriptional activity (Di Agostino et al., 
2006), we failed to observe any physical interaction between mutant p53 and NF-Y in our 
cells. The discrepancy could reflect different extraction conditions or biological settings, 
since the mutant p53/NF-Y interaction has been shown to occur upon DNA damage (Liu et 
al., 2011). 
  
Mutations in KRAS, p53, CDKN2A, BRCA2 and SMAD4 define the genetic landscape 
of PDAC; however, it remains unclear how each mutation contributes to the malignant 
evolution of this aggressive disease. We present evidence for a crucial role of mutant p53 in 
metastasis formation, which supports the attractive concept of targeting its gain-of-function 
activities to limit cancer cell dissemination and metastasis. However, mutant p53 is neither a 
targetable cell surface protein nor a druggable enzyme (Levine and Oren, 2009), and novel 
therapeutic modalities such as RNAi or restoring wild type p53 conformations have yet to 
show efficacy in clinical studies (Lehmann and Pietenpol, 2012). Hence, targeting 
downstream pathways or genes that mediate the activity of mutant p53, such as PDGFRb, 
pose an alternative treatment strategy.  
 
Owing to the early metastatic spread of pancreatic cancer, widespread use of 
PDGFRb inhibitors might require advances in early detection or combination with other 
therapies. Nonetheless, our study suggests that PDGFRb inhibition might prove 
immediately useful in pancreatic patients harboring p53 missense mutations either before 
(neoadjuvant) or after surgical resection (adjuvant) of localized disease (10-15% of PDAC 
cases), in patients with locally advanced inoperable non-metastatic disease (~30% of PDAC 
cases), or as a preventative approach in patients with familial predisposition to cancer 
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development. Moreover, PDGFRb inhibition as a therapeutic approach could be extended to 
other metastatic cancer types, e.g. colorectal, where the disease is often diagnosed before 
tumor cell dissemination. 
 
High levels of PDGFRb expression have recently been associated with tumor 
recurrence in primary colorectal cancer, another gastrointestinal tumor in which p53 is 
frequently mutated (Stellar et al., 2013). Accordingly, we noted correlations between 
elevated PDGFRb levels, more advanced tumor stage, and poorer disease-free survival in 
pancreatic as well as colorectal and ovarian cancer patients. These results indicate that 
PDGFRb levels might be used as a prognostic biomarker for cancer progression, and 
eventually used in conjunction with p53 to identify patient cohorts most likely to respond to 
therapies targeting this axis. Although further studies will be required to explore this 
notion, pharmacological inhibition of PDGFRb with the tyrosine kinase inhibitor imatinib, 
in combination with standard chemotherapy, has shown promise in treating metastatic 
colorectal cancer patients (Hoehler et al., 2013). 
 
In summary, we describe a gain-of-function activity of mutant p53 that promotes 
invasion and metastasis through increasing PDGFRB transcription and reverting the 
repressive function of the p73/NF-Y complex. While other activities of mutant p53 on cell 
behavior and survival exist (Freed-Pastor and Prives, 2012), our study provides a detailed 
molecular understanding of at least one aspect of the invasive behavior of cells expressing 
mutant p53, and offers a potential new target for therapy that might interfere with this 
activity. 
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2.6. Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suppl. Figure 2.1. Knockdown of Mutant p53 in Pancreatic Cancer Cells Alters a Myriad of Genes and 
Pathways 
(A) Heatmap of significantly changed genes (padj < 0.05) following mutant p53 depletion, as identified by RNA 
sequencing. Three individual clonal cell lines of KPC+sh.p53 and +sh.Ctrl were analyzed and representative top 
scoring genes are labeled. (B) Western blotting analysis of activated downstream PDGF receptor b pathways 
following knockdown of mutant p53 in KPC cells. Actin expression was used as loading control. (C) Blue bars 
that cross the threshold line (p < 0.05) represent top scoring pathways that are significantly changed in mutant 
p53-depleted KPC cells. Data was analyzed through the use of ingenuity pathway analysis. 
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Suppl. Figure 2.2. PDGFRb Expression Levels Determine the Invasive Ability of Murine and Human Cancer 
Cells without affecting cell proliferation 
(A) Western blotting analysis of PDGFRb, p53, and actin from KPflC cells stably expressing a GFP-, p53R175H-, 
p53R273H-, or PDGFRb-cDNA vector (upper panel). Quantification of invasion into collagen from the same cells 
(lower panel). The average of invaded cells from 9 replicates ±SD is shown. **p < 0.01, ****p < 0.0001. (B) Cell 
number over time (days) of KPC cells stably expressing sh.Ctrl or sh.PDGFRb (1 or 2). (C) Negative selection 
RNAi studies in KPC cells stably expressing dox-inducible sh.Ctrl, sh.RPA3 or sh.PDGFRb (1 or 2) using the tet-
on TRMPV system. Graphs represent the percentage of shRNA-expressing (Venus+ dsRed+) cells over time 
(days), normalized to initial measurement 1 d after dox treatment. (D) Schematic of dual-color competitive 
proliferation assay in vivo for evaluating effects of RNAi-mediated PDGFRb suppression in tumor growth. KPC 
cells were transduced with indicated experimental shRNAs (GFP+) and a neutral control shRNA (dsRED+) (left 
panel). Percentage of cells expressing indicated experimental shRNA (GFP+) or the neutral control shRNA 
(dsRED+) in pre-injected cells and tumors 2 weeks after injection. Values represent the mean of multiple pre-
injected or tumor-derived cell lines (right panel). 
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Suppl. Figure 2.3. PDGFRb Expression Levels of Different Human Cancer Cells Depend on the p53 Status 
(A) Western blotting analysis of PDGFRb, p53, and actin levels in human pancreatic, colon, lung, and breast 
cancer cells stably expressing sh.Ctrl or sh.p53 (1 or 2). Mutation of p53 as indicated. (B) Quantification of the 
invasion into collagen of human p53-/- ASPC pancreatic cancer cells stably expressing a GFP- or PDGFRb-cDNA 
vector. The average of invaded cells from 9 replicates ±SD is shown. ***p < 0.001. 
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Suppl. Figure 2.4. Mutant p53 Drives PDGFRB Transcription by Opposing the Repressive Function of the 
p73/NF-Y Complex 
(A) qRT-PCR for p73 in KPC+sh.p73 (1 or 2) or +sh.Ctrl cells. Data present mean normalized p73 expression ±SD 
of triplicate samples. A representative result of three repeated experiments is shown. *p < 0.05. (B) NF-YB and 
actin levels of KPflC cells infected with sh.NF-YB or sh.Ctrl as determined by western blotting. (C) After double 
infection using an empty control or HAp73α vector together with sh.Ctrl, sh.p53, or sh.p73, KPC cells were co-
transfected with the PDGFRB-promoter-luciferase construct and renilla-luciferase vector. Firefly-luciferase 
activity of GFP-vector cells was set to 1. Values are relative Firefly-luciferase (Fluc) units normalized by renilla 
expression (Rluc) ±SD of quadruplicate samples. **p < 0.01, ****p < 0.0001. A representative result of three 
repeated experiments is shown. (D) KPflC cells stably expressing sh.Ctrl or sh.NF-YB together with mutant p53 
(175H or 273H) were co-transfected with the PDGFRB-promoter-luciferase construct and Renilla-luciferase 
vector. Luciferase activity was measured as described above. ****p < 0.0001. (E) Quantification of invasion of the 
same cells as in (C). The average of invaded cells from 9 replicates ±SD is shown. A representative result of three 
repeated experiments is shown. *p < 0.05, **p < 0.01. (F). Quantification of invasion of the same cells as in (D). 
The average of invaded cells from 9 replicates ±SD is shown. A representative result of three repeated 
experiments is shown. *p < 0.05, **p < 0.01, ****p < 0.0001.  
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Suppl. Figure 2.5. Inhibition of PDGFRb Activity by RNAi or Small Molecules Decreases Metastatic 
Potential of Pancreatic Cancer Cells 
(A) Lung colonization assays after tail vein injection of PDGFRa-, PDGFRb (1 or 2)-, p53-, and control-depleted 
KPC cells. Hematoxylin and eosin (H&E) stains of representative sections of pulmonary lobes from indicated 
mice are shown, arrows indicate metastases. Scale bars represent 50 μm. (B) Relative nodule size of lung 
metastases from mice intravenously injected with PDGFRb (1 or 2)-, and control-depleted KPC cells. Data 
represent mean ±SD. (C) GPF immunohistochemistry on histological lung sections from lung colonization assay 
in (B). shRNA expression correlates with GFP signal, as the fluorescent marker is linked to the hairpin. Scale bars 
represent 1000 μm. (D) Western blotting for pPDGFRb, PDGFRb, and actin in human A2.1 cells after treatment 
with DMSO or crenolanib at varying doses. (E) Immunoprecipitation of PDGFRb from KPC cells treated with 
DMSO or crenolanib (300 nM) for different time periods. The input protein levels for PDGFRb, phospho-
Tyrosine, and actin and those present in immunoprecipitates for phospho-Tyrosine were determined by western 
blotting. (F) Propidium Iodide staining of KPC cells treated overnight with either DMSO, Crenolanib (0.3 (Creno 
Low) or 25 µM (Creno High)) or imatinib (3 µM).. 
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Suppl. Figure 2.6. PDGFRb acts autonomously in KPC cells to potentiate cell invasion and metastasis 
(A) Lung colonization assays after tail vein injection of crenolanib- or DMSO-treated KPflC cells. Representative 
merged brightfield/GFP images of whole lung as well as H&E stains of representative sections of pulmonary 
lobes are shown. Quantification of total number of lung metastatic nodules in individual mice (n > 6) (lower 
panel). Data presented as mean ±SD. Scale bars represent 100 μm. (B) Western blotting for pPDGFRb, PDGFRb, 
and tubulin of starved 3T3 cells, which were pre-treated with either DMSO or Imatinib (3 µM) for 4 h and 
subsequently stimulated for 15 min with conditioned media from KPC (sh.Ctrl or sh.p53) or 50 ng/µl PDGF-BB 
(left panel). Western blotting for p53 and tubulin of KPC+sh.Ctrl and +sh.p53 (right panel) 
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Suppl. Figure 2.7. Imatinib Reduces Invasiveness of KPC Cells and Metastases Formation in KPC Mice 
(A) MTS assay (E490) of KPC cells treated with imatinib with various doses for 72 h. Normalized values are 
expressed as means ±SD form quadruple replicates. (B) Quantification of invasion of KPC cells treated with 
either DMSO or imatinib at 3 μM. The average of invaded cells from 9 replicates ±SD is shown. A representative 
result of three repeated experiments is shown. ***p < 0.001. (C) Kaplan–Meier survival curves of mice treated 
with vehicle or imatinib (50 mg/kg) from 8 weeks of age. (D) Representative bright field images of pancreatic 
tumor, liver, lung and peritoneum from KPC mice treated with vehicle or imatinib. Black arrows denote 
metastases. (E) Quantification of pPDGFRb intensity in pancreatic tumors of KPC mice treated with vehicle or 
imatinib. pPDGFRb was assessed by immunofluorescence and its intensity scored from 0 (pPDGFRb low levels) 
to 3 (pPDGFRb high levels). 15 images per tumor from 7 mice per group were analyzed. 
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Suppl. Figure 2.8. Metastasis free survival of Colorectal and Ovarian Cancer Patients is Dictated by Mutant 
p53-regulated Genes 
(A) pPDGFRb levels in human PDAC samples (n = 961) stratified by p53 (left panel). Levels of pPDGFRb and 
p53 were determined by IHC and representative images are shown (right panel). **p < 0.01. Scale bars represent 
100 μm. (B) Kaplan-Meier survival curves of colorectal cancer patients (clinical variable = DFS) as a function of 
the expression levels of the 40 genes from the mutant p53 gene signature, PDGFRb, SLC40A1, and SNED1. (C) 
Kaplan-Meier survival curves of ovarian cancer patients (clinical variable = DFS). Patients were stratified as in 
(B).  
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3. Chapter 3 
Distinct miRNA signature of invasive pancreatic cancer 
 
 
3.1. Introduction 
Pancreatic cancer remains one of the leading causes of cancer deaths and has a 5-year 
survival rate of less than 5%. Given its resistance to both radiation and chemotherapy, 
surgical resection is the only curative treatment option to date. However, the number of 
patients that are eligible for curative surgery is limited due to the late stage detection of this 
disease. Moreover, front-line treatment options for advanced pancreatic cancer are not 
effective and prolong survival only by a few weeks. Thus, further studies of the molecular 
mechanisms underlying the aggressive nature of this disease are needed. These 
investigations might lead to the identification of biomarkers for early detection of pancreatic 
cancer as well as new therapeutic targets for the treatment of late stages of this disease. 
 
microRNAs (miRNAs or miRs) are small, non-coding RNA molecules of 22 
nucleotides in length, which regulate gene expression in a post-transcriptional manner. 
miRNAs coding sequences can appear as single genes or as polycistronic primary 
transcripts that are processed into multiple individual mature miRNAs (Mendell, 2008). The 
genomic organization of the miRNA clusters is often highly conserved; however, the role of 
the coordinated regulation and function remains unclear. The biogenesis of miRNA is a 
well-characterized biological process that has been studied in detail in the past few years. 
During the miRNA maturation process, the long pri-miRNA transcript that contains stem-
loop hairpin structures is processed by Drosha and Dicer to yield the mature miRNA 
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duplex. One strand of the mature duplex is then incorporated into the RISC complex, the 
effector machinery that mediates post-transcriptional silencing of target genes. The RISC 
complex containing a guide miRNA strand bind together to the 3’-untranslated region of 
messenger RNAs (mRNAs) and initiate degradation or inhibition of translation of their 
target mRNA, resulting in attenuated protein levels. miRNAs recognize their targets 
through imperfect sequence complementarity, which allows each of them to potentially 
regulate a large number of protein coding genes. More than 1,400 miRNAs, identified so far, 
have been defined to exhibit functional roles in widespread cellular processes, including 
proliferation, differentiation and development.  
 
Deregulated miRNA expression is a characteristic of human diseases, including 
cancer. miRNAs can serve as cancer biomarkers (Wang et al., 2014), and are implicated in 
the tumor development and maintenance (Szafranska et al., 2007). miRNA activity can be 
perturbed at different levels, including genetic alteration, transcriptional regulation, 
posttranscriptional modification and processing steps during miRNA biogenesis. Altered 
control of any of these steps provokes abnormal miRNA profiles that can lead to the 
aberrant expression of cancer genes (Esquela-Kerscher and Slack, 2006) or interfere with the 
molecular crosstalk within well-characterized cancer pathways (Olive et al., 2010). Examples 
for the former include the “oncomiR”-21 whose expression is enhanced in cancers, resulting 
in the downregulation of tumor suppressor genes, such as Pten and Bcl2, to induce 
proliferation and attenuate apoptosis. On the other hand, the tumor suppressor let-7 and its 
repressive function on the oncogenes RAS and HMGA2 are diminished in many cancers 
(Kong et al, 2012). Finally, a candidate miRNA that has emerged as a key component of the 
p53 tumor suppressor network is mir-34, the first identified miRNA to be transcriptionally 
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regulated by p53. miR-34 mediates the tumor suppressor effects of p53 and, when 
deregulated, confers resistance to apoptosis in cancer cells (He et al., 2007).  
 
Pancreatic ductal adenocarcinoma is a highly aggressive disease characterized by 
extensive invasion into the surrounding tissues and metastasis to distant organs during 
disease progression. Because miRNAs regulate important cancer genes and tumor networks, 
it is very likely that they are involved in tumor invasion, functioning as either metastasis 
suppressors or –mediators. Indeed, several miRNAs have been directly or indirectly linked 
to invasion and metastasis in different tumor types. While the tumor suppressor miR-124 
represses the invasive capabilities of pancreatic cancer cells through the inactivation of the 
Rho GTPase RAC1 (Wang et al., 2014), the oncogenic miR-155 acts as a metastasis mediator 
in breast cancer through the regulation of the TGFβ response in the epithelial-mesenchymal 
transition (Johansson et al., 2013). Together, miRNAs can modulate the metastatic 
phenotype of human cancers through the regulation of oncogenic and tumor suppressive 
networks.  
 
 Many metastatic cancers acquire mutations in the tumor suppressor p53, which can 
gain neomorphic functions to promote tumorigenesis. As discussed in Chapter 2, mutant 
p53 drives the invasive phenotype of pancreatic cancer cells via upregulation of PDGFRb. 
However, there are additional mechanisms by which mutant p53 exerts its gain of function 
such as the regulation of miRNA expression in cancer cells. On the one hand, it was 
reported that Dicer and global miRNA levels become attenuated by mutant p53 to increase 
invasion through enhanced recycling and activation of the growth factor receptors MET and 
EGFR (Muller et al., 2014). On the other hand, it was shown that mutant p53 drives the 
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expression of only miR-155 through a p63-dependent mechanism in breast cancer cells 
(Neilsen et al., 2013). Therefore, although the role of mutant p53 in modulating miRNAs to 
mediate oncogenesis has be revealed, whether mutant p53 alters the entire miRNA 
biogenesis pathway and/or impinges on distinct miRNAs are open questions. 
 
One of the most relevant gene networks in human cancer is the mitogen-activated 
protein kinase (MAPK) signal transduction pathway. The MAPK pathway is evolutionarily 
conserved and plays a key role in a myriad of biological processes, such as cell growth, 
differentiation, and apoptosis. MKK4, a modulator of the MAPK pathway, is a dual-specific 
tyrosine and serine/threonine protein kinase that activates both p38 and JNK in response to 
stress signals. MKK4 plays a role in suppressing prostate, ovarian, and liver cancer 
metastasis, and its decreased activation correlates with increased cell motility and 
invasiveness (Kim et al., 2001; Yamada et al., 2002; Tsai et al., 2014). How MKK4 mediates 
invasiveness seems to be cell type-specific and might involve JNK or NF-κB (Kim et al., 
2001; Tsai et al., 2014). However, how activated MKK4 levels become downregulated and 
whether miRNAs are involved in fine-tuning the complex MAPK cascade to induce an 
invasive phenotype remains elusive.  
 
In Chapter 3, we aim to explore whether the mutant p53-dependent miRNA 
signature contributes to cell invasion and metastasis in pancreatic cancer. RNA sequencing 
of miRNAs in pancreatic cancer cells expressing mutant p53 and a subsequent RNAi screen, 
identified miR-155 and miR-181b as mediators of mutant p53 that drive invasion. Moreover, 
we found that both miRNAs execute their oncogenic potential via the MAPK pathway, by 
decreasing the levels of activated MKK4. Our data suggest that mutant p53 drives invasion 
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through several mechanisms, including the regulation of miRNAs and their targets. This 
observation opens the question whether inhibition of one downstream effectors of mutant-
p53 are sufficient to effectively inhibit its gain of function. 
 
 
3.2. Results 
3.2.1. Mutant p53 regulates a distinct miRNA signature in pancreatic cancer 
To study whether mutant p53 regulates the miRNA profile in pancreatic cancer, we utilized 
pancreatic cancer cell lines isolated from tumors of genetically engineered KPC or KPflC 
mice. Both strains harbor a Cre-responsive, latent oncogenic Kras allele (lox-stop-lox KrasG12D), 
together with either a latent mutant p53R172H/wt knock in allele or a floxed p53fl/wt allele, and a 
tissue-specific Cre recombinase (Pdx1-Cre) (Morton et al., 2010). Pancreas-specific activation 
of Kras occurs in both strains, whereas the KPC strain expresses mutant p53, while KPflC 
cells lose p53 function. Importantly, the p53 status of these cells could be manipulated by 
retroviral transduction to either mediate knockdown of mutant p53 in KPC cells or to 
restore different mutant forms of p53 in KPflC cells. As described in the previous chapter, 
mutant p53 contributes to PDAC invasion and metastasis by modulating the expression of 
several genes. Accordingly, inhibition of the activity of mutant p53 or its downstream 
mediator PDGFRb had an anti-metastatic effect. Does mutant p53 also modulate the 
expression of miRNAs to influence the invasive phenotype of pancreatic cancer cells? 
 
To study whether miRNA networks are perturbed in pancreatic cancer cells, we 
performed small-RNA profiling of KPC cells to identify those miRNAs that are specifically 
regulated by mutant p53. Therefore, we infected KPC cells with retroviral vectors encoding 
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validated shRNAs directed to p53 (sh.p53) or control gene (sh.Ctrl). Four days following 
knockdown of mutant p53 in three independent clonal KPC populations, we conducted 
deep sequencing of RNAs of < 200 nt in size. Interestingly, we observed distinct miRNA 
expression changes in experimental versus control cells, rather than a global alteration of the 
miRNA signature. More specifically, we identified 9 and 7 miRNAs as significantly up- and 
down regulated, respectively, upon shRNA-mediated depletion of endogenous mutant p53, 
respectively (Table 3.1. and Figure 3.1.A).  
 
 Table 3.1. miRNAs expression changes in mutant-p53 expressing KPC cells compared to p53 knock down 
 
Mutant p53 can promote invasion and metastasis through a global reduction of 
miRNA levels mediated by downregulation of Dicer expression (Muller et al., 2014). 
However, our study revealed that the regulation of miRNAs by mutant p53 is Dicer-
independent in pancreatic cancer. First, as measured by western blotting and long RNA seq 
profiling (Figure 3.1.B), we did not observe downregulation of Dicer protein or mRNA 
transcript levels in response to mutant p53. Second, if Dicer levels were downregulated by 
mutant p53, we would have expected an accumulation of pri-miRNAs due to a failure in its 
maturation. However, we did not observe global alterations of pri-miRNAs in pancreatic  
UP DOWN 
miRNA Fold change miRNA Fold change 
miR-195 9.59 miR-1965 0.23 
miR-148a 6.35 miR-147 0.38 
miR-10b 5.40 miR-221 0.38 
miR-138 3.07 miR-3096 0.46 
miR-139 2.82 miR-222 0.46 
miR-187 2.41 miR-188 0.51 
miR-1306 2.21 miR-22 0.55 
miR-155 1.79   
miR-181b 1.68   
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Figure 3.1. Mutant p53 regulates a distinct miRNA signature in a Dicer-independent way 
(A) Bubble plot depicting the relative abundance and log2 ratio of miRNAs in KPC+sh.Ctrl relative to 
KPC+sh.p53 cells. (B) Protein and mRNA levels for Dicer in KPC+sh.Ctrl or +sh.p53. (C and D) Fold change 
expression levels of pri- and mature miRNA of KPC cells expressing mutant p53 compared to knock down. 
miRNA that are upregulated shown in (C) and downregulated shown in (D).  
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cancer cells expressing a mutant form of p53. Moreover, the same changes in pri-miRNAs 
were detected for mature miRNAs upon knockdown of mutant p53 (Figures 3.1C and 
3.1.D). Third, previous studies in human non-small cell lung carcinoma cell lines reported 
that, by interacting with p63, mutant p53 to activates transcription of Dicer (Muller et al., 
2014). Unlike these studies, we could not detect p63 expression in our pancreatic cancer 
system (described in Chapter 2) as analyzed by long RNAseq or western blotting. Hence, 
the underlying molecular mechanism whereby mutant p53 controls the expression of 
miRNAs seems to vary in different cell types and need not be linked to mechanisms that 
involve the regulation of Dicer expression levels. 
 
 
3.2.2. miR-155 and miR-181b are downstream mediators of pancreatic cancer invasion 
driven by mutant p53 
To elucidate whether miRNAs regulated by mutant p53 mediate the invasive and metastatic 
properties of pancreatic cancer, we screened each miRNA that was significantly altered 
upon knock down of mutant p53 (Figures 3.1.C and 3.1.D), as identified by small RNAseq, 
one-by-one in an in vitro invasion assay. miRNAs positively regulated by mutant p53 were 
overexpressed in KPflC cells that lack p53 function, in order to identify those that might 
mimick the enhanced invasive phenotype driven by mutant p53. In contrast, we transduced 
KPC cells with miRNAs that were negatively regulated by mutant p53 and looked for 
miRNAs that induced a decreased invasive phenotype, similar to the effect seen upon 
downregulation of mutant p53 (Figure 3.2.B). Although we failed to find miRNAs whose 
expression abrogated invasion driven by mutant p53 in KPC cells, we identified three 
miRNAs whose overexpression in KPflC increased invasiveness. miR-155 is highly  
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Figure 3.2. Identification of miR-155 and miR-181b as Downstream Mediators of Mutant p53 in Regulating 
Cell Invasion 
(A) One-by-one invasion assay screen. Quantification of invaded KPflC cells infected with miRNAs upregulated 
by mutant p53 (left panel) and KPC cells infected with miRNAs downregulated by mutant p53 (right panel). (B) 
qRT-PCR for miR-155, -181b, and -1306 in KPC+sh.Ctrl or +sh.p53 cells. (C) qRT-PCR for miR-155 and -181b in 
KPflC cells infected with miR-151, -181b, or -151/-181b. (D) Quantification of the invasion into collagen of cell 
lines from (C) compared to KPflC+GFP or +p53.R175H. Data presented as mean ±SD. *p < 0.05, **p < 0.01, ***p < 
0.001.  
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expressed in hematopoietic cells and was one of the first miRNAs implicated in cancer 
(Spoerl et al., 2013); miR-181b promotes the activation of the NF-κB signaling pathways and 
is involved in the resistance of pancreatic cancer cells to gemcitabine (Ma et al., 2011; 
Takiuchi D et al. 2013); and miR-1306 is a less well characterized miRNA for which direct 
targets and pathways are still unknown. 
 
We next verified by RT-qPCR that miR-155 and -181b expression levels were 
reduced upon knockdown of mutant p53, indicating that their expression depends on p53 
status (Figure 3.2.C). Conversely, miR-1306 expression levels did not change upon 
manipulation of mutant p53 levels, suggesting that its oncogenic properties are not 
regulated by mutant p53 (Figure 3.2.C). Overexpression of either miR-155 or miR-181b 
increased the invasive properties of KPflC cells to a level similar to that observed upon 
overexpression of a mutant form of p53. Simultaneous overexpression of miR-155 and -181b 
did not have a cooperative effect on invasiveness of KPflC cells, suggesting that both 
miRNAs might function redundantly and target the same mRNA transcripts (Figure 3.2.E). 
In short, mutant p53 orchestrates a cell invasion program in pancreatic cancer cells through 
the upregulation of miR-155 and miR-181b.  
 
 
3.2.3. miR-155 and miR-181b target Map3k10 to modulate invasiveness 
To gain an understanding of the downstream modulators regulated by miR-155 and -181b, 
we first generated a list of putative targets of both miRNAs (mirbase.org) and compared the 
overlap of predicted targets with the mutant p53-responsive genes identified by long 
RNAseq from our previous experiment (described in Chapter 2). We found 12 genes to be 
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putative targets of both miR-155 and -181b, and to be dependent on the p53 status (Figure 
S3.1, and 3.3.A). Amongst those genes, Map3k10 was the most promising candidate because 
it (i) carries a central role in the MAPK pathway; (ii) is a validatedmiR155 target (Figure 
3.3.B) (Zhu et al., 2012); and (iii) is overexpressed in PDAC tissue to promote the viability, 
proliferation, drug resistance (An et al., 2013). MAP3K10 phosphorylates the downstream 
kinase Mkk4 and is an upstream component of the JNK/p38 signaling pathways that result 
in the activation of a diverse range of proteins that play roles in cellular proliferation and 
differentiation, inflammation and immune responses. Although a previous study had 
suggested a repressive function of miR-155 on the MAPK pathway member MAP3K10 (Zhu 
et al., 2012), the role of miR-181b remains unknown.  
 
 In order to test the role of MAP3K10 in mutant p53-driven invasion, we first verified 
the dependency of MAP3K10 levels on mutant p53 by RT-qPCR and western blotting. 
Map3k10 mRNA and protein levels were increased upon knockdown of mutant p53, 
indicating that mutant p53 negatively regulates its expression, consistent with our RNAseq 
data (Figures 3.3.C and 3.3.D). Next, we tested the functional connection between mutant 
p53, miR-155 and -181b, and MAP3K10 in promoting tumor cell invasion of pancreatic 
cancer cells. According to our hypothesis, mutant p53 should enhance miR-155 and -181b 
expression to promote the degradation of the Map3k10 transcript and to potentiate the 
invasive phenotype of pancreatic cancer cells. Indeed, knockdown of MAP3K10 with two 
different shRNAs enhanced the invasive potential of KPflC cells to a similar extent as seen 
upon overexpression of mutant p53. Together, our data points to a mutant p53/miR-155 and 
-181b/MAP3K10 signaling axis that specifically impacts upon the invasive potential of 
pancreatic cancer cells (Figure 3.3.E) 
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Figure 3.3. mutant p53 induces an invasive phenotype through the miR-mediated downregulation of 
MAP3K10 
(A) Venn diagram of predicted targets of miR-155 and -181b, and mutant-p53-response genes as identified by 
long RNAseq. Map3k10 is the only overlapping gene. (B) Map3k10 3’ UTR and the putative binding sites for miR-
155 and 181b. (C) Western blotting analysis of MAP3K10, p53, and Actin in sh.p53- or sh.Ctrl-expressing KPC 
cells (upper panel). Heatmap of Map3k’s and their expression changes upon p53 depletion as identified by 
RNAseq. (D) qRT-PCR for Map3k10 in KPC+sh.p53 or +sh.Ctrl cells. Data presented as mean normalized 
Map3k10 expression ±SD of triplicate samples. A representative result of three repeated experiments is shown. 
(E) Quantification of the invasion into collagen of KPflC+GFP, +p53.R175H, and sh.Map3k10 (1 or 2). Data 
presented as mean ±SD. *p < 0.05, **p < 0.01, ***p < 0.001. 
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3.2.4. Mutant p53 inhibits MKK4 phosphorylation through the miR-155/-181b-Map3k10 
axis 
MKK4 is one of the downstream effectors of MAP3K10 that acts as a suppressor of 
metastasis in different tumor types, such as lung and ovarian cancer (Ahn et al., 2011; 
Yamada et al., 2002). Following the observation that mutant p53 represses MAP3K10 levels 
to promote cell invasion in pancreatic cancer cells, we investigated whether mutant p53 
regulates the activation of MKK4. To this end, we measured the levels of Ser-257 
phosphorylated Mkk4 levels upon manipulation of mutant p53. Levels of activated Ser-257 
pMKK4 were increased when mutant p53 was knocked down in KPC cells, whereas 
inhibitory phosphorylation of MKK4 at residue Ser-80 was not affected (Figure 3.4.A).  
  
To further explore whether mutant p53 exerts its oncogenic function through the 
regulation of MKK4 activity, we genetically manipulated MAP3K10 and mutant p53 in 
pancreatic cancer cells and analyzed MKK4 status by western blotting. In non-invasive, p53-
null KPflC cells, MAP3K10 and activated Ser-257 pMKK4 were expressed at high levels 
(Figure 3.4.B, lane 2). Accordingly, knock down of MAP3K10 resulted in reduced levels of 
Ser-257 pMKK4, whereas total levels of MKK4 remained unchanged. Importantly, 
overexpression of a mutant form of p53 in KPflC cells resulted in attenuated expression of 
MAP3K10 (presumably through elevated miR-155 and miR-181b expression levels) and 
consequently, decreased levels of activated pMKK4, rendering these cells more invasive as 
previously described (Figure 3.4.B lane 1). Despite the expression of a mutant form of p53 
leading to reduced levels of activated MKK4, consistent changes in the activated levels of 
the canonical substrates of MKK4, JNK and Jun, were not observed. Similarly, levels of 
phosphorylated JNK and c-JUN were not reduced upon depletion of p53 in KPC cells,  
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Figure 3.4. Levels of activated Mkk4 are dependent on the p53 status 
(A) Western blotting analysis of activated (S247), suppressed (S80), and total levels of MKK4, p53, and Actin in 
sh.p53- or sh.Ctrl-expressing KPC cells. (B) Western blotting analysis of MAP3K10, MKK4 (S257 and total), p53, 
and Actin in p53.R175H, sh.Ctrl, sh.Map3k10 (1, 2, or 3)-expressing cells. (C) Canonical downstream targets of 
MKK4. Protein levels of phospho-JNK, phospho-c-Jun, p53 and Actin were measured in KPflC cells expressing a 
GFP, p53.wt, or p53.R172H vector, and in KPC cells expressing sh.Ctrl (1,2, or 3) and sh.p53 (1,2, or 3). 
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suggesting the role for other compensatory regulators in these cells (i.e., MKK7) (Figure 
3.4.B). Together these results support the idea that mutant p53 governs the MAPK pathway 
through the regulation of the miR-155/miR-181b/MAP3K10 axis, resulting in the 
suppression of the metastasis suppressor MKK4. 
 
 According to previous reports (Ahn et al., 2011), we did not see a proliferative 
advantage of KPflC cells infected with two different shRNAs targeting Mkk4 (Figure 3.5.A). 
However, we confirmed that KPflC +sh.Mkk4 cells efficiently migrated in scratch-wound 
assays, despite the absence of mutant p53, which usually renders cells less migratory as seen 
with p53-null KPflC+sh.Ctrl cells (Figure 3.5.B). Next, we examined whether the invasive 
capacity of KPflC cells depends on MKK4 activity. As observed before, p53-null 
KPflC+sh.Ctrl cells invaded very poorly but their invasive potential was enhanced when E-
Cadherin, a crucial factor in epithelial cell-cell adhesion, was knocked down. Similarly, 
knockdown of MKK4 in KPflC initiated invasiveness (Figure 3.5.C), suggesting that MKK4 
functions as a suppressor of invasion.  
 
Others have proposed tumor- and metastasis suppressive functions of MKK4. Our 
studies in murine pancreatic cancer cells further support this idea. Limited data from 
pancreatic cancer patients show frequent heterozygous deletions of MKK4, a common 
characteristic of genes with tumor suppressive functions (Figure 3.4.F). Moreover, the tumor 
suppressor p53 is mutated in 75% of PDAC patients and mutations in this gene have been 
correlated with a worse disease-free outcome (see Chapter 2). The fact that tumors 
harboring mutations in p53 are also characterized by heterozygous loss of MKK4 could 
reinforce our findings that mutant p53 attenuates activating levels of MKK4 to increase 
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Figure 3.5. Low levels of activated MKK4 induce invasiveness 
(A) Cell number over time (days) of KPflC cells stably expressing sh.Ctrl or sh.Mkk4 (1 or 2). (B) Representative 
phase contrast images from live cell recordings of scratch-wound assays of KPflC cells stably expressing sh.Ctrl, 
sh.Mkk4 (1 or 2), and sh.Cdh at 0 and 10 h. (C) MKK4 and Actin levels of KPflC cells infected with shRNAs 
targeting a non-targeting control (Ctrl) or Mkk4 (1 or 2) as determined by western blotting. (D) Genetic 
configuration of p53 and MKK4 in human pancreatic, stomach, ovarian, colon and lung cancer. Depicted is the 
percentage of heterozygous or homozygous deletions in the presence or absence of mutations.  
  
Chapter 3 
85 
 
invasion. Together these results support a model in which mutant p53 promotes invasion in 
pancreatic cancer cells, in part, via an indirect mechanism that depends on its ability to 
repress the metastasis suppressor MKK4 through the regulation of the miR-155/miR-
181b/MAP3K10 axis (Figure 3.5). 
 
 
 
 
 
       Figure 3.6. miRNA-mediated mechanism of action of mutant p53 in promoting invasion 
 
 
3.3. Discussion 
miRNAs govern many cellular processes and deregulation of their biogenesis has been 
associated with several aspects of malignant progression. Here, we have shown that mutant 
p53 regulates a distinct miRNA profile to potentiate the invasive capacity of pancreatic 
cancer cells. By enhancing the expression of miR-155 and -181b, mutant p53 reduces the 
protein level of Map3k10 and, thereby, attenuates the ability of MAP3K10 to activate MKK4, 
a well-known metastasis suppressor gene in several cancer types. Therefore, mutant p53 not 
only potentiates the invasive capacity of pancreatic cancer cells through the direct regulation 
of genes such as PDGFRb (see Chapter 2), but also through the modulation of miRNA 
levels.  
 
 A global decrease of mature miRNA levels is a characteristic of human and murine 
cancers, and is involved in several aspects of tumorigenesis such as cell invasion and 
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metastasis. General downregulation of miRNA is often associated with a decreased 
expression of miRNA biogenesis enzymes, such as Dicer (Lu et al., 2005). Dicer is a 
transcriptional target of p63, and decreased levels of p63 coincide with attenuated levels of 
Dicer and mature miRNAs (Muller at al., 2014). However, as described here, pancreatic 
cancer cells expressing a mutant form of p53 exhibit an enhanced invasive potential, which 
is independent of a global decrease of mature miRNAs or mutant p53-dependent regulation 
of Dicer. Instead, mutant p53 promotes the aberrant expression of several distinct miRNAs 
in pancreatic cancer cells. The discrepancies may be explained by the fact that p63, a p53 
family member negatively regulated by mutant p53, is not expressed in KPC cells. 
Supporting a Dicer-independent activity of mutant p53 in enhancing pancreatic cancer cell 
invasion and metastasis, we observed an equal number of up- and downregulated miRNAs 
in response to mutant p53 knockdown. Moreover, only upregulated miRNAs seem to 
contribute to the invasive and metastatic phenotype conferred by mutant p53. Collectively, 
our data indicate that mutant p53 exerts its effects in pancreatic cancer cells through the 
regulation of particular miRNAs rather than by modulating the global biogenesis of their 
genetic regulators. 
 
Recently, miRNAs have been proposed to function as biomarkers of pancreatic 
cancer development and progression (Khan et al., 2013). Because the current 5-year survival 
rate for patients with pancreatic cancer is less than 5%, and surgical resection remains the 
most effective therapy, identifying markers affecting overall survival may improve our 
ability to define subsets of pancreatic cancer patients and will help to develop effective 
targeted therapies. Combination of clinicopathological data, follow-up analyses and miRNA 
expression studies have led to the identification of miR-21, miR-155 and miR-200 as bona-
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fide predictors of survival and clinical outcome in pancreatic cancer patients. Importantly, 
these miRNAs regulate, and are regulated by, genes that are typically altered in pancreatic 
cancer including p53, KRAS, p16, and BRCA1/2, thereby influencing DNA repair and cell 
cycle progression (Tang et al., 2013). miR-34 is involved in pancreatic cancer stem cell self-
renewal and/or cell fate determination, potentially via the direct modulation of 
downstream targets Bcl-2 and Notch, and restoration of miR-34 in mutant p53 or p53-null 
pancreatic tumors may hold significant promise as a novel molecular therapy (Ji et a;., 2009). 
Moreover, miRNAs have been linked to tumor progression and metastasis by mediating 
epithelial-mesenchymal transition (EMT). In breast cancer cells, miR-200 prevents EMT by 
inhibiting ZEB1 and ZEB2, repressors of E-Cadherin, whereas overexpression of miR-429 
reverses the transition in ovarian cancer cells (Kong et al., 2012). Thus, understanding the 
reciprocal relationships between miRNAs and these genes will be of significant value for 
determining the driving forces underlying this aggressive disease and for the development 
of new therapeutic avenues.  
 
Questions remain as to how mutant p53 regulates miR-155 and -181b expression. 
Elevated expression of both miRNAs in solid tumors, including pancreatic cancer, is well 
established (Liu et al., 2014; Papaconstantinou et al., 2014); however, the molecular 
mechanism underlying the Dicer-independent upregulation of these two miRNAs remains 
unclear. Expression of both miRNAs might be the consequence of the interaction of mutant 
p53 with specific transcription factors to induce miRNA transcription and expression. For 
example, the proto-oncogene c-MYC transcriptionally activates the oncogenic miR-17-92 
cluster, resulting in the tight control of E2F1 levels and cell cycle progression (O’Donnell et 
al., 2005). Alternatively, mutant p53 could modulate levels of miR-155 and -181b by 
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regulating the activity of epigenetic regulators. For example, BRCA1 epigenetically 
represses miR-155 expression via its association with HDAC2, which deacetylates histones 
H2A and H3 on the miR-155 promoter (Chang et al., 2011). 
 
Human pancreatic tumors are frequently characterized by a mono-allelic mutation in 
the tumor suppressor p53 and LOH of the remaining short arm of chromosome 17 (17p). An 
open debate has been why a cancer cell is under selective pressure to sustain both events. As 
described in Chapter 2 and 3, p53 mutants carry neomorphic functions and render a tumor 
more aggressive. LOH of 17p, and thereby the remaining wild type allele of p53, is thought 
to potentiate the gain of function ability of the mutant form. However, does the loss of 
chromosome arm 17p equal solely the loss of the remaining p53 allele? Here we propose 
another idea by which LOH of 17p reduces metastasis suppressive function of MKK4, 
located 10 cM centromeric to p53 on chromosome 17 (Figure 4.4). The data at hand suggest a 
metastasis-suppressive phenotype of activated MKK4, which is attenuated by heterozygous 
loss of 17p and further disabled in the presence of mutant p53. Mutant p53 is able to 
suppress activation of MKK4, resulting in increased invasion through yet unknown 
downstream mediators. This idea is supported by the fact that all heterozygous deletions of 
MKK4 occur in tumors with p53 mutations (Figure 3.4.F), but Mkk4 inactivating mutations 
are mutually exclusive with p53 mutations. 
 
Understanding the function of metastasis suppressor proteins can potentially help to 
identify patients at risk for metastasis development and to identify antimetastatic therapies. 
So far, a large body of evidence supports a role for MKK4 in inhibiting the metastatic spread 
of the primary tumor, including ovarian, prostate, breast, and pancreatic cancer (Whitmarsh 
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and Davis, 2007). However, the downstream mediators remain rather elusive and the 
MKK4-driven molecular output might depend on the environmental context. For example, 
in ovarian cancer cells, MKK4 suppresses cell invasion through the upregulation of cell 
cycle inhibitor p21. Induction of p21 is p53-independent and initiates reversible cell cycle 
arrest, rather than senescence (Lotan et al., 2008). Whether mutant p53-driven attenuation of 
MKK4 in pancreatic cancer cells result in reduced levels of p21 and escape from cell cycle 
arrest remains to be tested. 
 
However, this study leaves a few open questions. First, the functional outcome of 
miR-155 and -181b in invasion seems to be redundant, but how they affect MAP3K10 
protein levels, for example by inhibiting its translation or by targeting degradation, remain 
to be determined. Furthermore, the downstream effectors of MKK4, which mediate the 
metastasis-suppressive functions, are undefined. Equally important, but also unresolved, is 
the validation of the mutant p53-MKK4 axis in human pancreatic cancer samples. Do MKK4 
and MAP3K10 expression levels correlate with miR151- and -181b status? Do mutations in 
p53 co-occur with elevated levels of miR151 and -181b, and attenuated expression of 
MAP3K10 and MKK4? The answer to these questions will further strengthen our 
understanding of how mutant p53 exerts its oncogenic function in invasive pancreatic 
cancer. 
 
In summary, mutant p53 drives the invasive phenotype of pancreatic cancer through 
two distinct miRNAs, miR151 and -181b, to attenuate MAP3K10 and activated MKK4 levels. 
Even though each gene or miRNA has been associated to induce invasion, we show for the 
first time how they interconnect to yield a more aggressive cancer phenotype. Genetic 
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evidence for a metastasis suppressive function of MKK4 was previously linked to the 
sporadic presence of MKK4 mutations in ~5% of cancer cases. However, our data suggest a 
much more prominent role of MKK4 in tumors expressing mutant p53, which denote the 
majority of all pancreatic cancers. Therefore, the herein described mutant p53-MKK4 
signaling axis broadens our molecular understanding of invasive pancreatic cancer and 
might reveal biomarkers for early detection and vulnerabilities for new anti-metatsatic 
therapies. Moreover, our results unravel a novel mechanism of action of p53’s gain of 
function that explains the simultaneous presence of mutations in p53 and large deletions of 
the chromosome arm 17p. 
 
 
3.4. Chapter Contributions 
S.W. designed and performed the majority of the experiments. M.S. contributed 
intellectually to the design of the project. C.A.D. and V.T. conducted and analyzed small 
RNA sequencing. S.W.L. conceived and supervised the project  
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3.5. Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suppl. Figure 3.1. List of 
overlapping genes of 
predicted miR-155 and 
miR-181b targets with 
mutant p53-responsive 
genes as identified by 
RNAseq 
  
Gene name 
Aak1 
Dusp10 
Ets1 
Fbxo33 
Foxk1 
Gpd1l 
Map3k10 
Mef2a 
Mex3b 
Trim2 
Ttl 
Wnk1 
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4. Chapter 4 
Cooperative interactions between 17p tumor suppressors  
 
 
4.1. Introduction 
The cancer genome is characterized by genetic alterations that facilitate uncontrolled 
proliferation of tumor cells and prevent them from cell death. Genetic changes that drive 
tumorigenesis, such as particular deletions, amplifications, and somatic mutations, become 
selected as cancers are initiated and evolve. However, given the genetic instability of many 
tumors, most of the observed genomic alterations are passenger changes that do not confer a 
selective advantage to the developing tumor. Despite the abundance of data provided by 
genome-wide sequencing studies, our knowledge about driver genes and how they 
contribute to cancer progression remains incomplete. Therefore, functional studies are 
required for the validation of candidate genes and for the characterization of their actions. 
Combining genomic data with functional studies holds promise for improving cancer 
diagnosis, prognosis and therapy. 
 
Large heterozygous deletions occur frequently in the cancer genome, but their 
biological significance remains elusive (Table 1.1). If only partial loss of gene function can 
facilitate tumorigenesis, Knudson’s “two-hit” hypothesis for the bi-allelic inactivation of 
tumor suppressors (Knudson, 1971) might not apply to genes located in these regions. 
Indeed, most cancer-related deletions do not harbor known or putative tumor suppressor 
genes (Vogelstein et al., 2013), raising the possibility that only the simultaneous partial 
attenuation of multiple genes might collectively contribute to tumorigenesis. Certainly, 
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recent studies have confirmed this hypothesis by showing that heterozygous loss of 
multiple genes, clustered in the same chromosome region, cooperates to enhance 
tumorigenesis (Xue et al. 2012; Solimini et al., 2012). Formally, the same concept may also 
apply for large heterozygous deletions where a bona fide tumor suppressor gene has also 
been disrupted. Large heterozygous deletions encompassing regions on chromosome 17p 
are very common in human tumors. Here, the presence of the tumor suppressor p53 is 
widely thought to be the only link to selective pressure that cancer cells undergo to delete 
this region. However, deletions of the chromosome arm 17p reduce the dosage of many 
other neighboring genes, which could in principle contribute to tumorigenesis in a 
haploinsufficient manner, where mono-allelic loss suffices to promote oncogenic 
progression. The identification of cooperating genes could explain the forces driving 
selection against the normal homozygous presence of 17p, and in turn, this concept could be 
further expanded to include effects of deletion of other large chromosomal regions. 
 
 Hepatocellular carcinoma (HCC) is characterized by the recurrent, heterozygous loss 
of chromosome region 17p, and, therefore, represents an appropriate system to study the 
presence of linked tumor suppressor genes that cooperate during tumor progression. HCC, 
a common but understudied cancer for which there are few treatment options, has been 
successfully modeled and studied in mice (Zender et al., 2008; Xue et al., 2012). In particular, 
the mosaic mouse model of HCC is based on the isolation and ex vivo manipulation of 
mouse embryonic liver progenitor cells, followed by their retransplantation into recipient 
mice. The resulting tumors closely resemble the pathology and biology of the human 
disease. More specifically, the HCC mosaic mouse model utilizes MYC-overexpressing, 
p53null hepatocytes that are immortalized but not tumorigenic, providing a sensitized 
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background that is ideal for the identification of additional genetic alterations that might be 
involved in tumor initiation and progression. Large-scale RNAi screens can be carried out in 
the HCC ex vivo model, in which pools of shRNAs targeting recurrently deleted genes can 
be tested for their ability to promote tumorigenesis. This approach has successfully led to 
the identification of tumor suppressor genes, such as Xpo4 (Zender at al., 2008) and Dlc1 
(Xue et al., 2008). 
 
The combination of cancer genomics, RNAi, and mosaic mouse models can facilitate 
the functional annotation of frequently altered genes. One gene that frequently undergoes 
genetic alterations in HCC is the mitogen-activated protein kinase (MAPK) kinase 4 
(MKK4). Mkk4, located on chromosome 17p, just 10 cm centromeric to p53, is a non-
redundant component of stress activated MAPK signaling modules. In response to various 
stimuli, MKK4 phosphorylates and activates the c-JUN N-terminal protein kinase (JNK) and 
p38 families of MAPKs. Despite several studies analyzing the role of MAP kinases in 
cancers, the function of MKK4 in tumorigenesis is not well understood. Some experimental 
evidence suggests a pro-oncogenic role for MKK4 (Wang et al., 2004; Finegan and Tournier, 
2010), whereas others demonstrated a growth-suppressive function (Ahn et al., 2011; 
Nakamura et al., 2013). Consistent with a growth-suppressive role of MKK4, a wide 
spectrum of primary cancers shows loss-of-function mutations in MKK4, in a LOH 
background, at a fairly consistent rate (~5%) or harbor homozygous deletions that 
eliminated coding portions of the MKK4 locus (Teng et al., 1997; Su et al., 2002).  
 
 In this chapter, I aim to explore the hypothesis that frequent heterozygous deletions 
of chromosome region 17p arise as a single mechanism to facilitate the cosuppression of 
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multiple genes. By screening pools of shRNAs targeting the mouse orthologs of genes 
contained in the chromosomal region 17p in vivo, we identified the dual-specific kinase 
MKK4 as a tumor suppressor gene, whose loss cooperates with p53 deletion to drive 
tumorigenesis. Mkk4 suppression significantly enhanced the tumorigenic potential of p53-
depleted hepatocytes in ex vivo transplantation or transposon-based mouse models of HCC. 
Hepatocytes with stable RNAi-mediated MKK4 silencing showed increased activation of 
anti-apoptotic genes and survival genes, which are dependent on upregulation of NF-κB. 
Therefore, our study identifies and validates MKK4 as a potential haploinsufficient tumor 
suppressor on 17p and provides evidence that large deletion events target multiple genes 
that together drive tumorigenesis. 
 
 
4.2. Results 
4.2.1. In vivo RNAi screen for the identification of tumor suppressor genes on 
chromosome region 17p 
We have previously established an ex vivo transplantation model of hepatocellular 
carcinoma (HCC) that is suitable for conducting direct in vivo RNAi screens for genes that 
positively impact HCC development (Zender et al., 2008). Because (i) chromosome arm 
deletions might target multiple genes that cooperate to drive tumorigenesis, (ii) 17p is one of 
the most frequent genomic deletions among multiple human tumor types, we decided to 
conduct a positive selection screen for tumor suppressor genes on the short chromosome 
arm 17. To this end, we generated a library of 1,645 shRNAs that targeted all 274 genes 
contained in the chromosome region 17p (6 shRNAs per gene). The shRNAs were designed 
using on-chip oligonucleotide synthesis and a bar-coding strategy such that shRNAs could 
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be amplified from the mixtures in pools of a discrete size (~100 shRNAs per pool). Of note, 
all of the shRNAs used in this study were cloned into pMLS, a vector optimized for in vivo 
use, which coexpresses green fluorescent protein (GFP). The pools were individually 
screened for their ability to enhance tumor potential of immortalized, p53-/- liver progenitor 
cells (LPCs) overexpressing the MYC oncogene at low levels (Figure 4.1.A). These cells 
provide a ‘‘sensitized’’ background where a single additional lesion can trigger 
tumorigenesis and were therefore suitable for identifying genes that contribute to cancer. As 
previously described, tumors resulting from the subcutaneous injection of premalignant 
progenitor cells into recipient mice recapitulated the human disease with solid and 
trabecular growth pattern (Figure S4.1.A).  
 
To establish efficient screening conditions in our HCC ex vivo mouse model, we 
tested how knockdown of a potent tumor suppressor gene or a control gene affected the 
tumorigenic potential of the LPCs. First, we observed that shRNA-mediated depletion of the 
WNT-pathway regulator APC efficiently accelerated tumorigenesis, even when the library 
was diluted 1:50 or 1:100 (Figures S4.1B and S4.1.C). By contrast, an shRNA targeting a 
neutral control gene (Renilla) did not accelerate tumor development and most of the tumors 
that eventually arose were GFP-negative, indicating that the neutral shRNA did not confer a 
selective advantage during malignant progression. Dilution studies indicated that a pool of 
100 shRNAs can allow for outgrowth and enrichment of shRNAs that target genes with 
tumor suppressive functions. 
 
Upon subcutaneous injection of LPCs infected with the shRNA pools, tumors 
developed with varying latency. From a total of 16 analyzed shRNA pools, 4 accelerated 
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tumor growth and were GFP-positive (Figure S4.1.D). We then used deep sequencing of 
PCR-amplified shRNAs to analyze the shRNA representation in the preinjected cell pools 
and the resulting tumors (Figure 4.1.A). According to our hypothesis, enriched shRNAs in 
the tumor should constitute candidate ‘drivers’ of the disease. Putative tumor suppressor 
genes were then prioritized using an enrichment score based on (1) the number of shRNAs 
targeting the gene retrieved from the tumor, and (2) the extent shRNA enrichment in the 
tumor (> 15%). We identified 7 potential tumor suppressor genes (~2.6% of total tested 
genes) (Table 4.1.), most of which have not been recently associated with a tumor 
suppressive function. However, Mkk4 was the only gene that was targeted by two shRNAs, 
limiting the possibility of off-target effects (Figure 4.1.B). Therefore, we decided to follow up 
on Mkk4 and study its tumor suppressive function in HCC. 
 
Table 4.1. Putative tumor suppressor genes identified in the 17p screen 
 
 MKK4 is a dual-specificity kinase with a known role as a central mediator of the Jun 
N-terminal kinase (JNK) and p38 phosphorylation cascade. MKK4 is not only frequently 
deleted but also shows a mutation rate of ~5% in diverse tumor types, such as pancreatic, 
bile duct, breast, colon and lung cancer (Cunningham et al., 2006) More importantly, MKK4 
is genetically altered in cancer by deletion or mutation events. We confirmed that MKK4 
protein levels were efficiently reduced following the transduction of liver progenitor cells  
Candidate TSG Tumor # shRNA # Score 
Myh3 2 1 320.2 
Mkk4 2 2 302.0 
Glp2r 1 1 99.9 
Wdr8 1 1 97.4 
4933411G11Rik 1 1 35.7 
Rap1gab2 1 1 35.3 
Ywha 1 1 29.1 
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Figure 4.1. In vivo RNAi Screen identifies Mkk4 as a tumor suppressor gene on 17p 
(A) Schematic representation of the approach. E18 p53-/- liver progenitor cells were isolated and immortalized by 
overexpressing MYC at low levels. Subsequent infection with shRNA pools and subcutaneous injection allowed 
tumor growth. (B) Enrichment of two shRNAs targeting MKK4 in tumors compared to their representation in 
preinjected cell pools. Pie graphs show the representation of each sh.Mkk4 in the total shRNA population 
analyzed by high-throughput sequencing. (C) Validation of Mkk4 as a tumor suppressor gene. shRNA-mediated 
knockdown of MKK4 (upper panel, Actin as loading control) increases tumorigenesis of subcutaneously injected 
p53-/-;MYC LPC cells (lower panel). (D) Overexpression of Mkk4 cDNA (upper panel, Actin as loading control) in 
tumorigenic p53-/-;MYC liver cells reduces tumor burden upon subcutaneous injection.  
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with two independent sh.Mkk4 (Figure 4.1.C). Upon injections into the flanks of nude mice, 
LPCs infected with shRNAs targeting MKK4 (LPC + sh.Mkk4) developed tumors faster and 
at a higher penetrance than LPCs expressing an shRNA targeting a control gene (LPC + 
sh.Ctrl) (Figure 4.1.C). We next asked whether MKK4 overexpression in tumorigenic liver 
cancer cells of the same genotype (p53-/-;MYC overexpression at high levels) would attenuate 
their tumorigenic potential. Whereas tumor cells transduced with a GFP control plasmid 
consistently developed tumors upon their injection into the flank of nude mice, the tumor 
burden was significantly reduced in mice injected with tumor cells overexpressing MKK4 
(Figure 4.1.D). Together, these data suggest that MKK4 functions as a tumor suppressor 
gene in liver cancer. 
 
 
4.2.2. Combined loss of p53 and MKK4 cooperates to accelerate tumorigenesis 
The results above reveal a tumor suppressive activity of MKK4 in HCC; however, the 
question remained whether the simultaneous loss of both Mkk4 and p53 has a synergistic 
effect on tumor growth as compared to the depletion of each individual gene alone. To 
address this question, we used shRNA-encoding transposable elements in conditional p53 
knockout mice (p53fl/fl). The system allowed us to disrupt p53 gene function in a subset of 
mice upon induction of Cre expression and to suppress the function of MKK4 by shRNA-
mediated knockdown. Hydrodynamic injection was used to deliver transposable elements 
together with a sleeping beauty transposase (SB13) into hepatocytes of p53fl/fl mice. Transient 
expression of SB13 enables stable integration of the transposons in a subset of targeted liver 
cells. The transposons are engineered to encode a tamoxifen-inducible Cre recombinase 
(CreERT) together with cDNAs encoding oncogenes, and/or GFP-linked shRNAs. We 
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expressed MYC and β-Catenin, two oncogenes frequently altered in HCC, in hepatocytes to 
create a sensitized background for tumor initiation. Simultaneously, we transduced 
hepatocytes of these mice with either sh.Mkk4 (1 or 2) or sh.Ctrl and their expression was 
followed by the detection of the fluorescent protein GFP. Then, we treated on cohort of 
sh.Mkk4;p53fl/fl and sh.Ctrl;p53fl/fl mice with tamoxifen to induce Cre-mediated excision of the 
p53 gene or with drug-vehicle to allow the continued expression of p53 (Figure 4.2.A). 
 
After 6 weeks, we quantified the size of each tumor nodule on serial H&E sections of mouse 
livers of six different genotypes: sh.Ctrl,p53(+/+); sh.Ctrl,p53(-/-); sh.Mkk4.1,p53(+/+); 
sh.Mkk4.1,p53(-/-); sh.Mkk4.2,p53(+/+); and sh.Mkk4.2,p53(-/-). As expected, we did not 
observe any liver tumors in mice that expressed both Mkk4 and p53 at endogenous levels. 
Genetic disruption of either MKK4 or p53 in hepatocytes overexpressing MYC and β-
Catenin resulted in the development of a few liver tumor nodules, indicating that inhibition 
of MKK4 or p53 alone induces tumorigenesis inefficiently. However, sh.Mkk4-expressing 
mice with disrupted expression of the p53 gene developed liver tumors at high frequency 
(Figures 4.2.B and 4.2.C). Disruption of p53 in sh.Mkk4.1 mice resulted in an increased 
tumor burden compared to that in sh.Mkk4.2 mice. This discrepancy was also observed in 
the ex vivo HCC model and might be due to different knock down efficiencies of Mkk4. 
Collectively, our data imply that the impact of 17p deletions goes beyond the effects of p53 
mutation or, for that matter, the attenuation of any individual gene. 
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Figure 4.2. Cooperative effects of MKK4 and p53 suppression on tumorigenesis 
(A) Schematic representation of suppression of Mkk4 and p53, either simultaneously or individually. Tamixofen 
treatment induced Cre expression to disrupt p53 expression. shRNA expression mediated MKK4 knockdown. 
Combination of both strategies gives six different genotypes: sh.Ctrl,p53wt; sh.Ctrl,p53-/-; sh.Mkk4.1,p53wt; 
sh.Mkk4.1,p53-/-; sh.Mkk4.2,p53wt; and sh.Mkk4.2,p53-/-. (B) Quantification of liver tumor size from experimental 
mice from (A). (C) H&E section of livers. Tumors are marked by white arrows. 
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4.2.3. Decreased MKK4 activity cooperates with loss of p53 in hepatocellular carcinoma 
by triggering an anti-apoptotic response 
MKK4 is a dual-specific protein kinase that activates, together with MKK7, the p38 and JNK 
signaling pathways during development and in response to stress (Davis, 2000; Lee et al., 
2002). Recently, it has been proposed that silencing of MKK4 leads to upregulation of 
MKK7, which potentiates liver regeneration in a JNK-dependent manner (Wuestefeld et al., 
2013). However, in our model, MKK4 suppression did not change the expression or 
activation of MKK7, p38 or JNK as determined by levels of the phosphorylated proteins 
(Figures 4.3.A and S4.2.C). Because these results suggest that the tumor suppressive 
functions of Mkk4 do not involve the activation of the canonical pathway, we aimed to 
understand whether loss of MKK4 triggers a more complex and non-canonical gene 
signature to drive HCC. 
 
We sought to examine the effects of MKK4 suppression in proliferation and 
apoptosis resistance, two hallmarks of malignant growth. Using two individual shRNAs 
targeting MKK4 in p53-/- hepatocytes we observed increased levels of anti-apoptotic genes, 
such as Ciap1/2, Xiap1 and Bcl2 (Figure 4.3.B), compared to hepatocytes with normal levels 
of MKK4 (LPC+sh.Ctrl). NF-κB negatively regulates the apoptotic response by enhancing 
the expression of anti-apoptotic regulators and by antagonizing essential elements of the 
apoptotic signaling network. Importantly, we observed that knockdown of MKK4 
significantly enhanced the levels of phospho-p65, suggesting that MKK4 suppresses the 
expression anti-apoptotic genes through the modulation of the NF-κB pathway (Figure 
4.3.B).  
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Apart from its effect to enhance the expression of anti-apoptotic proteins, depletion 
of MKK4 in liver progenitor cells led to increased levels of activated ERK, as measured by 
phospho-ERK (Figure S4.2.A). Activation of ERK mediated by depletion of Mkk4 was 
dependent on NF-κB, as p-ERK levels were rescued in MKK4-depleted hepatocytes upon 
knockdown of p65 (Figure S4.2.B). Together, these results suggest that suppressive functions 
of MKK4 in hepatocellular carcinoma rely on its ability to modulate cell proliferation and 
apoptosis pathways, at least in part, through the regulation of NF-κB. 
 
To gain insight into the anti-apoptotic effects induced by the suppression of MKK4 
in hepatocytes in vivo, we subjected mice to a treatment with CD95 (FAS)-activating 
antibodies, a well-established model of acute liver failure (Ogasawara et al., 1993). First, 
p53fl/fl mice with stable intrahepatic expression of Mkk4- or control shRNAs, and tamoxifen-
inducible Cre recombinase were treated with tamoxifen to disrupt p53 gene function. Hence, 
we were able to determine the role of Mkk4 suppression in a p53-deficient background. 
Intravenous injection with anti-Fas antibody resulted in death of sh.Ctrl,p53-/- mice within 4 
h, due to acute liver failure associated with massive hepatic apoptosis and hemorrhagic 
necrosis (Figures 4.3.D and 4.3.E). However, MKK4 silencing resulted in protection of 
hepatocytes from FAS-induced apoptosis and significantly increased the survival of 
challenged mice. Accordingly, we observed a decreased number of apoptotic hepatocytes in 
sh.Mkk4-expressing livers as analyzed by cleaved Caspase-3 staining (Figure 4.3.E). These in 
vivo results confirm our studies in vitro and further support the idea that the anti-apoptotic 
pathway is induced by MKK4 -loss to potentiate liver tumor growth. 
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Figure 4.3. MKK4 suppression induces an anti-apoptotic pathway 
(A) Protein levels of canonical pathway members p-JNK, p-cJUN, p-p38 in LPCs infected with sh.Ctrl or –Mkk4 
(1 or 2). Actin served as a positive control. (B) Protein levels of Mkk4, Ciap1/2, Xiap1, Bcl2, p-p64, and Actin. (C) 
Schematic outline for the induction of acute liver failure by application of CD95-activating antibody into p53fl/fl 
mice with sh.Mkk4 (1 or 2) or sh.Ctrl expressing hepatocytes. (D) Survival analysis of mice with stable 
intrahepatic knockdown of Mkk4 or controls after triggering liver failure as depicted in (C). (E) Brightfield and 
GFP images of livers expressing sh.Mkk4 (1 or 2) or sh.Ctrl (upper panel). H&E and cleaved caspase 3 staining 
for apoptotic cells of mouse liver tissue (lower panel). Livers were taken upon mice succumbed to liver failure as 
described in (C).  
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4.2.4. 17p deletions are frequently large and target both MKK4 and p53 
To better define the frequently occurring 17p deletions in human cancers, we analyzed 
cancer genome datasets generated by array-based comparative genomic hybridization 
(aCGH) performed at Cold Spring Harbor Laboratory and the Cancer Genome Atlas 
(TCGA) project. We analyzed primary tumor samples and cell lines of HCC and colon, lung, 
ovarian, pancreas, and stomach cancers to determine the extent of chromosome 17p 
deletions (Figure 4.4.A). Approximately half of these tumors (and as many as 80% of 
ovarian tumors) harbor deletions of human chromosome 17p, often encompassing a large 
portion of, or even the entire, chromosome arm. When analyzing the exact chromosomal 
regions affected by 17p deletions in HCC, we noted that the most frequently deleted region 
is centered around the p53 gene and adjacent genes, such as MKK4. Together, these data are 
consistent with the notion that cancers select for chromosome arm 17 deletions at high 
frequency to target p53 and MKK4 loss. 
 
 Next, we studied the genetic context of MKK4 and p53 loss in more detail. First, we 
found that MKK4 and p53 loss were significantly associated with MYC amplifications or 
gains in the analyzed cancers types, including HCC, colon, lung, ovarian, pancreas, and 
stomach cancers. This result confirms that mouse models involving MYC overexpression 
and p53 loss mimic the human HCC genotype and represent a valid genetic system for 
exploring the involvement of additional candidate 17p tumor suppressor genes (Figure 
4.4.B). More importantly, the analysis revealed that heterozygous deletions of both MKK4 
and p53 co-occur in a vast majority of cancer patients. In contrast to p53, which usually 
exhibits inactivating mutation of the remaining allele, MKK4 mutations occurs only in ~5% 
of tumors, suggesting that MKK4 acts as a haploinsufficient tumor suppressor. In  
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Figure 4.4. Chromosome 17 deletion characteristics and co-occurring genomic aberrations 
(A) Size and extent of chromosome 17 deletions (in blue) and amplifications (in red) from individual HCCs, 
colorectal, lung, ovarian, pancreas, and stomach cancers based on aCGH datal analysis. The location of p53 and 
MKK4 are indicated. (B) p53 (heterozygous or homozygous) deletions co-occur with MKK4 deletions and MYC 
amplifications or gains. Each bar represents an individual tumor (from cbioportal.org). 
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agreement, partial knockdown of MKK4 significantly contributed to malignant progression 
in our mouse model. Therefore, the gene dosage of Mkk4 seems to influence the tumor 
suppressive function of MKK4 in liver cancer. 
 
 
4.3. Discussion 
Cosuppression of multiple genes on chromosome 17p produces additive or cooperative 
effects on tumor development. Here, we provide an expanded explanation for the frequent 
occurrence of 17p alterations in pointing to cooperativity between p53 and MKK4 
inactivation in cancer. We examined the dual impact of attenuating p53, the only 
functionally validated 17p tumor suppressor gene in HCC so far, and MKK4, the best-
scoring candidate tumor suppressor identified in an in vivo RNAi screen. Cosuppression of 
these two genes synergistically accelerated tumor growth compared to knockdown of each 
gene alone. MKK4 appears to act as a haploinsufficient tumor suppressor gene that mediates 
its anti-tumor activities, in part, by suppressing an anti-apoptotic response and modulating 
cell proliferation. Collectively, we suggest that haploinsufficiency of MKK4 cooperates with 
alterations of p53 in the malignant transformation of liver cancer cells, and possible in other 
forms of cancer. 
 
MKK4 is a dual specificity kinase that functions in the stress-activated kinase-
signaling cascade. Extracellular stimuli activate MKK4 to trigger phosphorylation of the 
JNK and p38 mitogen-activated protein kinases. Various, albeit conflicting, studies support 
a role for MKK4 dysregulation in tumorigenesis. While some investigations suggest a pro-
oncogenic potential of MKK4 (Wang et al., 2004; Finegan and Tournier, 2010), others have 
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proposed a tumor suppressive function (Yamada et al., 2002; Cunningham et al., 2006). We 
favor the latter interpretation and show that suppression of MKK4 function results in an 
increased liver cancer burden.  
 
MKK4 is heterozygously deleted in half of all tumors of different origins, including 
HCC, colorectal, lung, ovarian, pancreatic, and stomach cancers (Figure 4.4.A), suggesting 
that the reduction of MKK4 levels positively impacts on tumorigenesis. The presence of 
MKK4 loss-of-function mutations at a fairly consistent rate of ~5% in cancers of the 
pancreas, breast, colon, lung and testis further support its putative tumor suppressive role 
(Cunningham et al., 2006). Moreover, reduced expression of MKK4 in prostate, ovarian, and 
pancreatic tumors is linked with more advanced stages of cancer progression and shorter 
patient survival (Kim et al., 2001; Yamada et al., 2002; Whitmarsh and Davis, 2007). 
Additionally, a polymorphism in the promoter of the MKK4 gene (-1304T>G), which 
increases MKK4 promoter activity and, therefore, MKK4 mRNA and protein levels, 
correlates with reduced risk of AML, lung and colorectal cancer and might therefore play a 
protective role towards cancer development (Davies and Tournier, 2012).  
 
Given the somewhat ambiguous role of MKK4 in tumorigenesis, it is not surprising 
that the biological mechanism of MKK4-mediated tumor suppression remains poorly 
defined. Coexistent mutations of other tumor suppressor genes, such as p53, BRCA2 and 
p16, suggest that MKK4 may participate in distinctive tumor suppressive signaling 
pathways, in addition to its modulation of the canonical downstream mediators, p38 and 
JNK (Whitmarsh and Davis, 2007). The tumor suppressive role of MKK4 might include the 
induction of attenuated proliferation as well as increased apoptosis in response to specific 
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stimuli through the activation of the NF-κB signaling pathway. Similarly, while MKK4 plays 
a role in the formation of some primary tumors, it may suppress metastasis through 
interactions with distinct MAP kinases or other non-canonical downstream mediators 
(Whitmarsh and Davis, 2007). In metastatic human ovarian cancer cells, over expression of 
MKK4 triggers increased expression of the p53-inducible cell cycle inhibitor p21 (Lotan et 
al., 2008), pointing to one possible mechanism by which loss of p53 might complement 
MKK4 inactivation in tumor cells. Perhaps, distinct context dependent stimuli in different 
tissues dictate which signaling pathways are targeted by MKK4. 
 
The inactivation of tumor suppressor genes is a key feature of cancer formation and 
progression. Tumor suppressor genes are inactivated through mutations and subsequent 
loss of heterozygosity (LOH) or following homozygous deletion. The human MKK4 gene is 
located on chromosome 17p11.2 and lies centromeric to the p53 tumor suppressor gene. This 
arm of chromosome 17 is one of the most frequently deleted in human cancers. However, bi-
allelic deletion of MKK4 is not frequently observed in human tumors. Moreover, despite the 
high rate of 17p LOH, MKK4 experiences a low rate of inactivating mutations of only ~5%. 
Together, the genomic data suggest that complete loss of MKK4 function is not 
advantageous for a tumor cell. Our experimental data further imply that gene dosage of 
Mkk4 might be of importance for its tumor suppressive function. shRNA-mediated 
knockdown of MKK4 resulted in residual MKK4 mRNA levels and, therefore, a complete 
knockout was not mimicked. Therefore, we propose that MKK4 functions as a 
haploinsufficient tumor suppressor gene for which a single copy is insufficient to produce 
the normal level of gene expression. In Saccharomyces cerevisiae, the phenomenon of 
haploinsufficiency has been relatively well-studied, and more than 180 haploinsufficient 
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genes have been identified by profiling of heterozygous deletion strains. But why is gene 
dosage so important for some genes in the genome? Do haploinsufficient genes share 
genomic or functional attributes? And why do these haploinsufficiency show a wide range 
of penetrance, expressivity, and phenotypes?  
 
It seems unlikely that the biologically active tumor suppressor gene MKK4 is subject 
to a two-hit mutational mechanism in cancer. Therefore, the mechanism by which 
monolallelic loss drives tumorigenesis remains an interesting open question. For example, 
in the case of transcription factors, synergistic effects involving cooperative interactions in 
complexes offer an attractive explanation for haploinsufficiency. A system that requires 
oligomerization of different subunits is very sensitive to protein dosage and stoichiometric 
imbalances can affect such synergistic complexes. Moreover, various signals and 
informational pathways need to be integrated with a limited set of factors (Veitia, 2002). 
This combinatorial strategy may underlie many cases of haploinsufficiency, including gene 
expression, regulation and protein-protein interactions. For example, FBW7, a substrate 
recognition component of the SCF-type ubiquitin ligase, is frequently heterozygously 
mutated or deleted in human cancers. FBW7 dimerizes, and any single-allelic mutation 
reduces the amount of wild-type FBW7 by 50% and leads to haploinsufficiency of the 
remaining wild-type allele with regards to the requirement for dimeric FBW7 functions 
(Welcker and Clurman, 2008). FBW7 targets p27Kip1, which is also haploinsufficient for 
tumor suppression. p27Kip1 targets and inhibits other cycline-dependent kinases to arrest the 
cell cycle at G1. By lowering the inhibitory threshold, partial loss of p27Kip1 accelerates cell 
cycle progression (Siu et al., 2012). Furthermore, upon carcinogen treatment or irradiation, 
heterozygous p27Kip1 mice develop more tumors than wild-type mice but fewer than 
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homozygous mutants (Fero et al., 1998). However, in the case of MKK4, its tumor 
suppressive function depends on the kinase activity. Most somatic mutations affect protein 
stability or impair its kinase activity, resulting in rapid degradation of MKK4 through the 
ubiquitin-proteasome complex (Ahn et al., 2011). Therefore, reduced levels of MKK4 
through mono-allelic deletions or mutations might result in lower activated levels of its 
downstream mediators, that can have a causal effect on tumorigenesis.  
 
 Whole chromosome arm deletions are one of the major, but poorly understood, 
characteristics of the cancer genome. Genome instability can be an explanation for random 
deletion events; however, it does not explain the high selection pressure for deletion events 
of the short chromosome arm 17, which is observed across tumor types. The biological 
relevance of chromosome 17p deletions has not been studied in detail and loss of p53 
remains the single explanation of this frequent genomic alteration. Opposing this 
hypothesis, we have shown experimentally that 17p encompasses at least one additional 
tumor suppressor gene and that cosuppression of a linked 17p gene promotes tumor 
formation more potently than suppression of p53 alone. Large deletion events, such as those 
affecting 17p, might therefore specifically arise from selective pressure to attenuate the 
activity of multiple genes. The “cancer gene island model” hypothesizes that chromosomal 
regions encompassing high densities of genes with tumor suppressive functions and low 
densities of essential genes become targets of frequent heterozygous deletion events 
(Solimini et al., 2012). The presence of recurrent heterozygous large deletions can therefore 
be explained by an increase of proliferative fitness through cumulative haploinsufficiency. 
For example, this phenomenon has been recently observed for chromosome 8p, where the 
co-deletion of DLC1, FGL1, FBXO25, and TRIM35 accelerated tumor burden in a mouse 
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model of liver cancer, and their combined loss correlated with poor survival in human 
cancer patients (Xue et al., 2012). These studies challenge the prevailing view that bi-allelic 
inactivation of canonical tumor suppressor genes are critical for tumorigenesis, and instead 
suggest that mono-allelic disruption of linked cancer genes may collectively have a broad 
impact on cancer development and progression. Large deletions affecting other 
chromosomes (e.g., 3p, 5q, 9p) may similarly have wider consequences than what has been 
suggested to date. 
 
The early embryonic lethality due to anemia and severe hemorrhaging in the liver 
caused by the deletion of MKK4 has underscored the critical importance of its function(s) 
during development (Ganiatsas et al., 1998). However, if MKK4 is essential in liver cells, 
retention of a copy of the gene should be selected even though mono-allelic deletion of 
MKK4 predisposes to cancer. Understanding the physiological requirements for MKK4 
activity in signal transduction will be key in deciding whether therapeutic targeting of the 
MKK4 pathway will prove of clinical benefit, and may possibly explain how best to 
specifically modulate certain Mkk4-mediated functions but not others. 
 
 
4.4. Chapter Contributions 
S.W. and D.F.T designed and performed the majority of the experiments. D.A. contributed 
intellectually to the design of the project and helped performing western blots. T.K. 
performed genome data analysis.  S.W.L. conceived and supervised the project. 
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4.5. Supplementary Figures 
 
Suppl. Figure 4.1. Set up of in vivo RNAi screen 
(A) H&E sections of mouse tumors derived from p53-/-;MYC LPCs with APC knockdown. Mouse HCCs resemble 
the histopathological subtypes of HCC, with solid and trabecular growth pattern. (B) Tumor growth after 
subcutaneous injection of p53-/-;MYC LPCs expressing sh.Ctrl or -Apc at various dilutions. (C) Brightfield and 
GFP images of tumors from (B). (D) Screening results. 4 out of 16 tested shRNA pools accelerate tumorigenesis. 
 
Chapter 4 
115 
 
 
Suppl. Figure 4.2. MKK4-suppression induces ERK activation through NF-κB 
(A) pERK, tERK, tMKK4, and Actin levels of LPC cells infected with shRNAs targeting Mkk4 (1 or 2), or a 
nontargeting control (Ctrl) as determined by western blotting. (B) pERK, tERK, p-p65, tMKK4, and Actin levels 
of LPC+sh.Ctrl and LPC+sh.p65 superinfected with sh.Ctrl or sh.Mkk4. (C) pMKK7, tMKK7, and Actin levels of 
LPC+sh.Ctrl and LPC+sh.p65 superinfected with sh.Ctrl or sh.Mkk4. 
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5. Chapter 5  
Conclusions and Future Perspectives 
 
 
Genetic alterations affecting chromosome 17p are one of the most frequent aberrations in 
human cancers. Such abnormalities usually comprise mutations in the tumor suppressor 
gene p53 and loss of heterozygosity (LOH) of the remaining chromosome arm 17p, which 
often affects the 274 protein-coding genes contained in this chromosomal region. My thesis 
work set out to understand the functional relevance of genetic alterations of chromosome 
arm 17p in tumorigenesis and how these changes can be exploited for therapeutic benefit.  
 
 First, we analyzed the biological consequences induced by mutations in the tumor 
suppressor p53 and found that mutant p53 enhances the invasive and metastatic potential of 
pancreatic cancer cells through the regulation of multiple molecular mechanisms. We 
identified the platelet-derived growth factor receptor b (PDGFRb) as a necessary 
downstream mediator of mutant p53 action and demonstrated that reduction of PDGFRb 
activity impaired metastasis in a mouse model of pancreatic cancer. Inhibition of PDGFRb 
might therefore represent an alternative treatment strategy for metastatic tumors harboring 
mutations in p53. In addition, we unraveled a miRNA-mediated mechanism by which 
mutant p53 attenuates the metastasis suppressive functions of MKK4 to potentiate cell 
invasion. Together, these investigations shed light on the neomorphic functions of mutant 
p53 in pancreatic cancer. 
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Besides our efforts to understand the relevance of p53 mutations in pancreatic 
cancer, we gained insights into the biological significance of large deletions encompassing 
the chromosome region 17p. We provided evidence that the recurrent large deletions 
targeting chromosome 17p attenuate the potential tumor suppressor activity of multiple 
genes rather than acting solely to inactivate p53. To this end, we showed that loss of Mkk4 
enhanced the tumorigenic potential of premalignant p53-null hepatoblasts in a mouse 
model of hepatocellular carcinoma. A better understanding of the molecular mechanisms 
underlying these cooperative effects might provide unexpected vulnerabilities that may be 
relevant to the treatment of malignant diseases. 
 
 
5.1. Mutant p53 in Cancer: Challenges and Opportunities 
Functional inactivation of p53 is an almost universal feature of human cancer. Whereas p53 
deletions cause the loss of its tumor suppressive function, p53 mutants additionally acquire 
dominant negative activity over the wild-type allele as well as oncogenic properties that 
lead to a gain of function. Given frequent p53 mutations in cancers of different origins, a 
detailed understanding of neomorphic functions and their underlying mechanism is of high 
importance to understand the nature of all cancers. Even though a large number of studies 
performed on mutant p53 have revealed a wealth of information, only one decisive 
conclusion has emerged: there is no singular remedy that impedes the gain of function 
activities of mutant p53.  
 
Given the many cellular functions that are initiated by wild type p53, it would have 
been naïve to assume that the properties of gain of functions of p53 mutants are not equally 
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diverse. Indeed, multiple neomorphic functions have been ascribed to mutant p53, 
including its ability to promote cell invasion and metastasis, increased cell proliferation and 
survival, drug and apoptosis resistance, genomic instability, enhanced angiogenesis, and 
inflammation (Muller and Vousden, 2014). More recent studies have also reported a role of 
mutant p53 in cell reprogramming or in regulating the interaction of cancer cells with tumor 
stroma. In contrast to wild type p53, inactivation or mutation of p53 facilitates the 
dedifferentiation of somatic cells into pluripotent stem cells and, for example, initiates 
tumor formation by promoting the generation and expansion of the mammary epithelial 
stem cells (Lu et al., 2013). Therefore, as for wild type p53, mutant p53 affects many different 
cellular outcomes that most likely depend on the tumor-type and cellular context.  
 
Many important biological processes are regulated through different, but parallel, 
mechanisms in mammalian cells. Here, we have identified multiple mechanisms through 
which mutant p53 drives invasion and metastasis in pancreatic cancer: by regulating 
PDGFRB levels in a transcriptional manner and by modulating the miRNA profile to cause 
inactivation of MKK4. Moreover, previous studies have identified additional downstream 
mediators of mutant p53 that drive invasion and metastasis, such as integrin recycling 
(Muller et al., 2009), the mevalonate pathway (Freed-Pastor et al., 2012) or miRNA 
biogenesis (Su et al., 2010). Hence, the molecular mechanisms governed by mutant p53 to 
drive invasion seem versatile and redundant.  
 
How does mutant p53 promote its different neomorphic functions? A single base 
substitution in the DNA binding domain of p53 generally cancels its ability to bind to 
consensus DNA binding regions of target gene promoters. Whereas a few forms of mutant 
Chapter 5 
120 
 
p53 can recognize specific DNA structures to directly drive gene expression, most of them 
affect transcription of target genes through binding and modulating other transcription 
factors. Differently from wild type p53, mutant p53 binds to its family members p63 and 
p73. By inhibiting p63, mutant p53 regulates expression of Dicer, DEPDC1, Cyclin G2, and 
SHARP1, whereas inhibition of p73 leads to gene expression changes of PDGFRb. Moreover, 
mutant p53 also interacts with a wide variety of proteins, such as MRE11, SREBP, VDR, or 
NFR2, to modulate their cellular pathways and contribute to a more aggressive cancer 
phenotype (Muller and Vousden, 2014). Therefore, one of the main challenges in the field is 
the identification of interaction partners and the downstream pathways that are modulated 
by them. 
 
 Single base substitutions in the p53 gene that induce neomorphic functions mainly 
cluster in the DNA binding region, with only a few affecting other domains (Leroy et al., 
2013). Common hotspot mutations are clustered at codons 175, 245, 248, 249, 273, and 282; 
yet, their spectrum and frequency depends on the tumor type. The type of mutation 
classifies the mutant p53 protein into either a (i) contact mutant, or (ii) conformational 
mutant (Cho et al., 1994). Despite these oversimplified classifications, each mutation 
generates subtly different alterations in the structure and conformational stabilities of the 
p53 protein (Joerger and Fersht, 2007). Complicating experimental studies, different mutants 
are not alike in respect to their ability to inhibit wild type p53 and in their range of gain of 
functions Moreover, contrasting phenotypes generated by the same mutant in different 
tissue types could potentially reflect differential expression of mutant p53 targets, including 
p63 and p73. For example in breast and lung cancer cells, mutant p53 attenuates Dicer and 
global miRNA expression in a p63-dependent manner, whereas in pancreatic cancer cells, 
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mutant p53 induces the expression of distinct miRNAs and does not affect Dicer levels 
(Muller et al, 2014; Chapter 3). Remarkably, not only the position but also the type of the 
mutation influences the spectrum of p53 outputs (Muller and Vousden, 2014). Whereas the 
p53R280K mutant enhances invasion, p53R280T promotes proliferation and cell cycle 
progression. Hence, it remains a challenge to identify the mechanistic and functional 
consequences of each p53 mutation. Moreover, how these mutations affect disease 
progression and therapeutic responses remain a difficult question.  
 
 But why is the mutation pattern of p53 so versatile? The distribution of mutations in 
well-studied oncogenes and tumor suppressor genes are highly characteristic and 
nonrandom. Therefore, it is the pattern of mutations, rather than the mutation rate, that 
classifies driver genes into oncogenes or tumor suppressor genes. Oncogenes exhibit 
recurrent missense mutations at the same amino acid positions, whereas mutations in tumor 
suppressor genes are inactivating, cause protein-truncation and occur throughout the length 
of the gene (Vogelstein et al., 2013). For example, nearly all mutations in KRAS are at the 
identical amino acid, codon G12, and classify that gene unambiguously as an oncogene. 
Such mutations enhance the wild type activity of KRAS and make it constitutive active. On 
the other hand, in squamous cell carcinomas, mutations affecting the NOTCH1 gene are not 
recurrent and usually inactivating, therefore suggesting a tumor suppressive role. In the 
case of p53, however, missense mutations occur throughout the DNA binding domain, 
affect different amino acids, but do not cause protein-truncations. Therefore, the paradoxical 
distribution of mutations in the p53 gene does not fit the typical criteria for other well-
documented cancer genes. The presence of some hotspot mutations is accompanied by 
many other mutations throughout the p53 gene and, therefore, indicates a tumor 
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suppressive function. Consistently, mutations prevent DNA binding of p53 and cause a loss 
p53’s tumor suppressive function. Paradoxically, the missense mutations also induce a gain 
of function; however, they might not be under evolutionary selection. This assumption is 
supported by the fact that different mutations cause different types of gain of functions and 
activate varying downstream mediators. Therefore, a p53 mutation does not, as in the case 
of oncogenes, enhance wild type activity to cause oncogenic potential but rather induces a 
gain of function that by itself might not be enough to initiate tumor growth but only in 
combination with the loss of the tumor suppressive functions. Whereas cancer cells select 
for the loss of p53’s tumor suppressive function, the gain of functions might be an 
advantageous, but not necessary, addition to the aggressive phenotype. 
 
The impact of mutant p53 on tumorigenesis makes it an attractive therapeutic target. 
The most efficient therapeutic strategy would be to target mutant p53 directly. Given that 
the accumulation of mutant p53 is a requisite for its gain of function activities, enhancing 
the turnover of the mutant protein by inducing its proteosomal degradation represents one 
potential approach. Indeed, SAHA, a HDAC inhibitor, has shown promising results in 
destabilizing mutant p53 by preventing the interaction between HDAC6 and Hsp90 (Li et 
al., 2011). However, whether a decrease of mutant p53 levels and the simultaneous 
degradation of wild type p53, if still expressed, are sufficient for a therapeutic benefit, 
remains debatable. Given the antitumor effects observed upon reactivation of wild-type p53 
in several models (Xue et al., 2007), an alternative would be to restore wild type function of 
p53 mutants in order to induce apoptosis or senescence. This idea relies on the concept of 
reverting the conformational changes introduced by a given mutation. Small molecules, 
such as PRIMA-1 or PhiKan083, bind to the DNA binding domain of specific mutants to 
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promote correct folding and to restore wild type function (Boeckler et al., 2008). PRIMA-1 is 
currently in phase 1 clinical trials (Lehman et al., 2012). Despite these directed strategies, 
targeting downstream mediators in tumors expressing mutant forms of p53 may also hold 
promise. This approach requires the identification of commonalities of mechanisms through 
which mutant p53 proteins function, possibly by identifying interacting partners that exert 
relevant outcomes. For example, the small molecule RETRA inhibits the interaction between 
p73 and mutant p53, resulting in decreased cell survival and suppressed xenograft growth. 
Alternatively, the inhibition of downstream signaling pathways that are activated by 
mutant p53 might be exploited for therapeutic intervention. Some examples have proven 
successful in in vitro or in vivo mouse models and include the PDGFRb pathway by imatinib 
(Chapter 2), blocking the cholesterol synthesis pathway by statins (Freed-Pastor et al., 2012), 
and the EGFR pathway by EGFR inhibitors (Mueller et al, 2009). Another, yet 
underexplored, area is the identification mutant p53-dependent vulnerabilities, which 
would help utilizing synthetic lethality as a therapeutic strategy.  
 
 On occasion, single mutants become highly sensitive to specific second mutations, 
resulting in cell death (synthetic lethality) or a decrease in fitness (synthetic sickness). 
Therefore, synthetic lethality might be a promising strategy for specific targeting of tumor 
cells. Uncovering synthetic interactions, however, is not trivial because they are rare and not 
always directly conserved between organisms. The first synthetic lethal interaction was 
discovered in breast and ovarian tumor cells with BRCA1 and BRCA2 mutations, which are 
impaired for effective DNA double-strand break repair and, thus, sensitive to the inhibition 
of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and 
subsequent apoptosis (Farmer et al., 2005). Whether the same phenomenon can be applied 
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in tumors expressing mutant p53 is not clear. Identifying synthetic lethal genes is mostly 
based on genome-wide or kinome-wide RNAi screening, which has been extensively 
utilized to identify sensitizing targets to chemotherapeutic agents. In the case of mutant p53, 
such a screen would be carried out in isogenic cells lines in which mutant p53 either 
expressed or depleted by, for example, CRISPR-mediated modulation of the p53 gene locus. 
Such screens have not been carried out yet; however, a number of genes and pathways that 
may result in synthetic lethality in mutant p53-expressing tumors were recently identified 
using a computational approach (Wang and Simon, 2013). PLK1 was proposed to be a 
candidate for mutant p53 synthetic lethality due to its higher expression in tumors 
expressing mutant p53 and its inhibitory role in the transactivation of p53 function. 
However, PLK1 is an essential gene and the causal effect of its inhibition on normal cells 
might be equally deleterious. Therefore, the functional identification of synthetic lethal 
interaction with p53 mutants that cause a proliferative defect has yet to be carried out. 
Alternatively, there might be less obvious vulnerabilities created by mutant p53. As most 
neomorphic functions are pro-metastatic, a synthetic sickness screen might identify mutant 
p53-dependent interactions that cause invasion and metastasis. Here, one would compare 
the shRNA distribution in metastatic clones of distant organs to the primary tumor, carrying 
a mutant p53 or characterized by p53 knock down. Other vulnerabilities created by mutant 
p53 might be in the DNA damage pathway or cell metabolism.  
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5.2. Dissecting large deletions – the orchestral performance of concurrent 
loss of haploinsufficient genes 
The cancer genome is characterized by amplifications, deletions, rearrangements, point 
mutations, and loss of heterozygosity (LOH) that collectively result in tumorigenesis. In the 
case of chromosome 17p, common genetic alterations not only include p53 mutations, but 
also the concomitant loss of the other chromosome arm not affected by mutational events. In 
most cases, such deletions target the entire short chromosome arm of 17 and its 274 genes. 
This observation opens the question whether large deletions target only one driver gene but 
simultaneously cause the deletion of many passenger genes without any causal effect on 
tumorigenesis or, alternatively, whether they target multiple genes that cooperate to drive 
tumor outgrowth. 
 
Whether the loss of multiple genes from chromosome 17p contributes to the 
tumorigenic phenotype remains unclear. Our data from Chapter 4 suggest that the recurrent 
17p deletion events reflect the selective advantage of simultaneously targeting the two 
tumor suppressors MKK4 and p53. The combined loss of both genes maximizes 
proliferative fitness through cumulative effects. Others have functionally verified the 
presence of physically “linked gene clusters” on chromosome 6q and 8p (Scuoppo et al., 
2012; Xue et al., 2012). Moreover, sequencing studies investigating the contribution of 
recurrent heterozygous deletions to tumorigenesis indicate that large deletion events 
preferentially target regions of clustered genes that negatively regulate proliferation but 
spare essential genes (Solimini et al., 2012). The biased distribution of proliferation-
inhibitory genes over proliferation-inducing genes in these regions suggests a selective 
advantage for a cancer cell with large deletions. In addition to deletions, amplifications of 
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extended chromosome arm regions are also frequently observed and may result in the 
enhanced expression of multiple genes that induce proliferation (Zender et al., 2006). The 
idea of “linked gene clusters” challenges the prevailing view that a single gene in a region is 
the driver and that neighboring genes become altered simply as passenger events. 
Therefore, because hundreds to thousands of genes per tumor are affected by large 
deletions, it might be the combined loss of multiple growth control genes that affect 
tumorigenesis across many cancer types. Cumulative effects of gene loss may play an 
important role and might change the way in which we think about cancer evolution. 
 
The realization that large deletions or amplifications target multiple genes is a rather 
new concept underlying tumor evolution. Albeit exciting, it confronts us with many 
challenges, as functional studies with a single gene affected by a amplification or deletion 
will miss the causal consequences of linked genes on tumorigenesis. Moreover, regarding 
large deletions, only 22% of recurrent large deletions target known tumor suppressor genes, 
suggesting that potential tumor suppressive functions of many genes remains to be 
identified. However, the presence of cryptic tumor suppressor genes in large deletions 
might not be the only answer. For example, loss of regulatory long non-coding RNAs or 
altered 3D chromosome structures that impair binding of enhancers to promoters over great 
distances (or even across different chromosomes) could contribute to the impact of large 
chromosomal deletions on tumorigenesis. These events are not pinpointed by conventional 
sequencing analysis and, thus, the identification of their presence and function requires new 
experimental approaches. 
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 Large deletions often affect one allele only. Heterozygous loss of substantial 
chromosomal regions affects different chromosomes, occurs frequently in cancer patients, 
and is present in tumors of different origins. Therefore, the question becomes whether they 
harbor bona fide tumor suppressor genes for which single-copy loss has a functional role in 
driving tumor growth. Solimini et al. argue that most recurrent heterozygous deletions are 
not caused randomly, but that they impact tumorigenesis in a haploinsufficient manner 
(Solimini et al., 2012). Therefore, the impact on tumorigenesis of large deletions that occur 
heterozygously cannot be explained by Knudson’s “two-hit hypothesis” and, instead, 
questions the dogma that all important tumor suppressors behave according to the two-hit 
inactivation model. 
 
Some classical two-hit tumor suppressors also display haploinsufficiency, 
supporting the idea that haploinsufficiency carries a functional role in cancer. Notably, p53 
itself exhibits haploinsufficiency in that mice with heterozygous p53 deletions (p53+/-) show 
an intermediate survival compared to p53-null and wild-type mice, and some tumors that 
develop in the p53+/- animals retain an intact, functioning wild-type allele (Venkatachalam 
et al., 1998). Other classical cancer susceptibility genes that show haploinsufficiency are 
BRCA1 and BRCA2. BRCA1/2 carriers develop premalignant lesions that drive 
tumorigenesis by promoting loss of the second allele or, alternatively, of other tumor 
suppressor genes (Bellacosa et al., 2010). Other convincing examples of haploinsufficient 
genes include p27Kip1, DMP1, PTEN, RB, SMAD4, LKB1, NKX3.1, MSH2, and MAD2 
(Santarosa and Ashworth, 2004). Therefore, the idea that Knudson’s two-hit model of 
inactivation is more complex for most tumor suppressor genes is reasonable. One would 
need to determine whether loss of the second allele is at the normal cellular rate for such 
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events or whether it is facilitated by haploinsufficiency. Careful comparison of the genetic 
composition of resulting tumors in mice carrying either heterozygous or homozygous 
mutations in the gene of interest might hint at the answer. Such studies would help to find 
whether the haploinsufficient nature of classical tumor suppressor genes contributes to loss 
of the wild-type allele and in which cases this event is random. 
 
It is believed that the functional and molecular outcome of haploinsufficient tumor 
suppressor genes is, just like the classical tumor suppressor genes, highly tissue-specific and 
context-dependent. For example, gene dosage effects of heterozygous PML mutations 
become only apparent in mice carrying the translocation between human chromosomes 15 
and 17, creating a PML-RARα fusion protein, but not in a wild-type background (Rego et 
al., 2001). Thus, the tumorigenic advantage conferred by haploinsufficiency of a tumor 
suppressor gene is too low to be selected for but a second mutation in another tumor 
suppressor gene can synergies with the first. As a result, this cell could gain a phenotype 
either of proliferative increase or genomic instability; thereby, become selected for to drive 
tumorigenesis. 
 
 But what are the contributions of haploinsufficient genes on tumorigenesis? Based 
on the nature of haploinsufficiency that includes the partial reduction of gene function only, 
one might hypothesize that haploinsufficient genes produce a “sensitized background” for 
tumorigenesis to occur. This hypothesis might hold true given the fact that tumors initiated 
by alterations in haploinsufficient gene exhibit later onset and milder phenotypes than the 
corresponding tumor with homozygous gene loss (Santarosa and Ashworth, 2004). 
Therefore, haploinsufficiency that causes small proliferative advantages or modest 
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abnormalities in DNA repair mechanisms could increase the mutation rate. For example, 
haploinsufficiency of the NF1 gene is required to establish the NF1 homozygous state that 
initiates tumor growth. However, such phenomena are difficult to prove experimentally and 
whether they are of general applicability is unknown. Here, only the analysis of the 
sequence of events affecting each allele and their individual contribution to tumorigenesis 
could give the definitive answer. Moreover, whether the cooperative effects of multiple 
haploinsufficient genes together yield a stronger effect that cannot only sensitize but initiate 
tumor growth remains to be elucidated. Generating mouse models with large heterozygous 
deletions that are believed to carry multiple haploinsufficient genes, such as 17p, might give 
an answer to that question. 
 
 Haploinsufficiency has a well-established role in numerous developmental 
disorders, such as the Grieg’s syndrome (caused by haploinsufficiency of GLI3) (Kalff-Suske 
et al., 1999) or the type 2 Waardenburg’s syndrome (caused by haploinsufficiency of MITF) 
(Nobukuni et al., 1996). The notion that a partial decrease in gene dosage is relevant to 
cancer enjoys increasing acceptance, but is held back due to inadequate evidence. 
Convincing validation of a haploinsufficient gene would comprise evidence for retention of 
the wild-type allele, absence of deleterious mutations, continued expression of the protein 
product, as well as phenotypic effects on tumorigenesis. Developing quantitative assays that 
can assess and score partial differences in expression levels will be helpful in the future. 
Questions remain whether haploinsufficiency, just like transcriptional or post-translational 
regulation, can be harnessed for cancer prevention and therapy. Certainly, directly or 
indirectly targeting haploinsufficient tumor suppressor genes would require a quantitative 
analysis of their expression levels in the tumor of the patient, since the sole assessment of 
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their presence or absence would not be enough. Moreover, how the partial loss of certain 
genes changes vulnerabilities and dependencies of cancer cells has not been explored. 
Therefore, whether the activation or inhibition of alternative pathways or synthetic lethality 
approaches can be considered, as in the case with classical tumor suppressor genes, is not 
defined. 
 
In conclusion, the concept of physical linkage of haploinsufficient tumor suppressor 
genes from one heterozygous deletion event seem to have a more prevalent and impacting 
role in tumorigenesis than was previously assumed. The prevalence of heterozygous large 
deletions represents a new mechanism for cancer evolution and needs further investigation 
addressing the following points: Does the combined loss of genes affect the same or 
different cellular pathways? How do their molecular functions synergize? Is the cumulative 
reduction of dosage of genes with tumor-suppressive properties enough to initiate tumor 
growth or does it occur to particularly promote or enhance tumor progression? Does 
haploinsufficiency occur in the context of specific genetic or environmental insults? Does the 
concomitant loss of multiple genes create unexpected vulnerabilities and dependencies that 
can be harnessed for cancer therapies? If large deletions create cancer cell vulnerabilities, 
these might have been missed in studies of single genes. Therefore, chromosome arm 
deletions can create phenotypes unique from those arising through loss of a single tumor 
suppressor gene, and thus should be considered and studied as distinct events. 
 
Collectively, my thesis work illustrates how a well-studied tumor suppressor locus 
can impact on tumorigenesis that exceeds the simple loss or gain and, moreover, how such a 
locus can cooperate with other genes affected by genetic alterations. The situation is 
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complex: p53 mutations lead to gain of function activities and combined 
haploinsufficiencies that drive cancer in unique and unanticipated ways. The many genetic 
modifications affecting 17p contribute to tumorigenesis in different ways. This situation is 
reminiscent of the INK4a/ARF locus, where single deletion events can target at least three 
tumor suppressors that interact to influence tumorigenesis (Sharpless et al., 2003). Such 
events were expected to be the exception; however, our results, combined with emerging 
data from others, suggest that this might rather be the rule. If so, our view about 
mechanisms underlying of cancer evolution and therapeutic strategies might need to be 
expanded. If haploinsufficient genes act combinatorial and in a dosage-dependent manner, 
how do they affect cancer susceptibility and resistance? Such questions can only be 
addressed after identifying the causal genes and their effects, but the lack of mouse models 
with such complex genotypes prevents us, to date, from experimental studies. Mouse 
models of cancer susceptibility could be generated by enriching for combinations of alleles 
that are frequently genetically altered in the cancer genome. Despite the fact that the 
mapping of the number and chromosomal location of genes involved in various forms of 
cancer is time and labor intensive, rapid advances in mouse genome projects will help to 
accelerate the progress in detecting modifier loci. 
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6. Chapter 6 
Materials and Methods 
 
 
Retroviral Constructs, Antibodies and Reagents 
All vectors were derived from the Murine Stem Cell Virus (MSCV, Clontech) retroviral 
vector backbone. PDGFRb cDNA (Addgene, #23893) was subcloned into MSCV-PGK-Puro-
IRES-GFP (MSCV-PIG) (Hemann et al. 2003). miR30-based shRNAs were designed and 
cloned as previously described (Zuber et al. 2011) and sequences are available upon request. 
shRNAs were cloned in the MLP vector (MSCV-mir30-PGK-Puro-IRES-GFP) for constitutive 
expression and inducible shRNAs were cloned into the TRMPV-Neo vector (pSIN-TRE-
dsRed-miR30-PGK-Venus-IRES-NeoR) as previously described (Zuber et al. 2011). All 
constructs were verified by sequencing. 
  
p53 was detected using mAb NCL-P53-505 (Novocastra) and hAB OP43 
(Calbiochem). Anti-Actin (A3854) was purchased from Sigma. Anti-PDGFRa (3164) and –
PDGFRb (3169) antibodies were purchased from Cell Signaling. Alexa Fluor 568-Phalloidin 
(A12380) was purchased from Invitrogen. Crenolanib (CP-868596) and imatinib (I-5508) 
were purchased from Selleckchem and LC Laboratories, respectively.   
 
Cell Culture and Drug Treatments 
All cell lines were maintained in DMEM + 10% FBS, at 37° C in 5% CO2. Stable cell lines 
expressing shRNAs were generated by retroviral mediated gene transfer. Briefly, Phoenix or 
Ampho packaging cells (for murine or human cell lines, respectively) were transfected by 
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the calcium phosphate method with vectors expressing NF-YA, NF-YB, p53, p73, PDGFRa, 
PDGFRb or Renilla-control shRNAs, and the generated viruses were harvested to infect 
KPC, KPflC, or a series of human pancreatic, breast, lung and colon cancer cell lines. Infected 
cells were selected with puromycin and experiments were carried out on derived cell 
populations. To generate cells stably expressing mutant p53, p73 or PDGFRb, KPflC cells 
were infected with MSCV-p53-R175H, -R273H, PDGFRb or pcDNA3-HA-p73  and selected 
in puromycin and G418 respectively to yield stable pools. Cultured cells were treated with 
300 nm crenolanib and 3 µM imatinib. These concentrations were selected after determining 
the concentration required to fully inhibit the phosphorylation of PDGFRb without any 
effects on cell proliferation.  
 
Wound healing and Invasion Assays  
Wound healing assays were conducted as previously described (Goulimari et al., 2005). 
Briefly, cells were seeded in 6-well plates, grown until confluent, and wounding was 
performed with a 10- l microtiter tip that was cut longitudinally. Three-dimensional 
invasion assays were carried out as previously described (Kitzing et al., 2007). In brief, 24-
well transwell inserts (Greiner bio-one) were lined with collagen type 1 (BD Biosciences), 
and cells were seeded on the inverted inserts. The lower chambers were filled with medium 
containing 0.5% FBS and upper chambers containing the collagen matrix were filled with 
medium containing 20% FBS and the chemoattractant HGF.  
 
Immunostaining and Microscopy 
Live cell recordings were performed immediately after wounding for 18 h at 37 °C using a 
Zeiss observer Microscope. Pictures were acquired every 10 min with a motor-controlled 
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Leica DC 350 FX camera, which enables simultaneous recordings from multiple wells. For 
statistical analysis, the wound distance from each well was measured in duplicate at three 
randomly defined wound gap locations per frame recorded per experiment. Invasion assay 
inserts were fixed using 4% formaldehyde and stained using DAPI and Alexa568 phalloidin 
(Invitrogen) before confocal microscopy (Perkin Elmer Spinning Disk) was conducted. 
Images were analyzed using Imaris software.  
 
RT–qPCR 
Total RNA was isolated using TRIZOL (Invitrogen), and cDNA was obtained using the 
TaqMan reverse transcription reagents (Applied Biosystems). Real-time PCR was carried 
out in triplicate using SYBR Green PCR Master Mix (Applied Biosystems) on the ViiA™ 7 
Real-Time PCR System (Invitrogen). GAPDH or  -actin served as endogenous 
normalization controls.  
 
RNA sequencing and Data Analysis 
RNA of KPC samples was isolated and separated by size. Nucleotide sequencing of RNAs 
of >200 nt and <200 nt length was carried out as previously described (Djebali et al., 2012). 
Directional (stranded) libraries for Paired End (PE) sequencing on the Illumina platform 
were generated as described previously (Parkhomchuck et al., 2009). Primary data 
processing and library mapping was completed using the Spliced Transcripts Alignment to 
a Reference (STAR) software (Dobin et al., 2013). Differential expression analysis for 
sequence count data (FPKM values) was conducted using DESeq as described previously 
(Anders and Huber, 2010). 
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PDGFRb Luciferase Reporter Assay 
The promoter assay was performed as previously described (Hackzell et al., 2002). In brief, 
cells were seeded in 24-well plates and transiently transfected with 0.5 ug of expression 
plasmid, 2.0 ug of reporter plasmid, and 20 ng of renilla-luciferase vector (PGL4.74, 
Promega). After 36 h, cells were lysed (Dual-Luciferase Reporter Assay System, Promega), 
and firefly luciferase and renilla luciferase activities were measured (Varioskan Flash 
Multimode Reader, Thermo Scientific). Results shown were normalized to renilla activity 
and are representative of at least three independent replicates. 
 
Co-Immunoprecipitation 
To detect p53/p73 and p73/NF-Y binding, sub-confluent KPflC cells were infected with 
mutant p53 or an empty control construct and transiently transfected with HA.p73 
(Addgene) using Lipofectamine 2000 (Invitrogen). Thirty-six hours post-transfection, cells 
were lysed in RIPA Buffer (20 mM Tris pH 7.4, 1% TritonX-100, 37 mM NaCl, 2 mM EDTA, 
1% SDS, 0.5% NP-40, 10% Glycerol, phosphatase inhibitors [2.5 mM Sodium pyrophosphate, 
1 mM β-Glycerophosphate, 1 mM Na3VO4], and protease inhibitors [Roche]). Whole cell 
lysates (0.5 mg protein) were pre-cleared with A/G Sepharose beads (Invitrogen), incubated 
at 4° C with either anti-HA (Covance, 16B12) or anti-p53 antibody (Calbiochem, OP43) 
overnight and subsequently with protein A/G beads for 2 h. The bead pellet was 
extensively washed in lysis buffer three times and then electrophoresed on 10% SDS-PAGE 
gels followed by immunoblotting using anti-p53, anti-HA, anti-GFP (Cell Signaling, 2555) 
and anti-NF-YB (Santa Cruz, FL-207) antibodies. 
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To measure levels of endogenously phosphorylated PDGFRb, KPC cells were treated 
with the drug as described and harvested in phospho-lysis buffer (50 mM Tris pH 7.5, 1% 
Tween-20, 200 mM NaCl, 0.2% NP-40, phosphatase inhibitors [2.5 mM Sodium 
pyrophosphate, 1 mM β-Glycerophosphate, 1 mM Na3VO4], and protease inhibitors 
[Roche]). Anti-PDGFRb (Santa Cruz, 958) was used to immunoprecipitate PDGFRb from 
whole cell lysate samples containing 0.5 mg protein. Washed immunoprecipitates were 
subjected to SDS-Page and immunoblotted with anti-PTyr-100 antibody (Cell Signaling, 
9411).  
 
Chromatin Immunoprecipitation 
Chromatin Immunoprecipitation (ChIP) experiments were carried out as previously 
described (Beckerman et al., 2009). Briefly, KPC cells were treated with 1% formaldehyde 
prior to lysis in RIPA Buffer and sonication to yield 500 bp fragments. Protein A/G 
Sepharose beads were conjugated to anti-NF-YB antibody (Santa Cruz, 13045) which were 
subsequently used to immunoprecipitate NF-YB from 1 mg whole cell lysate. Quantitative 
ChIP was carried out on an ABI StepOne Plus using SYBR green dye. Genomic Location of 
the NF-YB site within the promoter of PDGFRB was located using a literature search 
(Hackzell et al., 2002). 
 
Immunohistochemistry and Immunofluorescence 
Tissues were fixed overnight in formalin, embedded in paraffin, and cut into 5- m thick 
sections. Sections were subjected to hematoxylin and eosin staining, and 
immunohistochemical and immunofluorescent staining following standard protocols. The 
following primary antibodies were used: mouse anti-GFP (Cell Signaling), rabbit anti-p-
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PDGFR-  (Tyr 1021) (Santa Cruz Biotechnology), mouse anti-p53 (OP43, Calbiochem) and 
rat anti-CK8 (DSHB). For immunofluorescence Alexa Fluor 488 goat anti-rabbit and Alexa 
Fluor 568 goat anti-rat were used as secondary antibodies, and DAPI was used as a 
chromogen. Images were acquired using a Zeiss Axio Imager D1 scope. 
 
shRNA Library Cloning, Recovery, and Determination of Representation 
The miR30 design based shRNA library was described before (Zender et al., 2008). Targeting 
sequences were selected on the basis of the DSIR algorithms. The library was subcloned into 
the MLS vector by a pooled approach. During the cloning procedure it was ensured by deep 
sequencing that a 1000- fold overrepresentation of each shRNA was maintained. 
 
Genomic DNA was isolated from liver tumors as indicated and the shRNA 
sequences were amplified using primers (Dow et al., 2012) flanking the miR30 cassette 
harboring the Illumina adaptor sequence. The same PCR approach was applied to the 
library pool plasmid DNA. Deep sequencing analyses were done using the Illumina GA IIx 
with a 46 bp single end run. Base calling and export of the sequencing results were done 
with multiple FASTA files via the Illumina Pipeline Vers. 1.8. Data analysis was done with a 
Perl-Script. The sequences were aligned to the shRNA library data (only 100% matches) and 
summarized. 
 
Mouse Studies 
All animal experiments were performed in accordance with a protocol approved by the 
Memorial Sloan-Kettering Institutional Animal Care and Use Committee. For colonization 
studies, KPC cells (1x105) were resuspended in 200 µl PBS and injected intravenously into 
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the tail vein of 8 week-old female athymic nude mice. Lungs were harvested 7 days post 
injection and analyzed for colonization by GFP positivity (Nikon SMZ1500) and histology. 
 
Pdx1-Cre (Hingorani et al., 2003), LSL-KrasG12D (Jackson et al., 2001) and LSL-p53R172H 
(Olive et al, 2004) mouse strains were previously described: Male Pdx1-Cre+/+, LSL-
p53R172H/R172H mice were bred with female LSL-KrasG12D/+ mice to generate KPC mice. Strains 
were maintained on mixed background. Mice were genotyped by polymerase chain reaction 
analysis as described previously (Hingorani et al., 2006). Mice were dosed twice daily by 
oral gavage with 50 mg/kg Imatinib in ddH2O or with ddH2O only. Organs and tumors 
were removed and fixed in 10% buffered formalin and tumor and metastatic burden was 
assessed by gross pathology and histology. 
 
Generation of Subcutaneous Tumors 
The indicated cell lines (LPC, MIT) were transduced by retroviruses expressing single 
(sh.Ctrl, sh.MKK4, sh.Apc) or pooled shRNAs (17p library, ~100 shRNA per pool). 1 × 106 
cells were injected subcutaneously (rear flanks) on nu/nu mice. Subcutaneous tumor 
volume was monitored by caliper measurements. 
 
Hydrodynamic Injection and FAS treatment 
Vectors for hydrodynamic tail vein injection were prepared using the QIAGEN EndoFree 
Maxi Kit (QIAGEN). For transposon-mediated gene transfer, animals received a 5:1 molar 
ratio of transposon to transposase- encoding plasmid (25 mg total DNA, unless otherwise 
stated). DNA was suspended in saline solution at a final volume of 10% of the animal’s 
body weight and injected via the tail vein in less than 10 s. Progression of liver cancer was 
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monitored at different time points by whole-liver GFP imaging using a Hamamatsu 
Imaging system.  
 
The Fas (CD95)-activating antibody Jo2 (Becton Dickinson Biosciences) (Ogasawara 
et al., 1993) was applied by intraperitoneal injection in a dose of 0.5 μg/g body weight. 
 
Human Data Sets 
The gene expression data and survival analyses of PDAC patients is from The International 
Cancer Genome Consortium (ICGC) pancreatic cancer project, which is stored at Gene 
Expression Omnibus (GEO) with accession number GSE50827. It includes gene expression 
data from 103 primary tumor samples, 89 of which contain disease-free survival and 
clinicopathological annotations, and used in the survival analysis according to previously 
described methods (Biankin et al., 2012).  
 
Gene expression data of ovarian, colorectal, and pancreatic cancer patients with 
annotated clinical outcomes were downloaded from GEO (GSE9899 (Tothill et al., 2008), 
GSE17537 (Smith et al., 2010), and GSE28735 (Zhang et al., 2012)). Preprocessed data were 
downloaded as provided in the data matrix files (GCRMA/RMA normalized Affymetrix 
expression microarray data) and gene set enrichment analysis (GSEA) was performed on 
each set after mean-centering across samples. Median of probes per gene was used to 
account for differential representation on the chip. GSEA analysis was used to evaluate 40-
gene signature. For survival analyses, gene expression data was clustered into groups using 
kmeans and Kaplan-Meier analyses was performed. Significance for these plots was 
determined using the logrank test. 
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For the Mkk4 project, we analyzed the aCGH data produced using representational 
oligonucleotide microarray analysis for the frequency and size of deletions in a series of 
human HCCs and breast, colon, and lung cancers available at Cold Spring Harbor 
Laboratory (Zender et al., 2008; Xue et al., 2012). We used this method to study gene dosage 
alterations in human HCC as described recently (Xue et al., 2012). Copy number aberrations 
(CNAs) were visualized from the individual representational oligonucleotide microarray 
analysis aCGH plots of the specific HCC samples using Integrated Genomics Viewer 
software (Broad Institute; http://www.broadinstitute.org/igv/home). In addition, 
available CNA from SNP6 arrays from the Cancer Genome Atlas 
(http://cancergenome.nih.gov/) for HCC and breast, colon, and lung adenocarcinomas 
were visualized using Integrated Genomics Viewer software and analyzed for the 
occurrence of chromosome 8p deletion. 
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